data_2grg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2grg _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.514 ' HB2' HG21 ' A' ' 8' ' ' THR . 30.0 Cg_endo . . . . . 0 C--O 1.236 0.392 0 CA-C-O 121.169 0.404 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.514 HG21 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.427 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.427 ' HG3' ' O ' ' A' ' 9' ' ' GLU . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.55 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.617 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.592 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.594 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.62 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.479 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.592 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 HD22 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.573 HG12 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.617 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.498 ' HE2' HD22 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.801 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.801 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.56 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.546 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.56 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.425 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.808 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.479 ' HA ' ' HZ1' ' A' ' 71' ' ' LYS . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.808 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.461 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.534 ' CB ' HD22 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.445 ' HA ' HG21 ' A' ' 44' ' ' ILE . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE1' HG12 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.435 HG12 ' HG3' ' A' ' 61' ' ' GLU . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.461 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.665 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.594 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.665 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.509 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.512 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo . . . . . 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.462 -0.331 0 CA-C-O 121.0 0.333 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.505 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.587 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.405 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.457 ' HB2' HD23 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.562 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.492 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.457 HD23 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.414 HG23 HD21 ' A' ' 18' ' ' LEU . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.505 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.563 HG13 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.587 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.632 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.632 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.529 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.492 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.453 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.534 HG22 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.529 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.43 HH11 ' HD3' ' A' ' 46' ' ' ARG . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.453 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.546 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.456 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.464 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.534 ' HA ' HG22 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.529 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE2' HG13 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.529 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.438 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.425 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.456 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.489 ' HE2' HD11 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.9 m80 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.562 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.489 HD11 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.411 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo . . . . . 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.425 ' HB2' HG21 ' A' ' 8' ' ' THR . 20.1 Cg_endo . . . . . 0 C--O 1.235 0.347 0 CA-C-O 121.158 0.399 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.425 HG21 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.407 HH11 ' HD3' ' A' ' 13' ' ' ARG . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.524 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.653 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.541 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.446 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.43 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.555 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.558 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.43 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.446 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.653 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.52 HG13 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.541 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.411 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.411 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.517 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.558 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.607 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.517 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.607 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.574 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.51 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.687 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.574 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.51 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.401 ' O ' ' HG2' ' A' ' 54' ' ' ARG . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.428 HG12 ' HB1' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.447 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.52 ' CE2' HG13 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.447 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.51 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.428 ' HB1' HG12 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.687 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.555 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.555 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.434 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo . . . . . 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.515 ' HB2' HG21 ' A' ' 8' ' ' THR . 41.3 Cg_endo . . . . . 0 C--O 1.236 0.421 0 CA-C-O 121.154 0.397 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.515 HG21 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.734 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.542 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.445 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.403 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.571 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.43 HD22 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.459 HG22 ' HZ3' ' A' ' 38' ' ' LYS . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.734 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.669 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.401 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.459 ' HZ3' HG22 ' A' ' 29' ' ' THR . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.871 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.871 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.539 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.568 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.555 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.5 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.673 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.555 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.576 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.58 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.542 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.458 ' HA ' HG22 ' A' ' 44' ' ' ILE . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.418 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.669 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.418 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.538 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.42 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.673 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.531 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.571 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.531 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.512 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.406 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 59.4 Cg_endo . . . . . 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo . . . . . 0 C--O 1.237 0.429 0 CA-C-O 120.891 0.288 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.434 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.519 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.536 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.401 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.422 ' HB2' HD22 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.545 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.601 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.405 HG22 ' HG2' ' A' ' 34' ' ' LYS . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.475 HG13 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.536 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.405 ' HG2' HG22 ' A' ' 29' ' ' THR . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.483 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.483 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.545 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.711 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.562 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.804 HD11 ' HZ2' ' A' ' 71' ' ' LYS . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.423 ' O ' HD23 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.536 ' CB ' HD22 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CE2' HG13 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.53 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.434 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.804 ' HZ2' HD11 ' A' ' 52' ' ' LEU . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.53 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo . . . . . 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 C--O 1.238 0.476 0 CA-C-O 121.18 0.408 . . . . 0.0 112.689 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.42 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 13' ' ' ARG . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.453 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.536 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.439 ' HB2' HD23 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.469 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.527 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.423 HG23 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.536 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.576 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.535 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.423 ' HG2' HG23 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.693 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.693 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.561 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.49 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.561 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.462 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.516 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.563 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.501 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.529 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.448 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.49 ' HA ' HG21 ' A' ' 44' ' ' ILE . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.556 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.556 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.445 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.432 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.529 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.563 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.499 ' HE2' HD11 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.469 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.499 HD11 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.453 HG21 ' HA ' ' A' ' 14' ' ' ALA . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.503 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo . . . . . 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' A' ' 9' ' ' GLU . 10.2 Cg_endo . . . . . 0 C--O 1.235 0.352 0 N-CA-C 112.854 0.29 . . . . 0.0 112.854 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . 0.404 ' CG ' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.403 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.525 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.433 ' HB2' HD12 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.643 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.452 ' N ' HD21 ' A' ' 23' ' ' ASN . 0.9 OUTLIER -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.428 HD22 ' HG1' ' A' ' 29' ' ' THR . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.433 HD12 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.552 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.428 ' HG1' HD22 ' A' ' 26' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.548 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.608 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.525 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.4 HG21 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.845 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.845 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.483 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.488 HG21 HG13 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.442 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.508 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.595 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.516 HD11 ' HZ1' ' A' ' 71' ' ' LYS . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.416 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.471 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.488 HG13 HG21 ' A' ' 44' ' ' ILE . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.66 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.536 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.66 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.608 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.536 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.439 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.416 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.595 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.484 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 30.9 m170 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.643 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.484 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.403 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.441 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 53.4 Cg_endo . . . . . 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.476 ' HB2' HG23 ' A' ' 8' ' ' THR . 19.3 Cg_endo . . . . . 0 C--O 1.237 0.464 0 CA-C-O 120.965 0.319 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.519 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.554 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.408 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.581 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.519 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.672 HG12 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.538 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.935 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.935 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.561 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.408 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.451 HG21 HG11 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.561 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.639 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.459 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.646 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.646 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.672 ' CE2' HG12 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.495 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.481 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.523 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.554 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.51 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.495 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.483 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo . . . . . 0 C--O 1.236 0.396 0 CA-C-O 121.141 0.392 . . . . 0.0 112.685 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.483 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.533 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.68 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.527 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.463 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.68 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.514 HG13 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.527 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.664 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.565 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.533 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.423 HG23 ' HA ' ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.565 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.456 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.648 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.537 HD12 ' HZ1' ' A' ' 71' ' ' LYS . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.401 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.431 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.556 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.423 ' HA ' HG23 ' A' ' 44' ' ' ILE . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.604 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.514 ' CE2' HG13 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.556 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.415 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.431 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.648 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.416 ' HE2' HD11 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.5 m170 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.416 HD11 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.533 HG21 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo . . . . . 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.237 0.453 0 CA-C-O 121.102 0.376 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.479 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.585 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.495 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.492 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.585 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.495 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.443 ' HG2' ' HH ' ' A' ' 60' ' ' TYR . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.619 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.619 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.466 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.602 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.604 HD11 ' HZ3' ' A' ' 71' ' ' LYS . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.574 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.535 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.427 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.443 ' HH ' ' HG2' ' A' ' 37' ' ' GLU . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.416 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.427 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.535 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HZ3' HD11 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.5 m170 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.416 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.479 HG21 ' HA ' ' A' ' 14' ' ' ALA . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo . . . . . 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.236 0.422 0 CA-C-O 120.971 0.321 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.605 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.488 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.416 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.471 ' HB2' ' ND2' ' A' ' 25' ' ' ASN . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.505 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.471 ' ND2' ' HB2' ' A' ' 23' ' ' ASN . 6.6 p30 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.488 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.414 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.605 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.412 HG12 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.712 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.595 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.712 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.555 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.555 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.509 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.433 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.674 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.54 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.498 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.406 HD21 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.455 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.463 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.488 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.488 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.455 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.674 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.531 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.516 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.531 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo . . . . . 0 C--O 1.236 0.384 0 CA-C-O 121.302 0.459 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.554 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.591 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.53 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' LEU . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.553 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.604 HD23 ' HG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.53 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.604 ' HG1' HD23 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.591 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.458 ' C ' ' HG ' ' A' ' 39' ' ' SER . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.907 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.907 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.535 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.553 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.535 HG13 ' O ' ' A' ' 41' ' ' ILE . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.489 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.46 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.561 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.538 HD13 ' HZ1' ' A' ' 71' ' ' LYS . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.628 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.407 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.524 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.487 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.53 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.457 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.457 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.404 ' HD1' ' HA ' ' A' ' 82' ' ' PRO . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.53 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.429 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.487 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.628 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.503 ' HE2' HD13 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.503 HD13 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.554 HG21 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.404 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 18.5 Cg_endo . . . . . 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo . . . . . 0 C--O 1.236 0.385 0 CA-C-O 121.109 0.379 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.67 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.67 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.535 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.49 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.403 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.619 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.619 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.598 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.577 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.42 HG23 HG13 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.598 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.437 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.577 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.486 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.506 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.5 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.65 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.456 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.58 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.42 HG13 HG23 ' A' ' 44' ' ' ILE . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.491 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.491 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.535 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.58 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.456 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.65 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HE2' HD11 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.447 HD11 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.522 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo . . . . . 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.505 ' HB2' HG23 ' A' ' 8' ' ' THR . 17.8 Cg_endo . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.237 0.432 . . . . 0.0 112.635 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.505 HG23 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.413 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.451 HG11 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.507 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.451 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.531 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.543 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.434 HG22 HD22 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.447 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.537 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.507 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.405 ' HG2' HG23 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.879 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.879 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.513 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.572 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.513 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.572 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.744 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.552 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.744 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.476 ' O ' HD21 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.559 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.415 HG12 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.524 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.541 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.524 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.537 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.541 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.415 ' HB2' HG12 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.552 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.474 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.451 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.474 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.413 HG21 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.451 ' HD3' HG11 ' A' ' 15' ' ' VAL . 57.0 Cg_endo . . . . . 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HB2' HG21 ' A' ' 8' ' ' THR . 17.9 Cg_endo . . . . . 0 C--O 1.235 0.352 0 CA-C-O 121.19 0.412 . . . . 0.0 112.657 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.437 HG21 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.507 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.527 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.595 HG21 HD22 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.547 HG12 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.551 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.551 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.507 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.403 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.426 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.53 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.713 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.515 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.486 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.428 HG12 ' HB3' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.547 ' CE2' HG12 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.435 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.485 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.428 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.515 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.713 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.507 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 26.6 m170 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.428 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 58.9 Cg_endo . . . . . 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 C--O 1.235 0.374 0 CA-C-O 121.256 0.44 . . . . 0.0 112.624 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.526 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.543 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.528 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.404 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.419 HG23 HD22 ' A' ' 18' ' ' LEU . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.543 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.565 HG12 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.528 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.72 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.72 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.715 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.57 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.567 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.55 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.497 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.587 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.55 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.527 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.527 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.433 HG12 ' HB3' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.558 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.446 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.558 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.565 ' CE2' HG12 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.446 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.433 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.587 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.2 m80 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo . . . . . 0 C--O 1.235 0.333 0 CA-C-O 121.249 0.437 . . . . 0.0 112.855 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.525 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.715 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.522 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.428 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.56 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.715 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.476 HG12 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.493 ' HE2' HD22 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.803 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.803 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.582 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.534 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.416 HG21 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.582 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.534 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.433 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.49 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.535 HD13 ' HZ2' ' A' ' 71' ' ' LYS . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.517 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.435 HG13 ' HB3' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.537 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.537 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.476 ' CE1' HG12 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.435 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.517 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HZ2' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.481 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.522 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 16.0 m170 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.428 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.481 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.454 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo . . . . . 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.236 0.411 0 CA-C-O 121.183 0.409 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.453 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.744 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.547 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.54 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.413 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.467 ' HB2' HD23 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.503 ' HB3' ' HB3' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.43 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.467 HD23 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.431 HG23 HD21 ' A' ' 18' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.744 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.565 HG12 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.419 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.527 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.549 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.503 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.512 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.438 HG23 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.549 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.44 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.72 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.452 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.495 ' O ' ' HD2' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.403 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.438 HG12 HG23 ' A' ' 44' ' ' ILE . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.565 ' CE2' HG12 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . 0.403 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.72 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo . . . . . 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 C--O 1.237 0.467 0 CA-C-O 121.004 0.335 . . . . 0.0 112.377 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.413 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.708 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.503 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.404 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.451 ' HB2' HD22 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.455 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.401 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.451 HD22 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.708 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.635 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.503 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.426 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.426 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.546 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.401 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.409 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.466 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.58 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.594 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.592 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.58 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.545 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.545 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.506 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.592 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.444 ' HZ3' HD11 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.455 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.444 HD11 ' HZ3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.506 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.413 HG23 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.404 ' HB2' HG22 ' A' ' 8' ' ' THR . 30.9 Cg_endo . . . . . 0 C--O 1.236 0.413 0 CA-C-O 121.15 0.396 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.404 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.528 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.418 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.557 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.457 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.582 HD23 ' HG1' ' A' ' 29' ' ' THR . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . 0.557 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' THR . . . . . 0.582 ' HG1' HD23 ' A' ' 26' ' ' LEU . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.418 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.447 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.478 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.51 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.633 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.633 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.472 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.51 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.766 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.511 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.42 HG12 ' HB1' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.59 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.59 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.405 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.405 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.518 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.42 ' HB1' HG12 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.484 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 14.2 m170 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.484 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.433 HG22 HG23 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.443 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.528 HG23 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo . . . . . 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.4 mmm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.755 0.312 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.429 ' HB2' ' HE2' ' A' ' 2' ' ' LYS . 9.8 tppt? -79.7 -59.39 2.76 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 177.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.9 m 69.87 135.32 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.318 -0.856 . . . . 0.0 112.279 177.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.1 m -82.49 104.52 12.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.474 175.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.488 HG23 ' HD2' ' A' ' 6' ' ' PRO . 87.1 mt -92.49 139.18 23.75 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.574 -169.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.548 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 30.0 Cg_endo -63.84 153.2 76.96 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.55 2.167 . . . . 0.0 112.942 -177.334 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.514 HG21 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.427 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.498 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.55 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.617 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.592 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.594 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.62 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.479 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.592 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 HD22 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.573 HG12 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.617 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.498 ' HE2' HD22 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.801 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.801 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.56 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.556 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.546 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.56 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.556 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.425 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.808 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.479 ' HA ' ' HZ1' ' A' ' 71' ' ' LYS . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.411 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.808 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.461 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.534 ' CB ' HD22 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.445 ' HA ' HG21 ' A' ' 44' ' ' ILE . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE1' HG12 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.527 HD12 ' HZ1' ' A' ' 83' ' ' LYS . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.509 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.461 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.665 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.594 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.665 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.509 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.512 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo -74.72 59.57 4.99 Favored 'Trans proline' 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.527 ' HZ1' HD12 ' A' ' 66' ' ' ILE . 46.2 mttm 46.67 52.57 11.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.425 -173.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.498 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 27.0 t-20 -64.2 106.9 1.17 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.656 -176.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -122.69 7.03 9.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.099 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -100.9 141.48 33.73 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.732 0.301 . . . . 0.0 110.55 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.753 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 1.2 mmp_? 55.64 73.81 0.41 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.576 0.703 . . . . 0.0 110.951 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.07 27.46 9.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.607 -178.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.53 45.33 3.07 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.411 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.8 p -143.11 124.29 11.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 21.2 m -105.38 131.9 21.35 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 111.289 -177.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.548 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 97.5 Cg_endo -88.01 123.15 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.805 2.336 . . . . 0.0 112.335 174.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -57.53 141.3 95.14 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.695 2.263 . . . . 0.0 111.837 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.65 -10.17 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 112.053 -175.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 151.96 10.24 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.053 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 8.8 mt -88.8 34.4 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.254 0.549 . . . . 0.0 110.279 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 23.6 m -69.6 97.81 1.08 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.41 -0.805 . . . . 0.0 109.595 178.68 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -79.23 139.15 37.99 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.516 -0.179 . . . . 0.0 110.516 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m 74.46 8.38 4.46 Favored 'General case' 0 N--CA 1.466 0.37 0 O-C-N 123.86 0.725 . . . . 0.0 111.955 175.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.32 141.2 48.47 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 174.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.44 ' CG2' ' HD2' ' A' ' 6' ' ' PRO . 51.4 mt -124.53 140.73 35.98 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -174.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.596 ' HD3' ' HD3' ' A' ' 92' ' ' PRO . 31.1 Cg_endo -67.41 154.97 72.27 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.149 1.899 . . . . 0.0 112.539 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.402 ' HB3' ' ND2' ' A' ' 84' ' ' ASN . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.505 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.587 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.405 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.411 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.457 ' HB2' HD23 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.562 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.492 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.457 HD23 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.414 HG23 HD21 ' A' ' 18' ' ' LEU . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.505 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.563 HG13 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.587 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.632 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.632 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.529 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.492 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.453 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.534 HG22 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.529 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.43 HH11 ' HD3' ' A' ' 46' ' ' ARG . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.453 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.546 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.456 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.464 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.534 ' HA ' HG22 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.529 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.485 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.563 ' CE2' HG13 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.529 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.438 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.425 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.427 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.456 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.489 ' HE2' HD11 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.9 m80 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.562 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.489 HD11 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.411 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo -72.88 55.64 2.83 Favored 'Trans proline' 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.485 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 41.6 mttm 60.07 22.78 11.98 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.061 -171.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.402 ' ND2' ' HB3' ' A' ' 13' ' ' ARG . 38.0 t-20 -70.23 114.27 8.21 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.589 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 45.5 pttt -128.74 7.88 5.72 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.772 -1.103 . . . . 0.0 109.4 -176.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.431 ' O ' ' HB2' ' A' ' 87' ' ' ARG . 73.6 m-20 64.0 -85.02 0.02 OUTLIER 'General case' 0 C--O 1.231 0.096 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.725 -169.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.431 ' HB2' ' O ' ' A' ' 86' ' ' ASN . 48.5 ttp180 164.08 -47.8 0.0 OUTLIER 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 177.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -68.87 148.48 50.17 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.693 -1.139 . . . . 0.0 110.049 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -78.36 65.69 3.33 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.001 178.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 m -83.76 106.41 14.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.278 0.561 . . . . 0.0 110.769 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -118.98 122.94 29.27 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.883 -178.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.596 ' HD3' ' HD3' ' A' ' 6' ' ' PRO . 76.8 Cg_endo -75.48 133.26 15.68 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 123.037 2.491 . . . . 0.0 112.654 -179.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -61.39 135.41 57.44 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.583 2.189 . . . . 0.0 111.754 176.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.2 p -73.58 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.683 0.754 . . . . 0.0 110.839 -178.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -85.67 20.97 16.0 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 112.848 -177.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.4 mm -79.03 -40.85 22.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.405 0.621 . . . . 0.0 109.537 176.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 t -87.6 135.98 33.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.319 178.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.558 -0.734 . . . . 0.0 110.592 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.5 tpp . . . . . 0 N--CA 1.48 1.065 0 CA-C-O 121.048 0.451 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -77.34 92.29 3.91 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.27 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -90.09 7.75 36.23 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.74 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.508 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 13.2 m -82.47 101.41 10.66 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.19 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.468 HG21 ' HD2' ' A' ' 6' ' ' PRO . 75.0 mt -109.96 139.24 21.13 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.763 -174.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.557 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 20.1 Cg_endo -62.66 151.37 83.96 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.52 2.147 . . . . 0.0 112.568 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.425 HG21 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.471 HH12 ' CD ' ' A' ' 88' ' ' GLU . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.524 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.653 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.541 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.446 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.43 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.555 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.558 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 59.7 m-80 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.43 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.446 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.653 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.52 HG13 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.541 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.411 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.411 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.517 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.558 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.607 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.517 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.607 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.574 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.51 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.687 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.574 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.51 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.401 ' O ' ' HG2' ' A' ' 54' ' ' ARG . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.508 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.469 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.428 HG12 ' HB1' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.447 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.508 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.52 ' CE2' HG13 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.447 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.51 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.428 ' HB1' HG12 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.469 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.687 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.555 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.555 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.555 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.434 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo -71.44 59.36 2.53 Favored 'Trans proline' 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.508 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.5 mttm 60.36 27.86 17.45 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.982 -174.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.426 ' HB3' ' HG1' ' A' ' 81' ' ' THR . 23.3 t-20 -66.0 107.57 1.92 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.723 174.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.436 ' HG2' ' OD1' ' A' ' 86' ' ' ASN . 43.5 tttm -145.29 105.35 4.04 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.25 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.443 ' HA ' ' HB ' ' A' ' 90' ' ' VAL . 3.2 p-10 42.43 44.01 3.3 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 123.953 0.783 . . . . 0.0 111.238 -175.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -43.81 -70.61 0.1 Allowed 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 114.779 -1.1 . . . . 0.0 112.851 -174.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . 0.471 ' CD ' HH12 ' A' ' 13' ' ' ARG . 0.9 OUTLIER -98.79 35.03 1.93 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.797 179.684 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 86.5 34.9 11.09 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.44 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.443 ' HB ' ' HA ' ' A' ' 86' ' ' ASN . 52.1 t -74.86 95.63 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.927 0.394 . . . . 0.0 110.661 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.4 m -94.35 115.59 65.43 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.262 175.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.557 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 52.7 Cg_endo -72.85 118.51 5.6 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.411 2.074 . . . . 0.0 112.887 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -79.97 91.32 1.18 Allowed 'Trans proline' 0 N--CA 1.455 -0.794 0 C-N-CA 122.455 2.103 . . . . 0.0 111.321 176.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.3 m -69.69 108.27 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-O 121.577 0.703 . . . . 0.0 111.813 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -148.32 53.19 0.53 Allowed Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.488 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 27.3 pt -83.39 -31.26 8.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.74 0.305 . . . . 0.0 111.158 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.0 p -108.18 137.05 46.82 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.51 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.441 -0.79 . . . . 0.0 110.169 -177.637 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.1 mtt . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.959 0.409 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -138.75 93.62 2.74 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 m -82.6 82.97 7.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.53 0.681 . . . . 0.0 111.011 -176.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 12.1 p -126.26 155.67 41.53 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.198 -0.91 . . . . 0.0 108.869 173.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.403 HG21 ' HD2' ' A' ' 6' ' ' PRO . 55.0 mt -131.22 137.78 31.39 Favored Pre-proline 0 C--N 1.322 -0.612 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 41.3 Cg_endo -69.42 155.03 68.21 Favored 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.074 1.85 . . . . 0.0 112.254 -179.06 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.515 HG21 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.734 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.542 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.445 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.403 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.571 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.568 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.43 HD22 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.445 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.459 HG22 ' HZ3' ' A' ' 38' ' ' LYS . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.734 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.669 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.401 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.459 ' HZ3' HG22 ' A' ' 29' ' ' THR . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.871 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.871 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.539 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.493 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.568 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.555 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.5 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.673 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.555 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.576 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.58 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.585 ' HG2' ' HA ' ' A' ' 98' ' ' ASN . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.542 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.458 ' HA ' HG22 ' A' ' 44' ' ' ILE . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.418 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.535 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.669 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.418 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.512 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.538 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.42 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.673 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.531 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.571 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.531 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.512 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.406 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 59.4 Cg_endo -72.48 54.81 2.46 Favored 'Trans proline' 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.535 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.1 mttm 63.83 31.76 13.85 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.863 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 5.4 t30 -70.06 96.74 1.09 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -102.21 -81.67 0.49 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.775 -176.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.612 ' HA ' HG21 ' A' ' 90' ' ' VAL . 4.2 p-10 -135.77 118.74 16.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.185 0.517 . . . . 0.0 110.825 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -138.77 -78.05 0.35 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.705 176.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -157.34 125.3 5.44 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.408 -176.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 82.04 2.0 90.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.458 177.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.612 HG21 ' HA ' ' A' ' 86' ' ' ASN . 34.6 m -89.77 -0.15 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.831 0.348 . . . . 0.0 111.28 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -78.14 121.93 84.61 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 121.221 0.534 . . . . 0.0 111.197 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.522 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 50.1 Cg_endo -68.57 136.3 35.91 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.951 2.434 . . . . 0.0 112.715 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 6.4 Cg_exo -73.24 104.68 1.83 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.548 2.165 . . . . 0.0 109.88 171.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.7 m -59.44 131.96 24.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.188 0.518 . . . . 0.0 111.868 -171.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 81.11 -58.52 4.82 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.45 -0.795 . . . . 0.0 113.202 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 46.7 mm -95.47 97.47 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.987 0.423 . . . . 0.0 111.737 -174.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 t -176.8 132.14 0.19 Allowed 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.989 175.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.585 ' HA ' ' HG2' ' A' ' 54' ' ' ARG . 8.8 p30 . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.077 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.478 0.963 0 CA-C-O 120.967 0.413 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? -103.09 107.93 18.93 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 m -64.75 116.56 6.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.427 0.632 . . . . 0.0 112.265 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 26.8 p -91.39 126.49 36.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.257 173.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 63.6 mt -133.82 137.82 29.46 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.861 -0.154 . . . . 0.0 110.752 -172.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.547 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 56.4 Cg_endo -71.64 160.92 46.88 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.669 2.246 . . . . 0.0 112.526 177.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.434 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.519 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.536 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.401 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.422 ' HB2' HD22 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.545 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.422 HD22 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.601 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.405 HG22 ' HG2' ' A' ' 34' ' ' LYS . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.475 HG13 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.536 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.405 ' HG2' HG22 ' A' ' 29' ' ' THR . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.483 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.483 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.545 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.711 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.562 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.804 HD11 ' HZ2' ' A' ' 71' ' ' LYS . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.423 ' O ' HD23 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.536 ' CB ' HD22 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.442 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.475 ' CE2' HG13 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.53 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.434 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.804 ' HZ2' HD11 ' A' ' 52' ' ' LEU . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.53 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.01 142.48 99.44 Favored 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.442 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 15.8 mttm -45.38 105.31 0.06 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.94 0.4 . . . . 0.0 111.627 179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -140.14 133.82 30.37 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.628 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.472 ' HE3' ' HB3' ' A' ' 85' ' ' LYS . 1.0 OUTLIER -141.96 120.83 12.75 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.448 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -106.94 -171.1 1.82 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -87.81 32.24 0.74 Allowed 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.485 -0.135 . . . . 0.0 111.083 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 66.15 -85.78 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.285 0 O-C-N 123.628 0.58 . . . . 0.0 110.285 -175.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.33 -98.24 0.5 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 121.306 -0.473 . . . . 0.0 113.3 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.2 m -87.29 57.11 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.547 0.689 . . . . 0.0 111.138 -175.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.7 m -68.88 142.42 93.49 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.482 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.547 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 72.7 Cg_endo -75.31 159.79 39.83 Favored 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 122.892 2.394 . . . . 0.0 112.007 176.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.18 117.11 3.79 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.395 2.064 . . . . 0.0 111.186 174.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.0 m -76.54 132.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.171 0.51 . . . . 0.0 111.468 -177.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 142.82 -168.04 26.09 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.797 179.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm -97.18 127.05 49.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 20.6 p -81.38 68.46 7.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.937 -176.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 72.5 m-20 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.451 -0.785 . . . . 0.0 109.64 175.159 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.434 ' HE2' ' HB3' ' A' ' 1' ' ' MET . 14.9 tmm? . . . . . 0 N--CA 1.477 0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mmmt -133.85 175.41 9.49 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.036 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -102.96 -28.42 12.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.001 0.429 . . . . 0.0 110.353 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.529 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 17.8 m -78.09 106.98 10.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.993 -178.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.467 HG22 ' HD2' ' A' ' 6' ' ' PRO . 84.0 mt -107.89 137.75 19.87 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.76 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.467 ' HD2' HG22 ' A' ' 5' ' ' ILE . 18.6 Cg_endo -60.0 149.95 81.31 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 122.677 2.252 . . . . 0.0 112.689 -177.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.42 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.639 ' HB3' HD22 ' A' ' 84' ' ' ASN . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.453 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.536 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.439 ' HB2' HD23 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.469 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.527 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.439 HD23 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.423 HG23 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.536 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.576 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.535 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.423 ' HG2' HG23 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.693 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.693 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.561 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.49 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.561 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.462 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.516 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.563 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.633 ' HA3' ' HA ' ' A' ' 96' ' ' ILE . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.529 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.529 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.448 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.49 ' HA ' HG21 ' A' ' 44' ' ' ILE . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.556 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.588 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.576 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.445 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.432 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.529 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.563 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.499 ' HE2' HD11 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.469 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.499 HD11 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.6 ' HB ' ' OD1' ' A' ' 84' ' ' ASN . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.503 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo -70.54 53.93 1.42 Allowed 'Trans proline' 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.588 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 7.0 mttm 56.55 21.16 5.44 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.368 177.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.639 HD22 ' HB3' ' A' ' 13' ' ' ARG . 21.3 p-10 -87.06 111.98 21.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.603 0.716 . . . . 0.0 111.058 -177.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.642 ' HZ3' ' HB3' ' A' ' 85' ' ' LYS . 0.6 OUTLIER -95.21 29.3 2.52 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.393 -178.806 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.459 ' HB3' HG11 ' A' ' 90' ' ' VAL . 23.4 t-20 72.78 159.32 0.22 Allowed 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.093 0.871 . . . . 0.0 109.554 -173.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.542 ' NE ' ' HA ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -54.26 -65.4 0.58 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.035 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 145.06 2.42 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 111.829 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 69.09 46.98 56.54 Favored Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.669 -0.696 . . . . 0.0 113.166 172.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.459 HG11 ' HB3' ' A' ' 86' ' ' ASN . 7.7 p -107.62 116.56 51.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.43 0.634 . . . . 0.0 111.079 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.7 t -120.71 97.66 48.38 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.532 174.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.459 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 27.6 Cg_endo -65.0 135.91 46.06 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.798 2.332 . . . . 0.0 112.551 -176.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.459 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 2.8 Cg_exo -75.91 138.43 20.9 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 123.018 2.479 . . . . 0.0 111.864 177.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 30.2 m -66.13 139.05 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.043 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -169.82 128.02 1.59 Allowed Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.376 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.633 ' HA ' ' HA3' ' A' ' 53' ' ' GLY . 11.2 pt -104.49 -38.57 4.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 176.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.495 ' HB ' ' O ' ' A' ' 96' ' ' ILE . 13.1 t 171.81 -43.07 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.446 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.464 ' HB2' ' O ' ' A' ' 97' ' ' THR . 7.0 t30 . . . . . 0 C--O 1.247 0.936 0 C-N-CA 124.037 0.935 . . . . 0.0 108.782 175.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.2 ptm . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -73.62 103.62 4.28 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.913 0.387 . . . . 0.0 110.206 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -116.38 98.93 6.85 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.199 0.523 . . . . 0.0 111.73 -175.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.428 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 14.9 m -92.55 101.87 14.31 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 27.0 mt -99.87 135.59 20.43 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.411 -166.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.404 ' HG2' ' CG ' ' A' ' 9' ' ' GLU . 10.2 Cg_endo -55.09 151.09 36.12 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.603 2.869 . . . . 0.0 112.854 177.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.404 ' CG ' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.403 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.548 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.525 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.433 ' HB2' HD12 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.643 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.452 ' N ' HD21 ' A' ' 23' ' ' ASN . 0.9 OUTLIER -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.428 HD22 ' HG1' ' A' ' 29' ' ' THR . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.433 HD12 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.552 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.428 ' HG1' HD22 ' A' ' 26' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.548 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.608 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.525 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.4 HG21 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.845 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.845 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.483 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.488 HG21 HG13 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.442 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.444 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.508 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.595 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.516 HD11 ' HZ1' ' A' ' 71' ' ' LYS . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.416 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.471 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.488 HG13 HG21 ' A' ' 44' ' ' ILE . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.66 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.536 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.661 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.608 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.536 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.439 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.416 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.595 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.484 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 30.9 m170 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.643 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.484 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.403 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.441 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 53.4 Cg_endo -70.29 63.73 2.1 Favored 'Trans proline' 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.661 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 33.8 mttm 49.95 29.63 3.52 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.2 48.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.588 0.709 . . . . 0.0 109.875 173.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -66.9 -34.96 78.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.032 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -148.41 135.97 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.192 175.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.422 ' NH2' HG11 ' A' ' 90' ' ' VAL . 19.3 mtm180 -132.7 -68.16 0.61 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.045 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -137.65 -143.42 0.17 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -74.83 50.33 2.21 Favored Glycine 0 CA--C 1.522 0.491 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.832 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.422 HG11 ' NH2' ' A' ' 87' ' ' ARG . 15.5 m -112.4 20.8 6.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.612 0.72 . . . . 0.0 109.903 178.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.552 ' HB ' ' HD2' ' A' ' 92' ' ' PRO . 23.5 m -84.67 163.26 47.49 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.788 -1.097 . . . . 0.0 109.468 175.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.552 ' HD2' ' HB ' ' A' ' 91' ' ' VAL . 1.9 Cg_endo -42.63 116.53 0.68 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 123.587 2.858 . . . . 0.0 113.069 179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -66.53 108.89 1.49 Allowed 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.781 2.321 . . . . 0.0 111.6 179.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.9 p -68.52 121.48 17.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.356 0.598 . . . . 0.0 110.586 -178.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 171.63 -89.09 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.3 mm -91.47 107.71 19.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 m 67.14 106.35 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 O-C-N 123.625 0.578 . . . . 0.0 110.953 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.309 -178.286 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 mtt . . . . . 0 N--CA 1.482 1.125 0 N-CA-C 111.254 0.094 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? 66.56 110.08 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 121.541 0.686 . . . . 0.0 110.237 -173.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.8 m -82.95 25.43 0.68 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.733 -174.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 m -102.01 102.95 13.53 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.677 HD12 ' HA ' ' A' ' 85' ' ' LYS . 27.1 mt -105.6 141.94 23.72 Favored Pre-proline 0 C--N 1.32 -0.675 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.342 -170.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.534 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 19.3 Cg_endo -63.93 149.62 90.19 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.097 1.865 . . . . 0.0 112.152 177.137 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.519 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.538 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.581 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.554 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.408 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.581 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.519 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.672 HG12 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.538 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.935 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.935 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.561 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.408 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.451 HG21 HG11 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.561 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.639 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.639 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.459 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.451 HG11 HG21 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.646 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.646 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.672 ' CE2' HG12 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.495 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.442 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.481 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.523 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.554 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.51 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.495 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.38 65.05 3.65 Favored 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.467 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 19.2 mttm 60.83 36.78 19.0 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.516 -179.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -89.86 104.28 16.86 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.658 177.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.677 ' HA ' HD12 ' A' ' 5' ' ' ILE . 55.6 mtmt -124.95 -50.73 1.7 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.937 172.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -156.68 101.69 2.0 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.096 0.474 . . . . 0.0 110.389 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 73.4 ttt180 -142.64 -66.27 0.39 Allowed 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -130.2 147.26 51.91 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.18 -147.87 18.58 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.148 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 22.0 m -118.05 162.43 16.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.037 0.446 . . . . 0.0 111.076 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.9 m -92.97 155.65 41.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.691 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.534 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 17.7 Cg_endo -59.95 152.03 67.48 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.835 2.357 . . . . 0.0 112.671 176.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -60.82 135.48 60.03 Favored 'Trans proline' 0 C--O 1.236 0.377 0 C-N-CA 122.801 2.334 . . . . 0.0 111.974 176.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.7 p -92.43 -20.76 6.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.465 0.65 . . . . 0.0 109.826 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -106.89 -143.56 11.24 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.77 176.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm 65.82 95.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 123.007 0.523 . . . . 0.0 111.745 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.6 p 53.54 70.67 0.57 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.648 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 55.4 t30 . . . . . 0 C--O 1.251 1.143 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.616 176.471 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.443 ' HE1' ' O ' ' A' ' 3' ' ' SER . 7.3 tmm? . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.3 mmmt -108.94 -59.69 1.85 Allowed 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -173.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.443 ' O ' ' HE1' ' A' ' 1' ' ' MET . 12.9 p -74.9 82.91 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.103 0.478 . . . . 0.0 111.88 -173.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.424 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 23.6 m -124.93 106.3 9.88 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.698 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 34.1 mt -91.49 133.38 31.36 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.525 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.483 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo -67.69 154.57 72.93 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.497 2.131 . . . . 0.0 112.685 177.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.483 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.533 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.68 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.527 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.463 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.463 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.68 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.514 HG13 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.527 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.664 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.565 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.533 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.423 HG23 ' HA ' ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.565 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.456 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.648 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.537 HD12 ' HZ1' ' A' ' 71' ' ' LYS . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.424 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.431 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.556 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.423 ' HA ' HG23 ' A' ' 44' ' ' ILE . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.604 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.604 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.514 ' CE2' HG13 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.714 HG13 ' HG2' ' A' ' 83' ' ' LYS . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.556 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.415 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.431 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.648 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.416 ' HE2' HD11 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.5 m170 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.416 HD11 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.533 HG21 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo -72.71 48.76 1.39 Allowed 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.821 ' HB3' ' HZ2' ' A' ' 83' ' ' LYS . 9.8 mtpm? 63.86 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.431 0.692 . . . . 0.0 112.441 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -156.04 146.8 22.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.602 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -137.43 -26.11 1.0 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.331 173.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 66.66 101.75 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.842 0.714 . . . . 0.0 112.085 178.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 64.7 mtm180 -134.78 149.71 50.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.916 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 59.37 85.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.321 0 O-C-N 123.863 0.727 . . . . 0.0 111.173 -178.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 146.41 -91.43 0.15 Allowed Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.206 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.5 122.2 63.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 120.917 0.389 . . . . 0.0 110.14 175.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.408 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 31.5 m -123.32 141.08 35.19 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.852 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 91' ' ' VAL . 2.1 Cg_endo -85.42 123.66 2.62 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 123.019 2.479 . . . . 0.0 111.741 175.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.96 72.68 3.88 Favored 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 122.573 2.182 . . . . 0.0 112.114 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -64.76 125.07 20.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.269 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.42 33.69 0.48 Allowed Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.643 -177.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 55.7 mt -98.33 135.34 33.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 31.4 m -61.81 137.26 58.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 178.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.2 t30 . . . . . 0 C--O 1.246 0.876 0 CA-C-O 118.433 -0.794 . . . . 0.0 111.198 -178.921 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.482 1.155 0 CA-C-O 120.922 0.391 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -75.94 126.42 30.97 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.4 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -165.57 115.48 1.04 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.059 0.456 . . . . 0.0 110.433 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 23.2 m -95.38 104.09 15.98 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 48.2 mt -90.83 135.72 28.54 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.79 -170.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.702 ' HG3' ' HD2' ' A' ' 93' ' ' PRO . 42.8 Cg_endo -67.69 159.16 53.92 Favored 'Trans proline' 0 C--O 1.237 0.453 0 C-N-CA 122.856 2.371 . . . . 0.0 112.441 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.479 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.585 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.495 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.492 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.492 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.585 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.495 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.443 ' HG2' ' HH ' ' A' ' 60' ' ' TYR . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.619 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.619 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.466 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.602 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.604 HD11 ' HZ3' ' A' ' 71' ' ' LYS . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.574 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.535 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.427 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.443 ' HH ' ' HG2' ' A' ' 37' ' ' GLU . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.64 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.416 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.427 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.535 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HZ3' HD11 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 23.5 m170 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.416 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 84' ' ' ASN . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.09 60.75 5.59 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.64 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 43.8 mttm 52.3 62.48 2.67 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.476 -174.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.533 ' HB3' ' HB ' ' A' ' 81' ' ' THR . 0.5 OUTLIER -76.73 157.58 31.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.003 -177.451 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.646 ' HD3' ' HG2' ' A' ' 88' ' ' GLU . 2.3 tmmt? 70.38 80.82 0.17 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.793 0.806 . . . . 0.0 110.856 179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -110.65 124.85 52.7 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 171.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 70.16 98.54 0.06 Allowed 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -169.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . 0.646 ' HG2' ' HD3' ' A' ' 85' ' ' LYS . 23.9 mt-10 -72.94 80.04 1.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.773 -170.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.01 -53.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.351 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.9 p -77.01 124.96 36.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.102 0.477 . . . . 0.0 110.18 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -118.24 153.51 51.57 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.578 -178.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.567 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 3.4 Cg_endo -49.94 119.66 5.11 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 123.347 2.698 . . . . 0.0 112.727 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.702 ' HD2' ' HG3' ' A' ' 6' ' ' PRO . 23.9 Cg_exo -64.91 100.66 0.36 Allowed 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.894 2.396 . . . . 0.0 111.687 176.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -109.11 179.24 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.638 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -174.28 -117.13 0.46 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.701 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 39.7 pt -103.91 152.51 6.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.9 t -99.4 156.67 16.89 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.323 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.561 -0.733 . . . . 0.0 109.254 178.874 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.8 ttm . . . . . 0 N--CA 1.48 1.038 0 CA-C-O 120.785 0.326 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -72.05 -50.4 28.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.465 175.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.8 m -90.49 92.97 9.1 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.023 0.44 . . . . 0.0 111.105 -177.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.1 m -93.31 139.21 30.9 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 31.7 mt -103.02 138.75 19.64 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.686 -167.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.547 ' CD ' ' HB3' ' A' ' 92' ' ' PRO . 53.4 Cg_endo -69.71 160.61 49.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.561 2.174 . . . . 0.0 112.065 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.549 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.605 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.488 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.416 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.529 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.516 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.471 ' HB2' ' ND2' ' A' ' 25' ' ' ASN . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.505 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.471 ' ND2' ' HB2' ' A' ' 23' ' ' ASN . 6.6 p30 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.488 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.414 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.605 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.412 HG12 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.712 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.595 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.712 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.494 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.555 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.555 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.509 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.433 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.674 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.509 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.54 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.498 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.406 HD21 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.455 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.463 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.533 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.488 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.488 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.455 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.674 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.531 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.529 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.516 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.531 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.94 57.9 3.28 Favored 'Trans proline' 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.533 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 48.4 mttm 53.47 59.79 4.13 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.731 -172.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.549 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 8.9 t30 -74.84 98.21 3.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.541 175.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 58.4 mtpt -89.24 109.93 20.76 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.602 -177.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -73.68 93.6 2.1 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 173.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -107.33 -26.95 10.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.77 -171.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -163.88 157.31 18.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.089 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.66 -131.12 10.49 Favored Glycine 0 N--CA 1.445 -0.718 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 53.8 t -76.12 98.98 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.893 0.378 . . . . 0.0 110.069 175.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.1 p -93.12 129.06 40.67 Favored Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.919 179.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.547 ' HB3' ' CD ' ' A' ' 6' ' ' PRO . 48.6 Cg_endo -68.96 127.47 15.28 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 123.137 2.558 . . . . 0.0 114.379 -172.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -93.42 -168.11 0.18 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 123.378 2.719 . . . . 0.0 110.932 169.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.2 t -116.31 -56.05 4.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.949 0.404 . . . . 0.0 110.467 178.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 85.14 -167.44 41.61 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.168 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.483 HG21 ' O ' ' A' ' 96' ' ' ILE . 26.7 mm 68.47 18.76 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-O 121.278 0.561 . . . . 0.0 110.382 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.7 p 51.61 98.82 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.92 0.888 . . . . 0.0 113.11 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.683 178.717 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -172.06 -33.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.266 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.5 m 63.1 31.14 16.0 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.082 179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.443 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 5.9 p -74.53 106.57 6.18 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.425 178.085 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.401 ' HA ' ' HG2' ' A' ' 92' ' ' PRO . 50.1 mt -91.28 135.08 28.65 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.478 -175.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.08 159.74 51.39 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.693 2.262 . . . . 0.0 112.51 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.554 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.591 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.53 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' LEU . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.553 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.604 HD23 ' HG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.53 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.604 ' HG1' HD23 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.591 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.458 ' C ' ' HG ' ' A' ' 39' ' ' SER . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.907 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.907 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.535 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.553 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.535 HG13 ' O ' ' A' ' 41' ' ' ILE . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.489 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.46 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.561 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.41 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.538 HD13 ' HZ1' ' A' ' 71' ' ' LYS . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.628 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.407 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.524 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.487 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.53 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.457 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.647 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.404 ' HD1' ' HA ' ' A' ' 82' ' ' PRO . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.53 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.429 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.487 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.628 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.503 ' HE2' HD13 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 31.1 m80 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.503 HD13 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.554 HG21 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.404 ' HA ' ' HD1' ' A' ' 65' ' ' TYR . 18.5 Cg_endo -62.22 154.36 63.61 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.647 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 36.7 mttm -44.5 100.94 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.016 0.436 . . . . 0.0 111.591 174.393 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -112.12 84.47 1.97 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -142.33 78.6 1.63 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.682 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -90.53 151.97 21.12 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.33 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.445 ' HD2' ' HA ' ' A' ' 87' ' ' ARG . 26.4 tpt180 -75.99 83.93 2.88 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.146 0.498 . . . . 0.0 110.676 -179.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -137.51 157.48 46.46 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.588 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.69 28.07 11.04 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.973 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.4 t -82.75 123.03 38.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.459 . . . . 0.0 110.168 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.436 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.9 p -130.92 114.17 16.4 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-O 121.316 0.579 . . . . 0.0 110.219 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 91' ' ' VAL . 21.2 Cg_exo -66.06 151.37 84.01 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -178.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 24.3 Cg_exo -65.42 165.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 123.102 2.535 . . . . 0.0 112.178 176.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.2 p -90.3 6.1 4.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.622 0.725 . . . . 0.0 110.741 -176.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 140.96 -164.03 26.52 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.155 177.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 13.4 tt -83.63 -25.89 7.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.072 0.463 . . . . 0.0 110.646 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.4 p -84.9 150.72 24.77 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.197 -178.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.384 -0.817 . . . . 0.0 110.107 179.681 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.513 ' HE1' ' HA ' ' A' ' 57' ' ' TYR . 1.4 tmt? . . . . . 0 N--CA 1.48 1.055 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt 50.75 33.71 8.85 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 113.169 0.804 . . . . 0.0 113.169 173.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.427 ' O ' HG13 ' A' ' 5' ' ' ILE . 18.1 m -132.06 30.78 4.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.016 0.436 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.5 p -62.22 105.38 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.821 178.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.561 HD13 ' HA ' ' A' ' 86' ' ' ASN . 68.1 mt -122.61 134.59 25.02 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.909 -178.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.42 159.11 51.94 Favored 'Trans proline' 0 C--O 1.236 0.385 0 C-N-CA 122.838 2.359 . . . . 0.0 112.653 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.67 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HG ' ' HB3' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.67 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.535 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.49 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.403 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.619 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.619 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.598 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.577 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.42 HG23 HG13 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.598 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.437 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.577 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.486 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.506 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.5 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.65 HD13 ' HZ3' ' A' ' 71' ' ' LYS . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.547 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.456 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.58 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.42 HG13 HG23 ' A' ' 44' ' ' ILE . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.491 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.491 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.535 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.58 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.419 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.456 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.65 ' HZ3' HD13 ' A' ' 52' ' ' LEU . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.447 ' HE2' HD11 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.447 HD11 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.522 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo -73.13 55.83 3.0 Favored 'Trans proline' 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . . . . . . . . . 48.2 mttm 54.52 73.81 0.38 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.193 -175.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -80.21 -28.54 38.59 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.451 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 60.17 -88.98 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.862 -176.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.561 ' HA ' HD13 ' A' ' 5' ' ' ILE . 28.6 t-20 -160.48 -63.52 0.06 Allowed 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.402 HH11 ' HD3' ' A' ' 87' ' ' ARG . 13.6 ttm-85 58.03 -95.02 0.05 Allowed 'General case' 0 CA--C 1.537 0.461 0 O-C-N 123.763 0.664 . . . . 0.0 111.292 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -147.85 162.47 39.2 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.793 0.33 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 144.05 -153.79 25.24 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.44 88.18 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.963 0.411 . . . . 0.0 110.031 176.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 4.4 p -92.02 109.9 40.45 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-O 121.352 0.596 . . . . 0.0 109.718 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -82.62 123.85 3.89 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 122.76 2.306 . . . . 0.0 112.938 -175.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -76.42 95.24 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.83 2.353 . . . . 0.0 110.459 172.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 p -79.31 129.2 37.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.427 0.632 . . . . 0.0 111.169 -174.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -126.65 -52.71 0.15 Allowed Glycine 0 N--CA 1.448 -0.508 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 178.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 69.9 mt -80.69 110.74 16.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 177.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -143.47 -45.35 0.28 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.021 0.438 . . . . 0.0 111.067 -177.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.697 -0.668 . . . . 0.0 110.572 -173.607 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.3 mtp . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 121.004 0.43 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.499 ' HD2' ' HE1' ' A' ' 57' ' ' TYR . 16.6 tppt? -109.5 91.02 3.48 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 p -91.98 99.88 12.64 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.512 0.672 . . . . 0.0 111.812 -173.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.486 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 23.1 m -114.35 102.96 10.6 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 170.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -100.83 135.2 20.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.692 -168.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.505 ' HB2' HG23 ' A' ' 8' ' ' THR . 17.8 Cg_endo -61.16 152.32 72.62 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.777 2.318 . . . . 0.0 112.635 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.505 HG23 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.413 ' HA ' HG21 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.451 HG11 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.447 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.507 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.409 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.451 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.531 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.543 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.434 HG22 HD22 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.447 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.537 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.507 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.405 ' HG2' HG23 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.879 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.879 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.513 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.572 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.513 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.572 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.744 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.552 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.744 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.476 ' O ' HD21 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.559 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.415 HG12 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.524 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.541 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.524 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.537 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.541 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.415 ' HB2' HG12 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.552 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.474 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.451 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.474 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.413 HG21 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.451 ' HD3' HG11 ' A' ' 15' ' ' VAL . 57.0 Cg_endo -71.43 64.86 2.89 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.532 ' HA ' HG13 ' A' ' 66' ' ' ILE . 8.1 mttm 59.41 37.48 23.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.571 -178.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -72.93 98.63 2.52 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 173.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.61 ' HG3' ' H ' ' A' ' 86' ' ' ASN . 22.9 tptm -132.72 177.64 7.47 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.976 -172.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.61 ' H ' ' HG3' ' A' ' 85' ' ' LYS . 10.2 t-20 67.69 -165.05 0.21 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 123.334 0.396 . . . . 0.0 110.319 173.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -112.62 107.9 16.77 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 177.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -123.65 -53.65 1.77 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.489 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.41 -121.55 3.99 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.335 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.72 116.84 16.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.837 0.351 . . . . 0.0 110.733 -179.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -92.15 133.94 29.35 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.166 176.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.486 ' HG3' ' O ' ' A' ' 4' ' ' SER . 46.7 Cg_endo -69.27 116.65 4.61 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.664 2.243 . . . . 0.0 112.327 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 3.5 Cg_exo -77.51 168.69 22.31 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.917 2.412 . . . . 0.0 111.556 177.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.2 p -82.72 74.85 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.326 1.06 . . . . 0.0 110.001 176.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -155.01 90.62 0.12 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.668 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 15.3 pt -111.47 108.39 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.165 0.507 . . . . 0.0 110.956 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 46.9 m -79.81 130.0 34.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.668 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.3 t30 . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.555 -0.736 . . . . 0.0 110.562 179.692 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 tpt . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.605 0.716 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -82.2 113.69 20.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.439 -177.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.1 p -95.2 0.02 53.61 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.098 0.475 . . . . 0.0 110.872 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.509 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 18.2 m -85.81 103.5 14.62 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.978 177.486 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.443 HG23 ' HD2' ' A' ' 6' ' ' PRO . 59.5 mt -107.7 141.14 22.41 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.988 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.465 ' CD ' ' HB3' ' A' ' 92' ' ' PRO . 17.9 Cg_endo -62.09 150.64 85.82 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.612 2.208 . . . . 0.0 112.657 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.437 HG21 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.41 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.507 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.527 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.595 HG21 HD22 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.547 HG12 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.551 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.551 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.507 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.426 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.403 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.426 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.53 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.713 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.609 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.509 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.515 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.486 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.428 HG12 ' HB3' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.473 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.547 ' CE2' HG12 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.435 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.485 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.428 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.515 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.713 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.507 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 26.6 m170 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.428 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 58.9 Cg_endo -72.47 52.91 2.09 Favored 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.473 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 30.8 mttm 63.92 -76.93 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.312 0.645 . . . . 0.0 111.434 -174.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 66.3 13.46 9.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 121.121 0.486 . . . . 0.0 111.294 176.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 35.7 mtpt -91.91 39.39 1.01 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.949 0.404 . . . . 0.0 111.218 -178.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -67.5 -41.64 84.18 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 5.6 tpt180 -152.85 138.85 18.15 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 176.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.95 -50.2 44.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.893 0.377 . . . . 0.0 110.481 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.37 -99.23 0.56 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.814 176.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.07 128.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.241 0.544 . . . . 0.0 111.162 -176.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.7 m -83.47 129.08 61.57 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.908 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.465 ' HB3' ' CD ' ' A' ' 6' ' ' PRO . 14.4 Cg_endo -57.57 118.83 5.77 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.493 2.795 . . . . 0.0 113.519 -176.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.24 122.2 5.11 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.617 2.212 . . . . 0.0 111.917 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 48.5 t -98.59 -48.5 12.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.163 0.506 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 88.04 170.26 45.85 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.932 -0.651 . . . . 0.0 111.803 -178.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.421 HG13 ' N ' ' A' ' 97' ' ' THR . 23.2 pt -76.26 -45.77 34.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 177.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.421 ' N ' HG13 ' A' ' 96' ' ' ILE . 18.9 m -149.56 -56.84 0.19 Allowed 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 . . . . . 0 C--O 1.244 0.769 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.293 174.706 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.1 ptp . . . . . 0 N--CA 1.481 1.098 0 CA-C-O 120.874 0.369 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.4 tppt? -135.43 94.71 3.15 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.3 m -117.83 42.79 2.55 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.295 0.569 . . . . 0.0 110.532 -176.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.613 ' HB2' HG13 ' A' ' 94' ' ' VAL . 14.6 m -78.4 106.11 10.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.082 177.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -114.0 133.43 22.33 Favored Pre-proline 0 C--N 1.32 -0.693 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.227 -176.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.411 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 37.0 Cg_endo -67.25 155.6 69.85 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.837 2.358 . . . . 0.0 112.624 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.526 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.543 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.528 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.404 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.419 HG23 HD22 ' A' ' 18' ' ' LEU . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.543 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.565 HG12 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.528 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.72 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.72 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.715 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.57 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.567 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.55 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.497 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.587 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.55 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.527 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.527 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.433 HG12 ' HB3' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.558 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.446 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.558 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.565 ' CE2' HG12 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.453 HG13 ' HA ' ' A' ' 83' ' ' LYS . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.433 ' HB3' HG12 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.587 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.2 m80 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.526 HG23 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo -72.46 61.91 3.54 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.453 ' HA ' HG13 ' A' ' 66' ' ' ILE . 0.6 OUTLIER 61.58 18.75 9.79 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.328 170.82 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -81.7 80.23 8.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.569 0.699 . . . . 0.0 109.769 172.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -59.3 -44.86 92.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.254 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -167.03 85.48 0.26 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.633 171.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.729 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 0.7 OUTLIER -67.07 -54.92 16.93 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.541 -174.157 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . 0.522 ' OE1' ' HB3' ' A' ' 87' ' ' ARG . 1.7 mp0 -82.8 158.77 22.66 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.774 175.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -89.92 44.55 3.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.796 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 29.6 m -96.13 146.54 7.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 120.903 0.382 . . . . 0.0 111.02 -176.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 5.0 m -129.78 102.72 17.72 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.397 0.617 . . . . 0.0 110.793 177.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.411 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 88.6 Cg_endo -82.36 177.16 7.34 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.865 2.376 . . . . 0.0 111.666 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -61.88 104.64 0.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.12 1.88 . . . . 0.0 111.508 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.613 HG13 ' HB2' ' A' ' 4' ' ' SER . 35.9 m -84.24 -14.24 11.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.896 -176.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -166.94 110.1 0.38 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.039 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 37.9 pt -99.82 -33.33 3.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.133 0.492 . . . . 0.0 110.602 177.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.0 m -95.98 87.64 4.65 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 20.5 m120 . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.61 -0.71 . . . . 0.0 109.734 178.067 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.4 tpt . . . . . 0 N--CA 1.481 1.078 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? 73.44 112.5 0.06 Allowed 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.298 0.639 . . . . 0.0 111.333 179.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.1 t -84.29 83.29 8.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.1 m -131.84 123.11 26.87 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.035 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 64.2 mt -128.56 136.77 29.63 Favored Pre-proline 0 C--N 1.327 -0.391 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -177.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.574 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 36.6 Cg_endo -65.6 156.95 61.05 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.915 2.41 . . . . 0.0 112.855 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.525 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.715 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.493 HD22 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.522 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.428 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.56 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.715 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.476 HG12 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.493 ' HE2' HD22 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.803 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.803 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.582 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.434 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.534 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.416 HG21 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.582 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.534 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.433 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.49 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.535 HD13 ' HZ2' ' A' ' 71' ' ' LYS . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.658 ' HA3' HD11 ' A' ' 96' ' ' ILE . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.527 HD13 ' HA ' ' A' ' 94' ' ' VAL . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.517 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.475 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.435 HG13 ' HB3' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.537 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.549 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.476 ' CE1' HG12 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.454 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.475 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.435 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.517 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HZ2' HD13 ' A' ' 52' ' ' LEU . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.481 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.522 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 16.0 m170 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.428 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.481 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.454 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.525 HG23 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.498 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo -64.79 165.46 20.95 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.549 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 27.0 mttm -47.85 100.81 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.0 0.428 . . . . 0.0 110.534 171.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . 0.429 ' H ' HD13 ' A' ' 66' ' ' ILE . 7.1 t30 -137.75 81.57 1.87 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.428 0.632 . . . . 0.0 110.388 -174.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -117.02 -42.71 2.91 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 172.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 m120 64.67 -72.84 0.06 Allowed 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.961 172.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 7.8 tpt180 -170.32 -57.69 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -174.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -175.3 89.54 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 114.369 -1.287 . . . . 0.0 108.809 173.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.53 -51.6 55.46 Favored Glycine 0 C--N 1.329 0.172 0 CA-C-N 115.734 -0.666 . . . . 0.0 113.153 -174.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.5 p -159.73 145.9 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -110.6 97.61 33.29 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-O 121.292 0.568 . . . . 0.0 111.398 178.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.574 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 56.1 Cg_endo -90.56 173.38 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.402 2.734 . . . . 0.0 111.582 176.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.34 116.66 4.01 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.077 1.852 . . . . 0.0 111.426 174.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.527 ' HA ' HD13 ' A' ' 55' ' ' LEU . 29.8 t -76.95 88.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.082 0.468 . . . . 0.0 110.632 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.01 -134.03 4.77 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.737 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.658 HD11 ' HA3' ' A' ' 53' ' ' GLY . 44.2 mm -128.51 -71.88 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.1 m -122.3 97.69 5.58 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 16.2 m120 . . . . . 0 C--O 1.25 1.102 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.737 -175.571 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.461 ' HA ' ' OE2' ' A' ' 88' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.674 0.273 . . . . 0.0 111.191 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -107.71 92.69 4.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.5 m -66.3 135.06 53.86 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.351 0.596 . . . . 0.0 112.573 -170.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -82.37 127.29 33.11 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.439 HG23 ' HD2' ' A' ' 6' ' ' PRO . 58.2 mt -125.67 139.21 33.54 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.43 -169.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.439 ' HD2' HG23 ' A' ' 5' ' ' ILE . 40.0 Cg_endo -67.94 158.74 56.01 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.551 2.167 . . . . 0.0 112.432 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.419 ' O ' ' HB2' ' A' ' 14' ' ' ALA . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.453 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.744 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.547 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.54 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.413 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.467 ' HB2' HD23 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.503 ' HB3' ' HB3' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.43 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.467 HD23 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.431 HG23 HD21 ' A' ' 18' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.744 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.565 HG12 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.419 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.527 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.549 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.503 ' HB3' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.512 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.438 HG23 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.549 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.44 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.72 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 98' ' ' ASN . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.495 ' O ' ' HD2' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.661 HD11 ' HA ' ' A' ' 94' ' ' VAL . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.403 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.509 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.438 HG12 HG23 ' A' ' 44' ' ' ILE . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.522 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.565 ' CE2' HG12 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.497 HG13 ' HA ' ' A' ' 83' ' ' LYS . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.509 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . 0.403 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.72 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.446 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo -72.67 59.6 3.39 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.522 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 45.4 mttm 67.14 -68.02 0.16 Allowed 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.214 -171.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 47.1 t30 60.7 89.2 0.07 Allowed 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.76 0.662 . . . . 0.0 111.571 177.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -111.39 -54.56 2.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.475 176.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.7 t30 60.7 -81.41 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.112 -177.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 27.5 ttm180 179.88 125.3 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . 0.461 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 13.5 pt-20 -93.28 -172.87 3.07 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 138.04 -45.99 1.02 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.4 t -107.34 117.02 52.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.36 129.79 76.55 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 121.023 0.44 . . . . 0.0 110.824 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.95 162.86 40.62 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 122.643 2.229 . . . . 0.0 112.413 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.53 132.87 48.35 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.841 2.361 . . . . 0.0 112.584 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.661 ' HA ' HD11 ' A' ' 55' ' ' LEU . 27.4 m -84.66 -167.57 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.029 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -99.27 124.04 8.1 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.41 177.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 11.4 pt -71.17 92.79 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.096 0.474 . . . . 0.0 111.368 -178.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.9 m 61.34 74.75 0.43 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.499 -177.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.501 ' HB3' ' HA3' ' A' ' 53' ' ' GLY . 13.2 m120 . . . . . 0 C--O 1.247 0.957 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.19 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.827 0.346 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -143.39 107.04 4.61 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 62.9 m -76.27 88.88 3.12 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.33 0.586 . . . . 0.0 110.973 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . 0.52 ' HB2' HD12 ' A' ' 55' ' ' LEU . 8.9 p -85.11 104.26 14.85 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.764 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 52.0 mt -121.19 134.79 24.52 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.922 -174.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.478 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 48.6 Cg_endo -70.93 159.32 52.89 Favored 'Trans proline' 0 C--O 1.237 0.467 0 C-N-CA 122.54 2.16 . . . . 0.0 112.377 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.413 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.708 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.413 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.503 ' HG ' ' HB2' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.404 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.451 ' HB2' HD22 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.455 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.401 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.451 HD22 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.708 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.635 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.503 ' HB2' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.426 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.426 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.546 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.401 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.409 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.466 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.546 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.58 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.594 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.592 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.58 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.594 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.52 HD12 ' HB2' ' A' ' 4' ' ' SER . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.545 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.545 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.635 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.506 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.424 ' HB3' HG13 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.592 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.444 ' HZ3' HD11 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.455 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.444 HD11 ' HZ3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.506 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.413 HG23 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.12 63.98 2.61 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.538 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 47.3 mttm 50.73 52.37 15.04 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.55 -175.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -74.83 98.7 3.58 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 174.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 38.8 pttt -154.66 168.08 27.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.18 -172.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 t30 71.07 -58.73 0.56 Allowed 'General case' 0 N--CA 1.471 0.598 0 O-C-N 123.977 0.798 . . . . 0.0 111.912 173.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -78.68 102.16 7.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -75.42 109.69 9.16 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.241 -176.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -77.81 -94.54 0.24 Allowed Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.023 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 62.0 t -105.06 108.34 24.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 p -89.01 131.63 40.53 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.314 -175.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.478 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 96.3 Cg_endo -81.06 177.17 8.17 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 123.052 2.502 . . . . 0.0 112.012 177.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -55.49 151.4 37.98 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.385 2.057 . . . . 0.0 112.035 174.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -66.62 -36.92 78.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -177.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 155.94 52.32 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.29 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 59.1 mt -81.26 92.97 2.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.023 0.44 . . . . 0.0 109.974 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.2 t -174.09 149.55 1.46 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.717 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.476 -0.773 . . . . 0.0 110.034 179.433 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.3 mmt . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.939 0.399 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 tppt? -113.96 -46.36 3.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.3 m 58.9 80.37 0.19 Allowed 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.769 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.3 m -95.55 114.14 25.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.65 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.556 HD12 ' HB2' ' A' ' 86' ' ' ASN . 55.6 mt -127.01 133.39 25.0 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.925 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.766 ' HB3' HG22 ' A' ' 94' ' ' VAL . 30.9 Cg_endo -65.94 155.16 70.83 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.676 2.251 . . . . 0.0 112.496 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.404 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.528 ' HA ' HG23 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.418 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.557 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.457 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB2' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.582 HD23 ' HG1' ' A' ' 29' ' ' THR . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . 0.557 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' THR . . . . . 0.582 ' HG1' HD23 ' A' ' 26' ' ' LEU . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.418 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.447 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.478 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.51 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB2' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.633 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.633 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.472 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.51 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.766 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.511 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' TYR . . . . . 0.518 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.42 HG12 ' HB1' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.59 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.69 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.405 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.405 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.518 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.42 ' HB1' HG12 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.484 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 14.2 m170 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.484 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.433 HG22 HG23 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.443 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.528 HG23 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.25 137.81 63.09 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' LYS . . . . . 0.69 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 16.2 mttm -30.44 99.85 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 O-C-N 124.348 1.03 . . . . 0.0 112.77 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 -128.65 90.81 3.12 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.956 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . 0.791 ' HD3' ' H ' ' A' ' 85' ' ' LYS . 0.0 OUTLIER -72.16 99.94 2.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.479 0.657 . . . . 0.0 109.691 178.495 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.556 ' HB2' HD12 ' A' ' 5' ' ' ILE . 26.4 t-20 -62.47 142.5 57.88 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.548 -179.19 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -73.24 73.81 1.29 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.524 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -70.61 172.8 7.99 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.369 0.604 . . . . 0.0 111.393 -175.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 103.31 -40.02 2.59 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -165.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.03 86.28 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 169.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.3 m -80.61 139.07 50.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.637 -173.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -67.41 121.66 8.8 Favored 'Trans proline' 0 CA--C 1.529 0.244 0 C-N-CA 122.994 2.462 . . . . 0.0 112.277 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -74.42 160.54 41.65 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.592 2.195 . . . . 0.0 112.222 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.766 HG22 ' HB3' ' A' ' 6' ' ' PRO . 45.0 t -92.94 -53.87 8.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.934 179.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.16 -130.19 5.82 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.316 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.1 mt -116.15 -47.03 4.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.893 0.378 . . . . 0.0 110.661 -178.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.6 p -128.36 124.6 36.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -177.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.4 t30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.819 176.406 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.534 ' HB2' HG22 ' A' ' 8' ' ' THR . 30.0 Cg_endo . . . . . 0 C--O 1.236 0.392 0 CA-C-O 121.169 0.404 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.534 HG22 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 8' ' ' THR . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 13' ' ' ARG . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.628 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.611 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.634 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.418 HD13 HD22 ' A' ' 18' ' ' LEU . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.606 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.412 HG23 HD21 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.586 HG11 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.628 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.566 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.786 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.786 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.553 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.553 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.823 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.41 ' HB3' ' O ' ' A' ' 46' ' ' ARG . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.823 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.57 ' CB ' HD23 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' HB2' ' A' ' 69' ' ' ALA . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.433 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CE1' HG11 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.433 HG12 ' HG3' ' A' ' 61' ' ' GLU . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.529 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.676 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.577 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.611 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.676 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.577 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.529 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo . . . . . 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.462 -0.331 0 CA-C-O 121.0 0.333 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 32' ' ' VAL . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.59 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.477 ' HB2' HD21 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.579 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.486 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.477 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.59 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.638 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.638 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.541 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.486 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.566 HG21 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.459 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.558 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.478 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.437 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.49 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.566 ' HA ' HG21 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.401 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.455 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.437 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.478 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 14' ' ' ALA . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HB2' HG22 ' A' ' 8' ' ' THR . 20.1 Cg_endo . . . . . 0 C--O 1.235 0.347 0 CA-C-O 121.158 0.399 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 13' ' ' ARG . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.531 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.675 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.558 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.451 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.461 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.568 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.0 m120 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.461 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.442 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.675 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.525 HG11 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.558 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.414 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.414 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.582 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.613 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.444 HG22 HG12 ' A' ' 59' ' ' VAL . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.613 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.586 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.702 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.586 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.571 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.571 ' HB2' HD23 ' A' ' 52' ' ' LEU . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.502 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.45 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.525 ' CE2' HG11 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.45 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.512 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.502 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.482 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.702 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.56 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.403 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo . . . . . 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.538 ' HB2' HG22 ' A' ' 8' ' ' THR . 41.3 Cg_endo . . . . . 0 C--O 1.236 0.421 0 CA-C-O 121.154 0.397 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.538 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' HH11 ' A' ' 13' ' ' ARG . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.757 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.548 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.457 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.59 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.4 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.452 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.457 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.757 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.677 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.432 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 37' ' ' GLU . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.88 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.88 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.544 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.492 HG21 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.568 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.515 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.688 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.568 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 57' ' ' TYR . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.401 ' HA ' ' HD3' ' A' ' 54' ' ' ARG . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.591 ' HB2' HD21 ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.496 HG11 ' HB2' ' A' ' 69' ' ' ALA . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.423 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.677 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.423 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.545 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.688 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.59 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.4 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.534 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo . . . . . 0 C--O 1.237 0.429 0 CA-C-O 120.891 0.288 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.516 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.613 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.444 ' HB2' HD21 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.574 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m120 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.457 HD13 HD22 ' A' ' 18' ' ' LEU . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.444 HD21 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.613 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.405 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.489 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.574 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.449 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.468 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.729 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.594 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.729 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 54' ' ' ARG . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.442 ' O ' HD22 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.556 ' CB ' HD23 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.49 ' CE2' HG11 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.493 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.444 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.594 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.516 HG22 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo . . . . . 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 C--O 1.238 0.476 0 CA-C-O 121.18 0.408 . . . . 0.0 112.689 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.411 HG13 ' CG2' ' A' ' 81' ' ' THR . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 13' ' ' ARG . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.466 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG21 ' CE1' ' A' ' 65' ' ' TYR . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.53 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.462 ' HB2' HD21 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.488 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.532 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.443 HD13 HD22 ' A' ' 18' ' ' LEU . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.556 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.593 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.53 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HG2' HG22 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.69 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.69 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.485 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.476 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.539 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.542 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.473 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.53 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.563 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.593 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.542 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.488 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 14' ' ' ALA . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo . . . . . 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HG2' ' HG2' ' A' ' 9' ' ' GLU . 10.2 Cg_endo . . . . . 0 C--O 1.235 0.352 0 N-CA-C 112.854 0.29 . . . . 0.0 112.854 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.421 ' HG2' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.418 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.55 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.561 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.437 ' HB2' HD11 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.657 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.9 m120 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.437 HD11 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.561 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.422 HG23 HD21 ' A' ' 18' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.567 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.617 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.55 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.873 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.873 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.491 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.444 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.508 HG22 HG12 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.444 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.625 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.429 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.504 ' HB2' HD21 ' A' ' 52' ' ' LEU . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.55 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.667 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.542 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.667 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.617 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.55 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.429 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.657 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.418 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.495 ' HB2' HG22 ' A' ' 8' ' ' THR . 19.3 Cg_endo . . . . . 0 C--O 1.237 0.464 0 CA-C-O 120.965 0.319 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.495 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' A' ' 81' ' ' THR . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.541 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.563 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.575 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.414 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.432 HD13 HD22 ' A' ' 18' ' ' LEU . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.595 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.541 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.933 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.933 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.481 HG22 HG12 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.65 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.413 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.536 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.658 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.658 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.684 ' CE2' HG11 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.51 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.489 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.536 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.487 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.508 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.575 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.414 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.508 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.51 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.499 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo . . . . . 0 C--O 1.236 0.396 0 CA-C-O 121.141 0.392 . . . . 0.0 112.685 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.499 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.564 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.705 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.47 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.449 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.449 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.47 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.705 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.522 HG11 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.531 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.672 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.672 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.416 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.473 HG22 HG12 ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.572 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.475 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.685 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.572 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.557 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.404 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.441 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.612 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.612 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.522 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.557 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.441 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.685 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.438 ' HE2' HD12 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.438 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.564 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo . . . . . 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.237 0.453 0 CA-C-O 121.102 0.376 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.449 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.408 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.612 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.549 HG11 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.494 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.622 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.622 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.531 HG13 HG22 ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.479 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.626 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.521 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.588 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.541 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.549 ' CE2' HG11 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.541 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.626 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.489 HG22 ' HA ' ' A' ' 14' ' ' ALA . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo . . . . . 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.236 0.422 0 CA-C-O 120.971 0.321 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.583 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.55 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.533 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.489 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.418 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.62 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.419 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.583 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.737 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.737 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.561 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.561 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.523 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.698 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.488 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.464 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.488 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 ' HB2' ' A' ' 69' ' ' ALA . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.508 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.508 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.411 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.464 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.698 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.538 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.55 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.533 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.538 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo . . . . . 0 C--O 1.236 0.384 0 CA-C-O 121.302 0.459 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.606 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.565 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.402 HD21 ' OG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.402 ' OG1' HD21 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.606 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.918 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.918 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.539 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.565 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 42' ' ' ALA . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.48 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.585 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.616 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.634 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.414 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.48 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.616 ' HB2' HD21 ' A' ' 52' ' ' LEU . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.566 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.469 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.566 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.634 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.509 ' HE2' HD12 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.509 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo . . . . . 0 C--O 1.236 0.385 0 CA-C-O 121.109 0.379 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.691 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.483 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.439 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.423 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.552 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.434 HD13 HD22 ' A' ' 18' ' ' LEU . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.691 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.543 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.483 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.421 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.629 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.629 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.6 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.552 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.573 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.6 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.504 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.531 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.549 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.543 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.579 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 67' ' ' GLY . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.497 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.497 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 58' ' ' SER . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.554 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.46 ' HE2' HD12 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.46 HD12 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.485 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo . . . . . 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.522 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.8 Cg_endo . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.237 0.432 . . . . 0.0 112.635 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.466 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.505 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.468 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.569 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.44 HD13 HD22 ' A' ' 18' ' ' LEU . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.548 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.426 HG23 HD21 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.552 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.505 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.402 ' HG2' HG22 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.442 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.92 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.92 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.518 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.569 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.427 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.575 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.753 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.573 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.753 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.545 ' O ' HD22 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.509 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.63 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.534 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.546 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.552 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.546 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.509 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.573 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.475 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.475 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.427 HG22 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.445 ' HD3' HG13 ' A' ' 15' ' ' VAL . 57.0 Cg_endo . . . . . 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.9 Cg_endo . . . . . 0 C--O 1.235 0.352 0 CA-C-O 121.19 0.412 . . . . 0.0 112.657 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.462 HG22 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.428 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.537 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.577 HD21 HG23 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.577 HG23 HD21 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.537 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.558 HG11 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.54 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.544 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.516 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.443 HG22 HG12 ' A' ' 59' ' ' VAL . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.547 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.728 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.523 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.509 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.436 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.558 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.436 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.523 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 C--O 1.235 0.374 0 CA-C-O 121.256 0.44 . . . . 0.0 112.624 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.544 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.557 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.529 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.427 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HB3' HD11 ' A' ' 27' ' ' LEU . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.43 HD13 HD22 ' A' ' 18' ' ' LEU . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.428 HD11 ' HB3' ' A' ' 21' ' ' ASP . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.557 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.747 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.747 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.741 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.579 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.467 HG22 HG12 ' A' ' 59' ' ' VAL . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.579 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.514 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.604 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.548 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.548 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.567 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.449 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.567 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE2' HG11 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.449 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.522 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.483 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 63.0 m-70 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.483 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.407 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.6 Cg_endo . . . . . 0 C--O 1.235 0.333 0 CA-C-O 121.249 0.437 . . . . 0.0 112.855 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.407 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.542 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.515 HD21 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.567 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.455 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.419 ' HB3' HD11 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.437 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.452 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.419 HD11 ' HB3' ' A' ' 21' ' ' ASP . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.567 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.729 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.483 HG11 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.428 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.515 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.812 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.812 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.591 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.543 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.461 HG22 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.591 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.543 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.518 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.475 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.492 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.522 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.492 ' HB2' HD23 ' A' ' 52' ' ' LEU . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.492 HG11 ' HB2' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.546 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CE1' HG11 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.48 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.476 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.492 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.522 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.479 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.479 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.48 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.502 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo . . . . . 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.236 0.411 0 CA-C-O 121.183 0.409 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.47 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.575 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.429 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.489 ' HB2' HD21 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.502 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.441 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.489 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.549 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' THR . . . . . 0.441 ' OG1' HD21 ' A' ' 26' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.774 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.579 HG11 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.404 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.418 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.553 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.502 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.485 HG22 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.54 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.744 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.489 ' HD2' ' O ' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.2 mp0 -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.579 ' CE2' HG11 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.744 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.487 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.487 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.47 HG22 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo . . . . . 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 C--O 1.237 0.467 0 CA-C-O 121.004 0.335 . . . . 0.0 112.377 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HZ ' ' A' ' 70' ' ' PHE . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.415 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.721 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.426 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.477 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.479 HD21 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.721 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.646 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.427 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.427 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.537 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.595 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.603 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.607 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.595 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.603 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.477 ' HB2' HD23 ' A' ' 52' ' ' LEU . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.537 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.561 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.646 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' PHE . . . . . 0.412 ' HZ ' HG21 ' A' ' 10' ' ' VAL . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.607 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.407 ' HG3' HD12 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.477 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.407 HD12 ' HG3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.432 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.415 HG22 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.415 ' HB2' HG22 ' A' ' 8' ' ' THR . 30.9 Cg_endo . . . . . 0 C--O 1.236 0.413 0 CA-C-O 121.15 0.396 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.415 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.549 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.482 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.563 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.482 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ASP . . . . . 0.563 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.453 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.504 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.646 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.646 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.78 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.593 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' TYR . . . . . 0.593 ' HB2' HD21 ' A' ' 52' ' ' LEU . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.595 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 17.3 mp0 -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.459 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.463 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.78 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.9 m-70 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.459 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo . . . . . 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.4 mmm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.755 0.312 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.424 ' HB2' ' HE2' ' A' ' 2' ' ' LYS . 9.8 tppt? -79.7 -59.39 2.76 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 177.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.9 m 69.87 135.32 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.318 -0.856 . . . . 0.0 112.279 177.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.1 m -82.49 104.52 12.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.474 175.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' HD2' ' A' ' 6' ' ' PRO . 87.1 mt -92.49 139.18 23.75 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.574 -169.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 30.0 Cg_endo -63.84 153.2 76.96 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.55 2.167 . . . . 0.0 112.942 -177.334 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.534 HG22 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 8' ' ' THR . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.509 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.628 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.611 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.634 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.418 HD13 HD22 ' A' ' 18' ' ' LEU . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.606 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.412 HG23 HD21 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.586 HG11 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.628 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.566 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.786 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.786 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.553 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.553 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.823 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.41 ' HB3' ' O ' ' A' ' 46' ' ' ARG . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.823 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.57 ' CB ' HD23 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' HB2' ' A' ' 69' ' ' ALA . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.433 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CE1' HG11 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.433 HG12 ' HG3' ' A' ' 61' ' ' GLU . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.529 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.676 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.577 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.611 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.676 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.577 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.529 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo -74.72 59.57 4.99 Favored 'Trans proline' 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 46.2 mttm 46.67 52.57 11.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.425 -173.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.509 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 27.0 t-20 -64.2 106.9 1.17 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.656 -176.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -122.69 7.03 9.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.099 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -100.9 141.48 33.73 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.732 0.301 . . . . 0.0 110.55 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.792 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 1.2 mmp_? 55.64 73.81 0.41 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.576 0.703 . . . . 0.0 110.951 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.07 27.46 9.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.607 -178.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.53 45.33 3.07 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.411 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.8 p -143.11 124.29 11.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 21.2 m -105.38 131.9 21.35 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 111.289 -177.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.586 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 97.5 Cg_endo -88.01 123.15 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.805 2.336 . . . . 0.0 112.335 174.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -57.53 141.3 95.14 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.695 2.263 . . . . 0.0 111.837 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.65 -10.17 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 112.053 -175.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 151.96 10.24 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.053 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 8.8 mt -88.8 34.4 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.254 0.549 . . . . 0.0 110.279 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 23.6 m -69.6 97.81 1.08 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.41 -0.805 . . . . 0.0 109.595 178.68 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -79.23 139.15 37.99 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.516 -0.179 . . . . 0.0 110.516 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m 74.46 8.38 4.46 Favored 'General case' 0 N--CA 1.466 0.37 0 O-C-N 123.86 0.725 . . . . 0.0 111.955 175.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.32 141.2 48.47 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 174.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.46 HG23 ' HD2' ' A' ' 6' ' ' PRO . 51.4 mt -124.53 140.73 35.98 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -174.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.607 ' HD3' ' HD3' ' A' ' 92' ' ' PRO . 31.1 Cg_endo -67.41 154.97 72.27 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.149 1.899 . . . . 0.0 112.539 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.413 ' HB3' ' ND2' ' A' ' 84' ' ' ASN . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 32' ' ' VAL . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.59 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.477 ' HB2' HD21 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.579 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.486 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.477 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.59 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.638 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.638 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.541 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.486 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.566 HG21 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.459 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.558 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.478 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.437 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.49 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.566 ' HA ' HG21 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.504 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.401 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.455 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.437 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.478 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 14' ' ' ALA . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -72.88 55.64 2.83 Favored 'Trans proline' 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.504 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 41.6 mttm 60.07 22.78 11.98 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.061 -171.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.413 ' ND2' ' HB3' ' A' ' 13' ' ' ARG . 38.0 t-20 -70.23 114.27 8.21 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.589 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 45.5 pttt -128.74 7.88 5.72 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.772 -1.103 . . . . 0.0 109.4 -176.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 87' ' ' ARG . 73.6 m-20 64.0 -85.02 0.02 OUTLIER 'General case' 0 C--O 1.231 0.096 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.725 -169.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 86' ' ' ASN . 48.5 ttp180 164.08 -47.8 0.0 OUTLIER 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 177.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -68.87 148.48 50.17 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.693 -1.139 . . . . 0.0 110.049 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -78.36 65.69 3.33 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.001 178.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 m -83.76 106.41 14.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.278 0.561 . . . . 0.0 110.769 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -118.98 122.94 29.27 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.883 -178.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.607 ' HD3' ' HD3' ' A' ' 6' ' ' PRO . 76.8 Cg_endo -75.48 133.26 15.68 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 123.037 2.491 . . . . 0.0 112.654 -179.077 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -61.39 135.41 57.44 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.583 2.189 . . . . 0.0 111.754 176.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.2 p -73.58 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.683 0.754 . . . . 0.0 110.839 -178.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -85.67 20.97 16.0 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 112.848 -177.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.4 mm -79.03 -40.85 22.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.405 0.621 . . . . 0.0 109.537 176.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 t -87.6 135.98 33.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.319 178.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.558 -0.734 . . . . 0.0 110.592 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.5 tpp . . . . . 0 N--CA 1.48 1.065 0 CA-C-O 121.048 0.451 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -77.34 92.29 3.91 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.27 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -90.09 7.75 36.23 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.74 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.536 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 13.2 m -82.47 101.41 10.66 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.19 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.489 HG23 ' HD2' ' A' ' 6' ' ' PRO . 75.0 mt -109.96 139.24 21.13 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.763 -174.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.606 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 20.1 Cg_endo -62.66 151.37 83.96 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.52 2.147 . . . . 0.0 112.568 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.476 HH12 ' CD ' ' A' ' 88' ' ' GLU . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.531 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.675 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.558 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.451 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.461 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.568 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.0 m120 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.461 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.442 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.675 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.525 HG11 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.558 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.414 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.414 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.582 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.613 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.444 HG22 HG12 ' A' ' 59' ' ' VAL . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.613 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.586 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.702 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.586 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.571 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.536 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.571 ' HB2' HD23 ' A' ' 52' ' ' LEU . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.502 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.45 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.51 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.525 ' CE2' HG11 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.45 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.512 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.502 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.482 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.702 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.56 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.403 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo -71.44 59.36 2.53 Favored 'Trans proline' 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.51 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.5 mttm 60.36 27.86 17.45 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.982 -174.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -66.0 107.57 1.92 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.723 174.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.453 ' HG2' ' OD1' ' A' ' 86' ' ' ASN . 43.5 tttm -145.29 105.35 4.04 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.25 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.459 ' HA ' ' HB ' ' A' ' 90' ' ' VAL . 3.2 p-10 42.43 44.01 3.3 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 123.953 0.783 . . . . 0.0 111.238 -175.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -43.81 -70.61 0.1 Allowed 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 114.779 -1.1 . . . . 0.0 112.851 -174.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.476 ' CD ' HH12 ' A' ' 13' ' ' ARG . 0.9 OUTLIER -98.79 35.03 1.93 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.797 179.684 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 86.5 34.9 11.09 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.44 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 86' ' ' ASN . 52.1 t -74.86 95.63 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.927 0.394 . . . . 0.0 110.661 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.4 m -94.35 115.59 65.43 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.262 175.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.606 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 52.7 Cg_endo -72.85 118.51 5.6 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.411 2.074 . . . . 0.0 112.887 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -79.97 91.32 1.18 Allowed 'Trans proline' 0 N--CA 1.455 -0.794 0 C-N-CA 122.455 2.103 . . . . 0.0 111.321 176.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.3 m -69.69 108.27 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-O 121.577 0.703 . . . . 0.0 111.813 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -148.32 53.19 0.53 Allowed Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.488 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 27.3 pt -83.39 -31.26 8.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.74 0.305 . . . . 0.0 111.158 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.0 p -108.18 137.05 46.82 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.51 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.441 -0.79 . . . . 0.0 110.169 -177.637 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.1 mtt . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.959 0.409 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -138.75 93.62 2.74 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 m -82.6 82.97 7.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.53 0.681 . . . . 0.0 111.011 -176.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.411 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 12.1 p -126.26 155.67 41.53 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.198 -0.91 . . . . 0.0 108.869 173.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.416 HG23 ' HD2' ' A' ' 6' ' ' PRO . 55.0 mt -131.22 137.78 31.39 Favored Pre-proline 0 C--N 1.322 -0.612 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.538 ' HB2' HG22 ' A' ' 8' ' ' THR . 41.3 Cg_endo -69.42 155.03 68.21 Favored 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.074 1.85 . . . . 0.0 112.254 -179.06 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.538 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' HH11 ' A' ' 13' ' ' ARG . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.757 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.548 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.457 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.59 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.4 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.452 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.457 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.757 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.677 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.432 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 37' ' ' GLU . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.88 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.88 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.544 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.492 HG21 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.568 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.515 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.688 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.568 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 57' ' ' TYR . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.57 ' HG2' ' HA ' ' A' ' 98' ' ' ASN . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' SER . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.591 ' HB2' HD21 ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.496 HG11 ' HB2' ' A' ' 69' ' ' ALA . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.423 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.544 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.677 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.423 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.545 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.688 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.59 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.4 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.534 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.48 54.81 2.46 Favored 'Trans proline' 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.544 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.1 mttm 63.83 31.76 13.85 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.863 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 5.4 t30 -70.06 96.74 1.09 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -102.21 -81.67 0.49 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.775 -176.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.623 ' HA ' HG21 ' A' ' 90' ' ' VAL . 4.2 p-10 -135.77 118.74 16.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.185 0.517 . . . . 0.0 110.825 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -138.77 -78.05 0.35 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.705 176.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -157.34 125.3 5.44 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.408 -176.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 82.04 2.0 90.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.458 177.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.623 HG21 ' HA ' ' A' ' 86' ' ' ASN . 34.6 m -89.77 -0.15 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.831 0.348 . . . . 0.0 111.28 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -78.14 121.93 84.61 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 121.221 0.534 . . . . 0.0 111.197 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.491 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 50.1 Cg_endo -68.57 136.3 35.91 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.951 2.434 . . . . 0.0 112.715 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.464 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 6.4 Cg_exo -73.24 104.68 1.83 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.548 2.165 . . . . 0.0 109.88 171.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.7 m -59.44 131.96 24.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.188 0.518 . . . . 0.0 111.868 -171.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 81.11 -58.52 4.82 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.45 -0.795 . . . . 0.0 113.202 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 46.7 mm -95.47 97.47 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.987 0.423 . . . . 0.0 111.737 -174.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 t -176.8 132.14 0.19 Allowed 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.989 175.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.57 ' HA ' ' HG2' ' A' ' 54' ' ' ARG . 8.8 p30 . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.077 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.478 0.963 0 CA-C-O 120.967 0.413 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? -103.09 107.93 18.93 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 m -64.75 116.56 6.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.427 0.632 . . . . 0.0 112.265 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 26.8 p -91.39 126.49 36.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.257 173.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 6' ' ' PRO . 63.6 mt -133.82 137.82 29.46 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.861 -0.154 . . . . 0.0 110.752 -172.287 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.548 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 56.4 Cg_endo -71.64 160.92 46.88 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.669 2.246 . . . . 0.0 112.526 177.744 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.516 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.613 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.444 ' HB2' HD21 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.574 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m120 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.457 HD13 HD22 ' A' ' 18' ' ' LEU . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.444 HD21 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.613 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.405 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.489 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.574 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.449 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.468 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.729 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.594 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.729 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 54' ' ' ARG . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.442 ' O ' HD22 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.556 ' CB ' HD23 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.453 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.49 ' CE2' HG11 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.493 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.444 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.594 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.516 HG22 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.01 142.48 99.44 Favored 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.453 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 15.8 mttm -45.38 105.31 0.06 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.94 0.4 . . . . 0.0 111.627 179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -140.14 133.82 30.37 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.628 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.471 ' HE3' ' HB3' ' A' ' 85' ' ' LYS . 1.0 OUTLIER -141.96 120.83 12.75 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.448 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -106.94 -171.1 1.82 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -87.81 32.24 0.74 Allowed 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.485 -0.135 . . . . 0.0 111.083 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 66.15 -85.78 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.285 0 O-C-N 123.628 0.58 . . . . 0.0 110.285 -175.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.33 -98.24 0.5 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 121.306 -0.473 . . . . 0.0 113.3 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.2 m -87.29 57.11 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.547 0.689 . . . . 0.0 111.138 -175.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.7 m -68.88 142.42 93.49 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.482 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.548 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 72.7 Cg_endo -75.31 159.79 39.83 Favored 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 122.892 2.394 . . . . 0.0 112.007 176.125 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.18 117.11 3.79 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.395 2.064 . . . . 0.0 111.186 174.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.0 m -76.54 132.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.171 0.51 . . . . 0.0 111.468 -177.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 142.82 -168.04 26.09 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.797 179.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm -97.18 127.05 49.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 20.6 p -81.38 68.46 7.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.937 -176.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 72.5 m-20 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.451 -0.785 . . . . 0.0 109.64 175.159 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.9 tmm? . . . . . 0 N--CA 1.477 0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mmmt -133.85 175.41 9.49 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.036 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -102.96 -28.42 12.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.001 0.429 . . . . 0.0 110.353 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.561 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 17.8 m -78.09 106.98 10.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.993 -178.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 84.0 mt -107.89 137.75 19.87 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.76 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' ILE . 18.6 Cg_endo -60.0 149.95 81.31 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 122.677 2.252 . . . . 0.0 112.689 -177.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.411 HG13 ' CG2' ' A' ' 81' ' ' THR . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.696 ' HB3' HD21 ' A' ' 84' ' ' ASN . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.466 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.41 HG21 ' CE1' ' A' ' 65' ' ' TYR . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.53 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.462 ' HB2' HD21 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.488 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.532 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.443 HD13 HD22 ' A' ' 18' ' ' LEU . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.556 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.593 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.53 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HG2' HG22 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.69 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.69 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.485 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.476 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.539 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.633 ' HA3' ' HA ' ' A' ' 96' ' ' ILE . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.561 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.542 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.473 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.53 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.563 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.605 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.593 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.542 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.488 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.609 ' HB ' ' OD1' ' A' ' 84' ' ' ASN . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo -70.54 53.93 1.42 Allowed 'Trans proline' 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.605 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 7.0 mttm 56.55 21.16 5.44 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.368 177.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.696 HD21 ' HB3' ' A' ' 13' ' ' ARG . 21.3 p-10 -87.06 111.98 21.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.603 0.716 . . . . 0.0 111.058 -177.699 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -95.21 29.3 2.52 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.393 -178.806 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HB3' HG11 ' A' ' 90' ' ' VAL . 23.4 t-20 72.78 159.32 0.22 Allowed 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.093 0.871 . . . . 0.0 109.554 -173.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.528 ' HA ' ' NE ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -54.26 -65.4 0.58 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.035 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 145.06 2.42 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 111.829 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 69.09 46.98 56.54 Favored Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.669 -0.696 . . . . 0.0 113.166 172.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.489 HG11 ' HB3' ' A' ' 86' ' ' ASN . 7.7 p -107.62 116.56 51.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.43 0.634 . . . . 0.0 111.079 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.7 t -120.71 97.66 48.38 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.532 174.247 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.493 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 27.6 Cg_endo -65.0 135.91 46.06 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.798 2.332 . . . . 0.0 112.551 -176.438 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 2.8 Cg_exo -75.91 138.43 20.9 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 123.018 2.479 . . . . 0.0 111.864 177.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 30.2 m -66.13 139.05 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.043 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -169.82 128.02 1.59 Allowed Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.376 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.633 ' HA ' ' HA3' ' A' ' 53' ' ' GLY . 11.2 pt -104.49 -38.57 4.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 176.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.523 ' HB ' ' O ' ' A' ' 96' ' ' ILE . 13.1 t 171.81 -43.07 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.446 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.476 ' HB2' ' O ' ' A' ' 97' ' ' THR . 7.0 t30 . . . . . 0 C--O 1.247 0.936 0 C-N-CA 124.037 0.935 . . . . 0.0 108.782 175.295 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.2 ptm . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -73.62 103.62 4.28 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.913 0.387 . . . . 0.0 110.206 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -116.38 98.93 6.85 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.199 0.523 . . . . 0.0 111.73 -175.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.42 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 14.9 m -92.55 101.87 14.31 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.212 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 27.0 mt -99.87 135.59 20.43 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.411 -166.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HG2' ' HG2' ' A' ' 9' ' ' GLU . 10.2 Cg_endo -55.09 151.09 36.12 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.603 2.869 . . . . 0.0 112.854 177.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.421 ' HG2' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.418 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.55 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.561 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.437 ' HB2' HD11 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.657 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.9 m120 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.437 HD11 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.561 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.422 HG23 HD21 ' A' ' 18' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.567 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.617 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.55 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.873 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.873 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.491 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.444 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.508 HG22 HG12 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.444 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.625 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.429 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.504 ' HB2' HD21 ' A' ' 52' ' ' LEU . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.55 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.667 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.542 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.673 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.617 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.55 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.429 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.657 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.418 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.29 63.73 2.1 Favored 'Trans proline' 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.673 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 33.8 mttm 49.95 29.63 3.52 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.2 48.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.588 0.709 . . . . 0.0 109.875 173.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -66.9 -34.96 78.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.032 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -148.41 135.97 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.192 175.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.433 ' NH2' HG11 ' A' ' 90' ' ' VAL . 19.3 mtm180 -132.7 -68.16 0.61 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.045 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -137.65 -143.42 0.17 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -74.83 50.33 2.21 Favored Glycine 0 CA--C 1.522 0.491 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.832 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.433 HG11 ' NH2' ' A' ' 87' ' ' ARG . 15.5 m -112.4 20.8 6.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.612 0.72 . . . . 0.0 109.903 178.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.549 ' HB ' ' HD2' ' A' ' 92' ' ' PRO . 23.5 m -84.67 163.26 47.49 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.788 -1.097 . . . . 0.0 109.468 175.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 91' ' ' VAL . 1.9 Cg_endo -42.63 116.53 0.68 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 123.587 2.858 . . . . 0.0 113.069 179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 17.9 Cg_exo -66.53 108.89 1.49 Allowed 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.781 2.321 . . . . 0.0 111.6 179.253 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.9 p -68.52 121.48 17.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.356 0.598 . . . . 0.0 110.586 -178.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 171.63 -89.09 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.3 mm -91.47 107.71 19.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 m 67.14 106.35 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 O-C-N 123.625 0.578 . . . . 0.0 110.953 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.309 -178.286 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 mtt . . . . . 0 N--CA 1.482 1.125 0 N-CA-C 111.254 0.094 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? 66.56 110.08 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 121.541 0.686 . . . . 0.0 110.237 -173.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.8 m -82.95 25.43 0.68 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.733 -174.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 m -102.01 102.95 13.53 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.698 HD11 ' HA ' ' A' ' 85' ' ' LYS . 27.1 mt -105.6 141.94 23.72 Favored Pre-proline 0 C--N 1.32 -0.675 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.342 -170.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.545 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 19.3 Cg_endo -63.93 149.62 90.19 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.097 1.865 . . . . 0.0 112.152 177.137 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.495 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' A' ' 81' ' ' THR . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.541 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.563 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.575 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.414 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.432 HD13 HD22 ' A' ' 18' ' ' LEU . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.595 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.541 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.933 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.933 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.481 HG22 HG12 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.65 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.413 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.536 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.658 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.658 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.684 ' CE2' HG11 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.51 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.489 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.536 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.487 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.508 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.575 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.414 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.508 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.51 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.38 65.05 3.65 Favored 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 19.2 mttm 60.83 36.78 19.0 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.516 -179.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -89.86 104.28 16.86 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.658 177.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.698 ' HA ' HD11 ' A' ' 5' ' ' ILE . 55.6 mtmt -124.95 -50.73 1.7 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.937 172.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -156.68 101.69 2.0 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.096 0.474 . . . . 0.0 110.389 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 73.4 ttt180 -142.64 -66.27 0.39 Allowed 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -130.2 147.26 51.91 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.18 -147.87 18.58 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.148 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 22.0 m -118.05 162.43 16.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.037 0.446 . . . . 0.0 111.076 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.9 m -92.97 155.65 41.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.691 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.545 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 17.7 Cg_endo -59.95 152.03 67.48 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.835 2.357 . . . . 0.0 112.671 176.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 34.1 Cg_exo -60.82 135.48 60.03 Favored 'Trans proline' 0 C--O 1.236 0.377 0 C-N-CA 122.801 2.334 . . . . 0.0 111.974 176.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.7 p -92.43 -20.76 6.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.465 0.65 . . . . 0.0 109.826 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -106.89 -143.56 11.24 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.77 176.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm 65.82 95.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 123.007 0.523 . . . . 0.0 111.745 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.6 p 53.54 70.67 0.57 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.648 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 55.4 t30 . . . . . 0 C--O 1.251 1.143 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.616 176.471 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.3 tmm? . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.3 mmmt -108.94 -59.69 1.85 Allowed 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -173.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.9 p -74.9 82.91 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.103 0.478 . . . . 0.0 111.88 -173.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.449 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 23.6 m -124.93 106.3 9.88 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.698 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 34.1 mt -91.49 133.38 31.36 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.525 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.499 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo -67.69 154.57 72.93 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.497 2.131 . . . . 0.0 112.685 177.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.499 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.564 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.705 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.47 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.449 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.449 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.47 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.705 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.522 HG11 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.531 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.672 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.672 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.416 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.473 HG22 HG12 ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.572 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.475 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.685 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.572 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.557 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.449 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.441 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.612 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.612 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.522 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.728 HG13 ' HG2' ' A' ' 83' ' ' LYS . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.557 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.441 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.685 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.438 ' HE2' HD12 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.438 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.564 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo -72.71 48.76 1.39 Allowed 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.728 ' HG2' HG13 ' A' ' 66' ' ' ILE . 9.8 mtpm? 63.86 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.431 0.692 . . . . 0.0 112.441 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -156.04 146.8 22.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.602 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -137.43 -26.11 1.0 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.331 173.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 66.66 101.75 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.842 0.714 . . . . 0.0 112.085 178.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 64.7 mtm180 -134.78 149.71 50.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.916 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 59.37 85.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.321 0 O-C-N 123.863 0.727 . . . . 0.0 111.173 -178.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 146.41 -91.43 0.15 Allowed Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.206 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.5 122.2 63.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 120.917 0.389 . . . . 0.0 110.14 175.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 31.5 m -123.32 141.08 35.19 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.852 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 91' ' ' VAL . 2.1 Cg_endo -85.42 123.66 2.62 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 123.019 2.479 . . . . 0.0 111.741 175.4 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.96 72.68 3.88 Favored 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 122.573 2.182 . . . . 0.0 112.114 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -64.76 125.07 20.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.269 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.42 33.69 0.48 Allowed Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.643 -177.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 55.7 mt -98.33 135.34 33.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 31.4 m -61.81 137.26 58.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 178.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.2 t30 . . . . . 0 C--O 1.246 0.876 0 CA-C-O 118.433 -0.794 . . . . 0.0 111.198 -178.921 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.482 1.155 0 CA-C-O 120.922 0.391 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -75.94 126.42 30.97 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.4 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -165.57 115.48 1.04 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.059 0.456 . . . . 0.0 110.433 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 23.2 m -95.38 104.09 15.98 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 48.2 mt -90.83 135.72 28.54 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.79 -170.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.736 ' HG3' ' HD2' ' A' ' 93' ' ' PRO . 42.8 Cg_endo -67.69 159.16 53.92 Favored 'Trans proline' 0 C--O 1.237 0.453 0 C-N-CA 122.856 2.371 . . . . 0.0 112.441 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.449 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.408 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.612 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.549 HG11 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.494 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.622 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.622 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.531 HG13 HG22 ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.479 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.626 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.521 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.588 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.541 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.654 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.549 ' CE2' HG11 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.541 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.626 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 84' ' ' ASN . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.09 60.75 5.59 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.654 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 43.8 mttm 52.3 62.48 2.67 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.476 -174.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.543 ' HB3' ' HB ' ' A' ' 81' ' ' THR . 0.5 OUTLIER -76.73 157.58 31.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.003 -177.451 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.667 ' HD3' ' HG2' ' A' ' 88' ' ' GLU . 2.3 tmmt? 70.38 80.82 0.17 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.793 0.806 . . . . 0.0 110.856 179.419 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -110.65 124.85 52.7 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 171.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 70.16 98.54 0.06 Allowed 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -169.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.667 ' HG2' ' HD3' ' A' ' 85' ' ' LYS . 23.9 mt-10 -72.94 80.04 1.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.773 -170.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.01 -53.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.351 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.9 p -77.01 124.96 36.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.102 0.477 . . . . 0.0 110.18 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -118.24 153.51 51.57 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.578 -178.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.565 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 3.4 Cg_endo -49.94 119.66 5.11 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 123.347 2.698 . . . . 0.0 112.727 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.736 ' HD2' ' HG3' ' A' ' 6' ' ' PRO . 23.9 Cg_exo -64.91 100.66 0.36 Allowed 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.894 2.396 . . . . 0.0 111.687 176.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -109.11 179.24 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.638 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -174.28 -117.13 0.46 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.701 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 39.7 pt -103.91 152.51 6.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.9 t -99.4 156.67 16.89 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.323 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.561 -0.733 . . . . 0.0 109.254 178.874 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.8 ttm . . . . . 0 N--CA 1.48 1.038 0 CA-C-O 120.785 0.326 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -72.05 -50.4 28.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.465 175.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.8 m -90.49 92.97 9.1 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.023 0.44 . . . . 0.0 111.105 -177.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.1 m -93.31 139.21 30.9 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.136 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 31.7 mt -103.02 138.75 19.64 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.686 -167.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.585 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 53.4 Cg_endo -69.71 160.61 49.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.561 2.174 . . . . 0.0 112.065 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.562 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.583 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.55 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.533 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.489 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.418 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.62 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.419 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.583 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.737 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.737 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.561 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.561 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.523 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.698 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.488 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.464 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.488 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 ' HB2' ' A' ' 69' ' ' ALA . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.541 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.508 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.508 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.411 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.464 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.698 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.538 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.55 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.533 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.538 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.94 57.9 3.28 Favored 'Trans proline' 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.541 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 48.4 mttm 53.47 59.79 4.13 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.731 -172.556 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.562 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 8.9 t30 -74.84 98.21 3.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.541 175.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 58.4 mtpt -89.24 109.93 20.76 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.602 -177.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -73.68 93.6 2.1 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 173.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -107.33 -26.95 10.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.77 -171.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -163.88 157.31 18.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.089 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.66 -131.12 10.49 Favored Glycine 0 N--CA 1.445 -0.718 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 53.8 t -76.12 98.98 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.893 0.378 . . . . 0.0 110.069 175.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.1 p -93.12 129.06 40.67 Favored Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.919 179.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.585 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 48.6 Cg_endo -68.96 127.47 15.28 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 123.137 2.558 . . . . 0.0 114.379 -172.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -93.42 -168.11 0.18 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 123.378 2.719 . . . . 0.0 110.932 169.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.2 t -116.31 -56.05 4.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.949 0.404 . . . . 0.0 110.467 178.289 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 85.14 -167.44 41.61 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.168 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.481 ' O ' HG22 ' A' ' 96' ' ' ILE . 26.7 mm 68.47 18.76 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-O 121.278 0.561 . . . . 0.0 110.382 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.7 p 51.61 98.82 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.92 0.888 . . . . 0.0 113.11 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.683 178.717 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -172.06 -33.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.266 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.5 m 63.1 31.14 16.0 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.082 179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 5.9 p -74.53 106.57 6.18 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.425 178.085 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.4 ' HA ' ' HG2' ' A' ' 92' ' ' PRO . 50.1 mt -91.28 135.08 28.65 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.478 -175.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.08 159.74 51.39 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.693 2.262 . . . . 0.0 112.51 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.606 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.565 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.402 HD21 ' OG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.402 ' OG1' HD21 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.606 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.918 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.918 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.539 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.565 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 42' ' ' ALA . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.48 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.585 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.616 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.634 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.414 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.48 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.616 ' HB2' HD21 ' A' ' 52' ' ' LEU . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.566 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.648 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.566 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.634 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.509 ' HE2' HD12 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.509 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -62.22 154.36 63.61 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.648 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 36.7 mttm -44.5 100.94 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.016 0.436 . . . . 0.0 111.591 174.393 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -112.12 84.47 1.97 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -142.33 78.6 1.63 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.682 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -90.53 151.97 21.12 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.33 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.458 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 26.4 tpt180 -75.99 83.93 2.88 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.146 0.498 . . . . 0.0 110.676 -179.521 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -137.51 157.48 46.46 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.588 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.69 28.07 11.04 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.973 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.4 t -82.75 123.03 38.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.459 . . . . 0.0 110.168 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.44 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.9 p -130.92 114.17 16.4 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-O 121.316 0.579 . . . . 0.0 110.219 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 21.2 Cg_exo -66.06 151.37 84.01 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -178.15 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 24.3 Cg_exo -65.42 165.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 123.102 2.535 . . . . 0.0 112.178 176.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' HD21 ' A' ' 55' ' ' LEU . 9.2 p -90.3 6.1 4.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.622 0.725 . . . . 0.0 110.741 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 140.96 -164.03 26.52 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.155 177.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 13.4 tt -83.63 -25.89 7.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.072 0.463 . . . . 0.0 110.646 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.4 p -84.9 150.72 24.77 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.197 -178.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.384 -0.817 . . . . 0.0 110.107 179.681 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.477 ' HE3' ' H ' ' A' ' 58' ' ' SER . 1.4 tmt? . . . . . 0 N--CA 1.48 1.055 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt 50.75 33.71 8.85 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 113.169 0.804 . . . . 0.0 113.169 173.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.43 ' O ' HG13 ' A' ' 5' ' ' ILE . 18.1 m -132.06 30.78 4.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.016 0.436 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.5 p -62.22 105.38 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.821 178.535 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.588 HD11 ' HA ' ' A' ' 86' ' ' ASN . 68.1 mt -122.61 134.59 25.02 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.909 -178.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.42 159.11 51.94 Favored 'Trans proline' 0 C--O 1.236 0.385 0 C-N-CA 122.838 2.359 . . . . 0.0 112.653 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.691 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.483 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.439 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.423 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.552 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.434 HD13 HD22 ' A' ' 18' ' ' LEU . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.691 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.543 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.483 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.421 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.629 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.629 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.6 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.552 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.573 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.6 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.504 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.531 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.549 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.543 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.579 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.477 ' H ' ' HE3' ' A' ' 1' ' ' MET . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.497 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.497 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 58' ' ' SER . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.554 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.46 ' HE2' HD12 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.46 HD12 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.485 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo -73.13 55.83 3.0 Favored 'Trans proline' 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' LYS . . . . . . . . . . . . . 48.2 mttm 54.52 73.81 0.38 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.193 -175.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -80.21 -28.54 38.59 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.451 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 60.17 -88.98 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.862 -176.076 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.588 ' HA ' HD11 ' A' ' 5' ' ' ILE . 28.6 t-20 -160.48 -63.52 0.06 Allowed 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 87' ' ' ARG . 13.6 ttm-85 58.03 -95.02 0.05 Allowed 'General case' 0 CA--C 1.537 0.461 0 O-C-N 123.763 0.664 . . . . 0.0 111.292 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -147.85 162.47 39.2 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.793 0.33 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 144.05 -153.79 25.24 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.44 88.18 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.963 0.411 . . . . 0.0 110.031 176.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 4.4 p -92.02 109.9 40.45 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-O 121.352 0.596 . . . . 0.0 109.718 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 76.6 Cg_endo -82.62 123.85 3.89 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 122.76 2.306 . . . . 0.0 112.938 -175.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 4.3 Cg_exo -76.42 95.24 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.83 2.353 . . . . 0.0 110.459 172.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 p -79.31 129.2 37.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.427 0.632 . . . . 0.0 111.169 -174.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -126.65 -52.71 0.15 Allowed Glycine 0 N--CA 1.448 -0.508 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 178.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 69.9 mt -80.69 110.74 16.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 177.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -143.47 -45.35 0.28 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.021 0.438 . . . . 0.0 111.067 -177.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.697 -0.668 . . . . 0.0 110.572 -173.607 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.3 mtp . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 121.004 0.43 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.518 ' HD2' ' HE1' ' A' ' 57' ' ' TYR . 16.6 tppt? -109.5 91.02 3.48 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.463 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 p -91.98 99.88 12.64 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.512 0.672 . . . . 0.0 111.812 -173.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.491 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 23.1 m -114.35 102.96 10.6 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 170.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -100.83 135.2 20.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.692 -168.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.8 Cg_endo -61.16 152.32 72.62 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.777 2.318 . . . . 0.0 112.635 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.466 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.505 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.468 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.569 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.44 HD13 HD22 ' A' ' 18' ' ' LEU . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.548 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.426 HG23 HD21 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.552 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.505 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.402 ' HG2' HG22 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.442 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.92 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.92 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.518 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.569 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.427 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.575 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.753 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.573 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.753 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' O ' HD22 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.509 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.63 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.534 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.546 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.552 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.546 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.509 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.573 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.475 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.475 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.427 HG22 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.445 ' HD3' HG13 ' A' ' 15' ' ' VAL . 57.0 Cg_endo -71.43 64.86 2.89 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.52 ' HA ' HG13 ' A' ' 66' ' ' ILE . 8.1 mttm 59.41 37.48 23.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.571 -178.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -72.93 98.63 2.52 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 173.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.603 ' HG3' ' H ' ' A' ' 86' ' ' ASN . 22.9 tptm -132.72 177.64 7.47 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.976 -172.157 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.603 ' H ' ' HG3' ' A' ' 85' ' ' LYS . 10.2 t-20 67.69 -165.05 0.21 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 123.334 0.396 . . . . 0.0 110.319 173.633 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -112.62 107.9 16.77 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 177.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -123.65 -53.65 1.77 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.489 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.41 -121.55 3.99 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.335 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.72 116.84 16.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.837 0.351 . . . . 0.0 110.733 -179.038 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -92.15 133.94 29.35 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.166 176.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.491 ' HG3' ' O ' ' A' ' 4' ' ' SER . 46.7 Cg_endo -69.27 116.65 4.61 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.664 2.243 . . . . 0.0 112.327 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 3.5 Cg_exo -77.51 168.69 22.31 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.917 2.412 . . . . 0.0 111.556 177.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.2 p -82.72 74.85 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.326 1.06 . . . . 0.0 110.001 176.549 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -155.01 90.62 0.12 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.668 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 15.3 pt -111.47 108.39 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.165 0.507 . . . . 0.0 110.956 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 46.9 m -79.81 130.0 34.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.668 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.3 t30 . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.555 -0.736 . . . . 0.0 110.562 179.692 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 tpt . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.605 0.716 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.4 ' HD2' ' HB2' ' A' ' 4' ' ' SER . 17.2 tppt? -82.2 113.69 20.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.439 -177.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.1 p -95.2 0.02 53.61 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.098 0.475 . . . . 0.0 110.872 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.545 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 18.2 m -85.81 103.5 14.62 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.978 177.486 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.469 HG23 ' HD2' ' A' ' 6' ' ' PRO . 59.5 mt -107.7 141.14 22.41 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.988 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.482 ' CD ' ' HB3' ' A' ' 92' ' ' PRO . 17.9 Cg_endo -62.09 150.64 85.82 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.612 2.208 . . . . 0.0 112.657 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.462 HG22 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.428 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.537 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.577 HD21 HG23 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.6 m120 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.577 HG23 HD21 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.537 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.558 HG11 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.54 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.544 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.516 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.443 HG22 HG12 ' A' ' 59' ' ' VAL . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.547 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.728 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.523 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.509 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.436 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.485 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.558 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.437 HD11 ' HG2' ' A' ' 83' ' ' LYS . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.523 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 10.1 m-70 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.47 52.91 2.09 Favored 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.485 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 30.8 mttm 63.92 -76.93 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.312 0.645 . . . . 0.0 111.434 -174.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 66.1 t30 66.3 13.46 9.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 121.121 0.486 . . . . 0.0 111.294 176.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.41 ' HB3' ' HE2' ' A' ' 85' ' ' LYS . 35.7 mtpt -91.91 39.39 1.01 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.949 0.404 . . . . 0.0 111.218 -178.017 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -67.5 -41.64 84.18 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 5.6 tpt180 -152.85 138.85 18.15 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 176.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.95 -50.2 44.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.893 0.377 . . . . 0.0 110.481 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.37 -99.23 0.56 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.814 176.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.07 128.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.241 0.544 . . . . 0.0 111.162 -176.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.7 m -83.47 129.08 61.57 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.908 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.482 ' HB3' ' CD ' ' A' ' 6' ' ' PRO . 14.4 Cg_endo -57.57 118.83 5.77 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.493 2.795 . . . . 0.0 113.519 -176.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.24 122.2 5.11 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.617 2.212 . . . . 0.0 111.917 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 48.5 t -98.59 -48.5 12.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.163 0.506 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 88.04 170.26 45.85 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.932 -0.651 . . . . 0.0 111.803 -178.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.441 HG13 ' N ' ' A' ' 97' ' ' THR . 23.2 pt -76.26 -45.77 34.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 177.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.441 ' N ' HG13 ' A' ' 96' ' ' ILE . 18.9 m -149.56 -56.84 0.19 Allowed 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 . . . . . 0 C--O 1.244 0.769 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.293 174.706 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.1 ptp . . . . . 0 N--CA 1.481 1.098 0 CA-C-O 120.874 0.369 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.4 tppt? -135.43 94.71 3.15 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.3 m -117.83 42.79 2.55 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.295 0.569 . . . . 0.0 110.532 -176.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 94' ' ' VAL . 14.6 m -78.4 106.11 10.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.082 177.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -114.0 133.43 22.33 Favored Pre-proline 0 C--N 1.32 -0.693 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.227 -176.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 37.0 Cg_endo -67.25 155.6 69.85 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.837 2.358 . . . . 0.0 112.624 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.544 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.557 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.529 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.427 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HB3' HD11 ' A' ' 27' ' ' LEU . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.43 HD13 HD22 ' A' ' 18' ' ' LEU . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.428 HD11 ' HB3' ' A' ' 21' ' ' ASP . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.557 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.747 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.747 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.741 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.579 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.467 HG22 HG12 ' A' ' 59' ' ' VAL . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.579 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.514 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.604 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.548 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.548 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.567 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.449 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.567 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE2' HG11 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.449 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.522 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.483 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 63.0 m-70 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.483 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo -72.46 61.91 3.54 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.429 ' HA ' HG13 ' A' ' 66' ' ' ILE . 0.6 OUTLIER 61.58 18.75 9.79 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.328 170.82 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -81.7 80.23 8.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.569 0.699 . . . . 0.0 109.769 172.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -59.3 -44.86 92.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.254 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -167.03 85.48 0.26 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.633 171.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.769 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 0.7 OUTLIER -67.07 -54.92 16.93 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.541 -174.157 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 87' ' ' ARG . 1.7 mp0 -82.8 158.77 22.66 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.774 175.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -89.92 44.55 3.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.796 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 29.6 m -96.13 146.54 7.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 120.903 0.382 . . . . 0.0 111.02 -176.374 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 5.0 m -129.78 102.72 17.72 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.397 0.617 . . . . 0.0 110.793 177.551 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.462 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 88.6 Cg_endo -82.36 177.16 7.34 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.865 2.376 . . . . 0.0 111.666 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -61.88 104.64 0.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.12 1.88 . . . . 0.0 111.508 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.62 HG12 ' HB2' ' A' ' 4' ' ' SER . 35.9 m -84.24 -14.24 11.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.896 -176.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -166.94 110.1 0.38 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.039 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 37.9 pt -99.82 -33.33 3.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.133 0.492 . . . . 0.0 110.602 177.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.0 m -95.98 87.64 4.65 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 20.5 m120 . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.61 -0.71 . . . . 0.0 109.734 178.067 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.4 tpt . . . . . 0 N--CA 1.481 1.078 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? 73.44 112.5 0.06 Allowed 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.298 0.639 . . . . 0.0 111.333 179.238 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.1 t -84.29 83.29 8.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.1 m -131.84 123.11 26.87 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.035 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.424 HG23 ' HD2' ' A' ' 6' ' ' PRO . 64.2 mt -128.56 136.77 29.63 Favored Pre-proline 0 C--N 1.327 -0.391 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.619 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 36.6 Cg_endo -65.6 156.95 61.05 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.915 2.41 . . . . 0.0 112.855 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.407 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.542 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.515 HD21 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.567 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.455 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.419 ' HB3' HD11 ' A' ' 27' ' ' LEU . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.437 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.452 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.419 HD11 ' HB3' ' A' ' 21' ' ' ASP . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.567 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.729 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.483 HG11 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.428 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.515 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.812 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.812 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.591 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.543 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.461 HG22 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.591 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.543 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.518 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.475 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.492 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 96' ' ' ILE . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.532 HD11 ' HA ' ' A' ' 94' ' ' VAL . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.492 ' HB2' HD23 ' A' ' 52' ' ' LEU . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.492 HG11 ' HB2' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.551 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CE1' HG11 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.48 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.476 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.492 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.522 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.479 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.479 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.48 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.502 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo -64.79 165.46 20.95 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.551 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 27.0 mttm -47.85 100.81 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.0 0.428 . . . . 0.0 110.534 171.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASN . . . . . 0.451 ' H ' HD12 ' A' ' 66' ' ' ILE . 7.1 t30 -137.75 81.57 1.87 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.428 0.632 . . . . 0.0 110.388 -174.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -117.02 -42.71 2.91 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 172.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 m120 64.67 -72.84 0.06 Allowed 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.961 172.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 7.8 tpt180 -170.32 -57.69 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -174.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -175.3 89.54 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 114.369 -1.287 . . . . 0.0 108.809 173.546 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.53 -51.6 55.46 Favored Glycine 0 C--N 1.329 0.172 0 CA-C-N 115.734 -0.666 . . . . 0.0 113.153 -174.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.5 p -159.73 145.9 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -110.6 97.61 33.29 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-O 121.292 0.568 . . . . 0.0 111.398 178.161 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.619 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 56.1 Cg_endo -90.56 173.38 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.402 2.734 . . . . 0.0 111.582 176.018 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.34 116.66 4.01 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.077 1.852 . . . . 0.0 111.426 174.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.532 ' HA ' HD11 ' A' ' 55' ' ' LEU . 29.8 t -76.95 88.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.082 0.468 . . . . 0.0 110.632 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.01 -134.03 4.77 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.737 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 53' ' ' GLY . 44.2 mm -128.51 -71.88 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.1 m -122.3 97.69 5.58 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 16.2 m120 . . . . . 0 C--O 1.25 1.102 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.737 -175.571 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.467 ' HA ' ' OE2' ' A' ' 88' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.674 0.273 . . . . 0.0 111.191 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -107.71 92.69 4.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.5 m -66.3 135.06 53.86 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.351 0.596 . . . . 0.0 112.573 -170.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -82.37 127.29 33.11 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.459 HG23 ' HD2' ' A' ' 6' ' ' PRO . 58.2 mt -125.67 139.21 33.54 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.43 -169.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.459 ' HD2' HG23 ' A' ' 5' ' ' ILE . 40.0 Cg_endo -67.94 158.74 56.01 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.551 2.167 . . . . 0.0 112.432 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.47 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.575 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.429 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.489 ' HB2' HD21 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.502 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.441 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.489 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.549 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' THR . . . . . 0.441 ' OG1' HD21 ' A' ' 26' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.774 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.579 HG11 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.404 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.418 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.553 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.502 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.485 HG22 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.54 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.744 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 98' ' ' ASN . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.489 ' HD2' ' O ' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 94' ' ' VAL . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.2 mp0 -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.579 ' CE2' HG11 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.492 HG13 ' HA ' ' A' ' 83' ' ' LYS . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.744 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.487 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.487 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.47 HG22 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo -72.67 59.6 3.39 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.526 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 45.4 mttm 67.14 -68.02 0.16 Allowed 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.214 -171.228 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 47.1 t30 60.7 89.2 0.07 Allowed 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.76 0.662 . . . . 0.0 111.571 177.333 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -111.39 -54.56 2.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.475 176.357 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.7 t30 60.7 -81.41 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.112 -177.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 27.5 ttm180 179.88 125.3 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 13.5 pt-20 -93.28 -172.87 3.07 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 138.04 -45.99 1.02 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.4 t -107.34 117.02 52.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.36 129.79 76.55 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 121.023 0.44 . . . . 0.0 110.824 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.95 162.86 40.62 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 122.643 2.229 . . . . 0.0 112.413 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.53 132.87 48.35 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.841 2.361 . . . . 0.0 112.584 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.685 ' HA ' HD11 ' A' ' 55' ' ' LEU . 27.4 m -84.66 -167.57 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.029 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -99.27 124.04 8.1 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.41 177.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 11.4 pt -71.17 92.79 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.096 0.474 . . . . 0.0 111.368 -178.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.9 m 61.34 74.75 0.43 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.499 -177.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.526 ' HB3' ' HA3' ' A' ' 53' ' ' GLY . 13.2 m120 . . . . . 0 C--O 1.247 0.957 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.19 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.827 0.346 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -143.39 107.04 4.61 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.823 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 62.9 m -76.27 88.88 3.12 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.33 0.586 . . . . 0.0 110.973 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . 0.548 ' HB2' HD13 ' A' ' 55' ' ' LEU . 8.9 p -85.11 104.26 14.85 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.764 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 52.0 mt -121.19 134.79 24.52 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.922 -174.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.468 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 48.6 Cg_endo -70.93 159.32 52.89 Favored 'Trans proline' 0 C--O 1.237 0.467 0 C-N-CA 122.54 2.16 . . . . 0.0 112.377 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HZ ' ' A' ' 70' ' ' PHE . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.415 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.721 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.426 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.477 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.0 m120 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.479 HD21 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.721 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.646 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.427 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.427 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.537 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.595 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.603 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.607 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.595 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.603 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.548 HD13 ' HB2' ' A' ' 4' ' ' SER . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.477 ' HB2' HD23 ' A' ' 52' ' ' LEU . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.537 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.561 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.646 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' PHE . . . . . 0.412 ' HZ ' HG21 ' A' ' 10' ' ' VAL . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.607 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.407 ' HG3' HD12 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.477 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.407 HD12 ' HG3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.432 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.415 HG22 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.12 63.98 2.61 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.541 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 47.3 mttm 50.73 52.37 15.04 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.55 -175.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -74.83 98.7 3.58 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 174.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 38.8 pttt -154.66 168.08 27.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.18 -172.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 t30 71.07 -58.73 0.56 Allowed 'General case' 0 N--CA 1.471 0.598 0 O-C-N 123.977 0.798 . . . . 0.0 111.912 173.229 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -78.68 102.16 7.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.362 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -75.42 109.69 9.16 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.241 -176.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -77.81 -94.54 0.24 Allowed Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.023 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 62.0 t -105.06 108.34 24.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 p -89.01 131.63 40.53 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.314 -175.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.468 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 96.3 Cg_endo -81.06 177.17 8.17 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 123.052 2.502 . . . . 0.0 112.012 177.202 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -55.49 151.4 37.98 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.385 2.057 . . . . 0.0 112.035 174.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -66.62 -36.92 78.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -177.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 155.94 52.32 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.29 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 59.1 mt -81.26 92.97 2.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.023 0.44 . . . . 0.0 109.974 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.2 t -174.09 149.55 1.46 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.717 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.476 -0.773 . . . . 0.0 110.034 179.433 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.3 mmt . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.939 0.399 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 tppt? -113.96 -46.36 3.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.3 m 58.9 80.37 0.19 Allowed 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.769 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.3 m -95.55 114.14 25.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.65 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.574 HD11 ' HB2' ' A' ' 86' ' ' ASN . 55.6 mt -127.01 133.39 25.0 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.925 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.79 ' HB3' HG22 ' A' ' 94' ' ' VAL . 30.9 Cg_endo -65.94 155.16 70.83 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.676 2.251 . . . . 0.0 112.496 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.415 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.549 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.482 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.563 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.482 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ASP . . . . . 0.563 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.453 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.504 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.646 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.646 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.78 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.593 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' TYR . . . . . 0.593 ' HB2' HD21 ' A' ' 52' ' ' LEU . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.703 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 17.3 mp0 -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.459 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.463 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.78 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.9 m-70 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.459 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.25 137.81 63.09 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' LYS . . . . . 0.703 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 16.2 mttm -30.44 99.85 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 O-C-N 124.348 1.03 . . . . 0.0 112.77 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 -128.65 90.81 3.12 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.956 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LYS . . . . . 0.845 ' HD3' ' H ' ' A' ' 85' ' ' LYS . 0.0 OUTLIER -72.16 99.94 2.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.479 0.657 . . . . 0.0 109.691 178.495 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.574 ' HB2' HD11 ' A' ' 5' ' ' ILE . 26.4 t-20 -62.47 142.5 57.88 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.548 -179.19 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -73.24 73.81 1.29 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.524 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -70.61 172.8 7.99 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.369 0.604 . . . . 0.0 111.393 -175.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 103.31 -40.02 2.59 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -165.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.03 86.28 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 169.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.3 m -80.61 139.07 50.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.637 -173.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -67.41 121.66 8.8 Favored 'Trans proline' 0 CA--C 1.529 0.244 0 C-N-CA 122.994 2.462 . . . . 0.0 112.277 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -74.42 160.54 41.65 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.592 2.195 . . . . 0.0 112.222 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.79 HG22 ' HB3' ' A' ' 6' ' ' PRO . 45.0 t -92.94 -53.87 8.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.934 179.246 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.16 -130.19 5.82 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.316 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.1 mt -116.15 -47.03 4.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.893 0.378 . . . . 0.0 110.661 -178.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.6 p -128.36 124.6 36.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -177.161 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.4 t30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.819 176.406 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.534 ' HB2' HG22 ' A' ' 8' ' ' THR . 30.0 Cg_endo . . . . . 0 C--O 1.236 0.392 0 CA-C-O 121.169 0.404 . . . . 0.0 112.942 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.534 HG22 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 8' ' ' THR . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 13' ' ' ARG . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.628 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.611 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.634 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.418 HD13 HD22 ' A' ' 18' ' ' LEU . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.606 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.412 HG23 HD21 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.586 HG11 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.628 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.566 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.786 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.786 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.553 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.553 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.823 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.41 ' HB3' ' O ' ' A' ' 46' ' ' ARG . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.823 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.57 ' CB ' HD23 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' HB2' ' A' ' 69' ' ' ALA . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.433 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CE1' HG11 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.433 HG12 ' HG3' ' A' ' 61' ' ' GLU . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.529 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.676 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.577 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.611 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.676 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.577 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.529 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo . . . . . 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo . . . . . 0 N--CA 1.462 -0.331 0 CA-C-O 121.0 0.333 . . . . 0.0 112.539 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 32' ' ' VAL . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.59 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.477 ' HB2' HD21 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.579 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.486 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.477 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.59 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.638 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.638 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.541 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.486 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.566 HG21 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.459 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.558 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.478 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.437 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.49 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.566 ' HA ' HG21 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.401 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.455 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.437 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.478 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.9 m80 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 14' ' ' ALA . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HB2' HG22 ' A' ' 8' ' ' THR . 20.1 Cg_endo . . . . . 0 C--O 1.235 0.347 0 CA-C-O 121.158 0.399 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 13' ' ' ARG . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.531 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.675 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.558 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.451 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.461 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.568 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.428 ' HB2' HD22 ' A' ' 25' ' ' ASN . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.428 HD22 ' HB2' ' A' ' 23' ' ' ASN . 59.7 m-80 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.461 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.442 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.675 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.525 HG11 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.558 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.414 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.414 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.582 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.613 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.444 HG22 HG12 ' A' ' 59' ' ' VAL . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.613 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.586 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.702 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.586 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.571 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.571 ' HB2' HD23 ' A' ' 52' ' ' LEU . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.502 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.45 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.525 ' CE2' HG11 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.45 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.512 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.502 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.482 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.702 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.56 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.403 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo . . . . . 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.538 ' HB2' HG22 ' A' ' 8' ' ' THR . 41.3 Cg_endo . . . . . 0 C--O 1.236 0.421 0 CA-C-O 121.154 0.397 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.538 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' HH11 ' A' ' 13' ' ' ARG . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.757 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.548 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.457 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.59 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.4 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.452 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.457 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.757 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.677 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.432 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 37' ' ' GLU . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.88 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.88 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.544 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.492 HG21 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.568 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.515 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.688 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.568 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 57' ' ' TYR . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.401 ' HA ' ' HD3' ' A' ' 54' ' ' ARG . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.591 ' HB2' HD21 ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.496 HG11 ' HB2' ' A' ' 69' ' ' ALA . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.423 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.677 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.423 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.545 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.688 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.59 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.4 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.534 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo . . . . . 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo . . . . . 0 C--O 1.237 0.429 0 CA-C-O 120.891 0.288 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.516 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.613 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.444 ' HB2' HD21 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.574 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.457 HD13 HD22 ' A' ' 18' ' ' LEU . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.444 HD21 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.613 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.405 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.489 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.574 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.449 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.468 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.729 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.594 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.729 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 54' ' ' ARG . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.442 ' O ' HD22 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.556 ' CB ' HD23 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.49 ' CE2' HG11 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.493 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.444 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.594 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.516 HG22 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo . . . . . 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 C--O 1.238 0.476 0 CA-C-O 121.18 0.408 . . . . 0.0 112.689 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.411 HG13 ' CG2' ' A' ' 81' ' ' THR . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 13' ' ' ARG . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.466 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.41 HG21 ' CE1' ' A' ' 65' ' ' TYR . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.53 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.462 ' HB2' HD21 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.488 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.532 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.443 HD13 HD22 ' A' ' 18' ' ' LEU . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.556 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.593 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.53 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HG2' HG22 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.69 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.69 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.485 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.476 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.539 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.542 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.473 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.53 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.563 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.593 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.542 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.488 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 14' ' ' ALA . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo . . . . . 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HG2' ' HG2' ' A' ' 9' ' ' GLU . 10.2 Cg_endo . . . . . 0 C--O 1.235 0.352 0 N-CA-C 112.854 0.29 . . . . 0.0 112.854 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.421 ' HG2' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.418 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.55 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.561 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.454 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.437 ' HB2' HD11 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.657 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.453 HD22 ' N ' ' A' ' 23' ' ' ASN . 0.9 OUTLIER -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.437 HD11 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.561 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.422 HG23 HD21 ' A' ' 18' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.567 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.617 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.55 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.873 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.873 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.491 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.444 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.508 HG22 HG12 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.444 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.625 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.429 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.504 ' HB2' HD21 ' A' ' 52' ' ' LEU . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.55 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.667 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.542 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.667 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.617 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.55 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.429 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.422 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 30.9 m170 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.657 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.418 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.495 ' HB2' HG22 ' A' ' 8' ' ' THR . 19.3 Cg_endo . . . . . 0 C--O 1.237 0.464 0 CA-C-O 120.965 0.319 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.495 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' A' ' 81' ' ' THR . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.541 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.563 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.575 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.414 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.432 HD13 HD22 ' A' ' 18' ' ' LEU . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.595 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.541 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.933 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.933 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.481 HG22 HG12 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.65 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.413 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.536 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.658 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.658 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.684 ' CE2' HG11 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.51 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.489 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.536 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.487 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.508 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.575 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.414 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.508 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.51 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.499 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo . . . . . 0 C--O 1.236 0.396 0 CA-C-O 121.141 0.392 . . . . 0.0 112.685 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.499 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.564 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.705 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.47 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.449 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.449 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.47 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.705 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.522 HG11 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.531 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.672 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.672 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.416 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.473 HG22 HG12 ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.572 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.475 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.685 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.572 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.557 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.404 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.441 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.612 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.612 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.522 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.557 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.441 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.685 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.438 ' HE2' HD12 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.5 m170 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.438 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.564 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo . . . . . 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 C--O 1.237 0.453 0 CA-C-O 121.102 0.376 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.449 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HA ' ' HD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.408 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.612 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.549 HG11 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.494 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.622 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.622 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.531 HG13 HG22 ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.479 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.626 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.521 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.588 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.541 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.549 ' CE2' HG11 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.541 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.626 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 23.5 m170 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.489 HG22 ' HA ' ' A' ' 14' ' ' ALA . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo . . . . . 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo . . . . . 0 C--O 1.236 0.422 0 CA-C-O 120.971 0.321 . . . . 0.0 112.065 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.583 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.55 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.533 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.493 ' HB2' ' ND2' ' A' ' 25' ' ' ASN . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.493 ' ND2' ' HB2' ' A' ' 23' ' ' ASN . 6.6 p30 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.489 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.418 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.62 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.419 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.583 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.737 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.737 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.561 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.561 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.523 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.698 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.488 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.464 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.488 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 ' HB2' ' A' ' 69' ' ' ALA . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.508 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.508 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.411 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.464 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.698 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.538 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.55 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.533 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.538 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo . . . . . 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo . . . . . 0 C--O 1.236 0.384 0 CA-C-O 121.302 0.459 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.606 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 75' ' ' HIS . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.565 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.402 HD21 ' OG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.402 ' OG1' HD21 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.606 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.918 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.918 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.539 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.565 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 42' ' ' ALA . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.48 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.585 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.616 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.634 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.414 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.48 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.616 ' HB2' HD21 ' A' ' 52' ' ' LEU . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.566 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.469 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.566 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.634 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.509 ' HE2' HD12 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.401 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 31.1 m80 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.509 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo . . . . . 0 C--O 1.236 0.385 0 CA-C-O 121.109 0.379 . . . . 0.0 112.653 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.691 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.483 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.439 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.423 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.552 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.434 HD13 HD22 ' A' ' 18' ' ' LEU . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.691 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.543 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.483 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.421 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.629 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.629 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.6 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.552 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.573 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.6 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.504 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.531 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.549 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.543 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.579 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 67' ' ' GLY . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.497 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.497 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 58' ' ' SER . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.554 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.46 ' HE2' HD12 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.46 HD12 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.485 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo . . . . . 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.522 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.8 Cg_endo . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.237 0.432 . . . . 0.0 112.635 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.466 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.505 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.468 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.569 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.44 HD13 HD22 ' A' ' 18' ' ' LEU . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.548 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.426 HG23 HD21 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.552 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.505 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.402 ' HG2' HG22 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.442 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.92 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.92 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.518 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.569 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.427 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.575 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.753 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.573 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.753 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.545 ' O ' HD22 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.509 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.63 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.534 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.546 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.552 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.546 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.509 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.573 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.475 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.475 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.427 HG22 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.445 ' HD3' HG13 ' A' ' 15' ' ' VAL . 57.0 Cg_endo . . . . . 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.9 Cg_endo . . . . . 0 C--O 1.235 0.352 0 CA-C-O 121.19 0.412 . . . . 0.0 112.657 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.462 HG22 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.428 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.537 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.577 HD21 HG23 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.528 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.577 HG23 HD21 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.537 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.558 HG11 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.54 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.544 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.516 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.443 HG22 HG12 ' A' ' 59' ' ' VAL . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.547 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.728 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.523 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.509 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.436 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.558 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.436 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.523 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.528 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 26.6 m170 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 C--O 1.235 0.374 0 CA-C-O 121.256 0.44 . . . . 0.0 112.624 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.544 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.557 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.529 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.427 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HB3' HD11 ' A' ' 27' ' ' LEU . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.43 HD13 HD22 ' A' ' 18' ' ' LEU . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.428 HD11 ' HB3' ' A' ' 21' ' ' ASP . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.557 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.747 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.747 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.741 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.579 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.467 HG22 HG12 ' A' ' 59' ' ' VAL . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.579 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.514 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.604 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.548 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.548 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.567 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.449 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.567 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE2' HG11 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.449 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.522 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.483 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.2 m80 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.483 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo . . . . . 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.407 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.6 Cg_endo . . . . . 0 C--O 1.235 0.333 0 CA-C-O 121.249 0.437 . . . . 0.0 112.855 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.407 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.542 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.515 HD21 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.567 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.455 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.542 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.437 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.452 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.419 HD11 ' HB3' ' A' ' 21' ' ' ASP . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.567 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.729 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.483 HG11 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.428 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.515 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.812 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.812 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.591 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.543 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.461 HG22 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.591 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.543 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.518 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.475 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.492 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.522 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.492 ' HB2' HD23 ' A' ' 52' ' ' LEU . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.492 HG11 ' HB2' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.546 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CE1' HG11 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.48 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.476 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.492 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.522 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.479 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 16.0 m170 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.479 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.48 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.502 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo . . . . . 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.236 0.411 0 CA-C-O 121.183 0.409 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.47 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.575 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.429 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.489 ' HB2' HD21 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.502 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.441 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.489 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.549 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . 0.441 ' OG1' HD21 ' A' ' 26' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.774 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.579 HG11 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.404 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.418 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.553 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.502 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.485 HG22 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.54 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.744 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.489 ' HD2' ' O ' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.579 ' CE2' HG11 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.744 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.487 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.487 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.47 HG22 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo . . . . . 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 C--O 1.237 0.467 0 CA-C-O 121.004 0.335 . . . . 0.0 112.377 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HZ ' ' A' ' 70' ' ' PHE . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.415 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.721 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.426 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.477 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.479 HD21 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.721 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.646 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.427 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.427 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.537 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.595 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.603 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.607 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.595 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.603 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.477 ' HB2' HD23 ' A' ' 52' ' ' LEU . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.537 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.561 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.646 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . 0.412 ' HZ ' HG21 ' A' ' 10' ' ' VAL . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.607 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.407 ' HG3' HD12 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.477 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.407 HD12 ' HG3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.432 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.415 HG22 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo . . . . . 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.415 ' HB2' HG22 ' A' ' 8' ' ' THR . 30.9 Cg_endo . . . . . 0 C--O 1.236 0.413 0 CA-C-O 121.15 0.396 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.415 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.549 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.482 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.563 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.482 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.407 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . 0.563 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.453 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.504 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.646 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.646 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.78 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.593 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' TYR . . . . . 0.593 ' HB2' HD21 ' A' ' 52' ' ' LEU . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.595 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.459 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.463 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.78 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.407 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 14.2 m170 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.459 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo . . . . . 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.4 mmm . . . . . 0 N--CA 1.483 1.203 0 CA-C-O 120.755 0.312 . . . . 0.0 111.163 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.424 ' HB2' ' HE2' ' A' ' 2' ' ' LYS . 9.8 tppt? -79.7 -59.39 2.76 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 177.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.9 m 69.87 135.32 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.318 -0.856 . . . . 0.0 112.279 177.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.1 m -82.49 104.52 12.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.474 175.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' HD2' ' A' ' 6' ' ' PRO . 87.1 mt -92.49 139.18 23.75 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.574 -169.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.586 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 30.0 Cg_endo -63.84 153.2 76.96 Favored 'Trans proline' 0 C--N 1.347 0.465 0 C-N-CA 122.55 2.167 . . . . 0.0 112.942 -177.334 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -66.52 -26.48 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.278 -175.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.534 HG22 ' HB2' ' A' ' 6' ' ' PRO . 8.8 t -58.68 -26.87 64.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.97 0.414 . . . . 0.0 110.805 178.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 8' ' ' THR . 27.4 mm-40 -96.78 -47.78 5.74 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.497 178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 96.1 t -66.96 -36.55 77.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.931 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.06 -62.23 3.75 Favored Pre-proline 0 CA--C 1.542 0.636 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -178.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_endo -65.46 -30.23 52.83 Favored 'Trans proline' 0 C--N 1.35 0.612 0 C-N-CA 121.93 1.753 . . . . 0.0 113.009 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.509 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 49.2 mtt180 -77.41 -12.43 59.96 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-O 120.658 0.266 . . . . 0.0 111.576 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -83.24 149.36 26.85 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.085 0.469 . . . . 0.0 111.595 -176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.5 m -119.99 6.27 6.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.322 178.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.56 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -159.82 151.09 21.75 Favored Glycine 0 N--CA 1.443 -0.859 0 N-CA-C 110.246 -1.142 . . . . 0.0 110.246 179.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.4 m -151.82 127.89 10.42 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 117.674 0.737 . . . . 0.0 111.514 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.628 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 16.6 mt -108.82 119.61 40.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.024 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 80.5 m -93.84 113.53 25.58 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 21.6 m-85 -108.26 155.71 20.17 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.453 177.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.611 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 33.7 t70 -86.64 168.7 13.38 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.35 173.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.634 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.9 pt-20 -68.87 -18.1 64.09 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 120.857 0.361 . . . . 0.0 110.615 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -85.09 12.16 8.3 Favored 'General case' 0 N--CA 1.456 -0.17 0 CA-C-O 121.113 0.482 . . . . 0.0 109.917 173.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 41.3 m-85 64.67 27.52 13.18 Favored 'General case' 0 CA--C 1.521 -0.151 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.142 175.129 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -98.44 129.85 45.06 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.805 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.418 HD13 HD22 ' A' ' 18' ' ' LEU . 38.5 tp -62.62 128.38 35.71 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.084 0.469 . . . . 0.0 111.404 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -109.03 -54.22 2.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.658 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.606 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 9.7 t70 -131.49 140.91 49.65 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.076 -176.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.412 HG23 HD21 ' A' ' 18' ' ' LEU . 22.1 m -124.13 119.69 30.18 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.87 175.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m -133.49 149.33 51.73 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.837 0.351 . . . . 0.0 111.09 -177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.14 -151.85 42.78 Favored Glycine 0 N--CA 1.448 -0.55 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.536 176.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.586 HG11 ' CE1' ' A' ' 65' ' ' TYR . 35.5 t -63.99 -16.38 18.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.2 0.524 . . . . 0.0 111.095 -179.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.628 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.46 -14.45 28.8 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.379 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -72.67 -34.76 67.44 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.08 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.2 m -94.09 -17.88 7.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.047 0.451 . . . . 0.0 110.897 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -79.26 146.3 8.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.913 174.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.72 159.03 22.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.021 0.438 . . . . 0.0 111.467 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.566 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -110.7 1.3 17.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.755 -172.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.786 ' HB2' ' HD3' ' A' ' 40' ' ' PRO . 1.2 m -48.0 -65.77 0.69 Allowed Pre-proline 0 CA--C 1.545 0.759 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -168.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.786 ' HD3' ' HB2' ' A' ' 39' ' ' SER . 79.1 Cg_endo -93.7 2.47 3.2 Favored 'Trans proline' 0 C--N 1.351 0.689 0 C-N-CA 122.143 1.895 . . . . 0.0 113.483 -171.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' ILE . 49.2 mt -71.55 -39.47 70.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 111.983 0.364 . . . . 0.0 111.983 -171.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.13 -42.77 95.51 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.041 0.448 . . . . 0.0 111.13 -177.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.553 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 11.4 tp10 -63.35 -37.8 88.68 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.704 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.562 HG12 ' O ' ' A' ' 40' ' ' PRO . 23.5 mm -77.31 -27.33 15.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.439 -0.504 . . . . 0.0 110.501 -179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.568 HG13 ' O ' ' A' ' 41' ' ' ILE . 34.2 mt -62.22 -45.56 98.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.484 0.183 . . . . 0.0 110.92 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.553 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.0 ptm180 -66.16 -43.04 88.1 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 120.927 0.394 . . . . 0.0 110.74 178.222 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 99.5 mttt -59.0 -46.02 89.21 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.155 177.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.823 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 44.8 m -70.04 -25.54 63.61 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.929 179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.41 ' HB3' ' O ' ' A' ' 46' ' ' ARG . 9.1 t30 -59.63 -37.98 80.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.997 0.427 . . . . 0.0 110.1 177.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.21 -31.08 43.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.155 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.424 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 50.7 mm-40 -76.0 -49.02 18.8 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.613 0.597 . . . . 0.0 112.613 -175.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.823 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.4 pp -107.84 170.48 7.96 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.305 0.574 . . . . 0.0 112.092 -170.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.49 -81.65 0.49 Allowed Glycine 0 N--CA 1.444 -0.798 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.878 170.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.9 tmm_? -106.72 7.11 30.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.441 0.639 . . . . 0.0 110.377 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -101.96 161.14 13.9 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.302 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.474 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -101.82 107.02 3.11 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 121.125 -0.559 . . . . 0.0 112.898 -179.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.57 ' CB ' HD23 ' A' ' 52' ' ' LEU . 45.6 t80 -85.37 129.1 34.88 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 177.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.2 m -65.76 113.69 4.49 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-O 121.164 0.507 . . . . 0.0 110.68 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.513 HG11 ' HB2' ' A' ' 69' ' ' ALA . 31.5 m -102.17 -31.56 3.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.497 -176.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -133.46 100.14 4.72 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.374 -176.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.433 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.6 tt0 -104.42 112.5 25.57 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.25 0.547 . . . . 0.0 110.38 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 19.4 t70 -117.64 167.18 11.57 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.82 -21.87 64.28 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.183 0.515 . . . . 0.0 110.596 -179.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -86.5 -58.83 2.46 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.741 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.586 ' CE1' HG11 ' A' ' 32' ' ' VAL . 55.4 m-85 -137.99 165.89 25.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.626 -173.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.433 HG12 ' HG3' ' A' ' 61' ' ' GLU . 77.6 mt -129.41 122.68 56.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.249 178.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.529 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.6 141.4 15.53 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.971 -0.559 . . . . 0.0 112.336 -178.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 31.3 m-70 -126.31 131.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.29 141.52 30.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.747 0.308 . . . . 0.0 111.119 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.474 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 75.5 m-85 -132.08 144.59 50.84 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.491 176.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.676 ' HE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -85.93 111.81 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 172.402 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.577 ' HE2' HD12 ' A' ' 77' ' ' ILE . 24.4 mmmt -105.28 -175.49 2.81 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.781 -177.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.13 89.9 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.149 0.499 . . . . 0.0 111.701 -177.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.95 8.75 83.19 Favored Glycine 0 N--CA 1.449 -0.455 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.064 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.611 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 9.3 m170 -147.69 169.68 19.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.074 0.464 . . . . 0.0 111.693 -176.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.676 ' CD1' ' HE2' ' A' ' 71' ' ' LYS . 23.4 m-85 -116.69 128.34 55.26 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.681 -179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.577 HD12 ' HE2' ' A' ' 72' ' ' LYS . 44.4 mt -128.92 135.4 62.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.686 179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 59.1 t -106.64 115.05 47.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.276 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -95.88 119.87 35.14 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.493 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.529 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 88.7 m-85 -94.66 118.06 31.12 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.034 -178.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 74.1 p -105.46 145.0 29.95 Favored Pre-proline 0 C--N 1.318 -0.79 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.039 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HA ' ' CD2' ' A' ' 65' ' ' TYR . 74.2 Cg_endo -74.72 59.57 4.99 Favored 'Trans proline' 0 N--CA 1.473 0.303 0 C-N-CA 123.068 2.512 . . . . 0.0 112.578 -177.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 46.2 mttm 46.67 52.57 11.04 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.425 -173.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.509 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 27.0 t-20 -64.2 106.9 1.17 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.656 -176.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -122.69 7.03 9.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.099 -177.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -100.9 141.48 33.73 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.732 0.301 . . . . 0.0 110.55 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.792 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 1.2 mmp_? 55.64 73.81 0.41 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 121.576 0.703 . . . . 0.0 110.951 -178.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -113.07 27.46 9.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.607 -178.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.53 45.33 3.07 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.411 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.8 p -143.11 124.29 11.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 21.2 m -105.38 131.9 21.35 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.18 0.514 . . . . 0.0 111.289 -177.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.586 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 97.5 Cg_endo -88.01 123.15 1.66 Allowed 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.805 2.336 . . . . 0.0 112.335 174.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -57.53 141.3 95.14 Favored 'Trans proline' 0 C--O 1.233 0.225 0 C-N-CA 122.695 2.263 . . . . 0.0 111.837 177.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.65 -10.17 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.276 -0.42 . . . . 0.0 112.053 -175.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.81 151.96 10.24 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.053 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 8.8 mt -88.8 34.4 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.254 0.549 . . . . 0.0 110.279 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 23.6 m -69.6 97.81 1.08 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 46.6 m-80 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.41 -0.805 . . . . 0.0 109.595 178.68 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.9 tppt? -79.23 139.15 37.99 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 110.516 -0.179 . . . . 0.0 110.516 -179.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m 74.46 8.38 4.46 Favored 'General case' 0 N--CA 1.466 0.37 0 O-C-N 123.86 0.725 . . . . 0.0 111.955 175.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -116.32 141.2 48.47 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 174.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.46 HG23 ' HD2' ' A' ' 6' ' ' PRO . 51.4 mt -124.53 140.73 35.98 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -174.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.607 ' HD3' ' HD3' ' A' ' 92' ' ' PRO . 31.1 Cg_endo -67.41 154.97 72.27 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.149 1.899 . . . . 0.0 112.539 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -67.02 -27.9 41.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 21.2 m -55.24 -32.67 62.5 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.968 177.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -92.92 -46.62 7.41 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.019 0.437 . . . . 0.0 110.394 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -66.84 -38.93 82.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.696 -172.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.1 tp -56.34 -62.51 4.73 Favored Pre-proline 0 CA--C 1.545 0.756 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -178.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.83 -18.43 41.56 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 122.139 1.892 . . . . 0.0 113.328 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.413 ' HB3' ' ND2' ' A' ' 84' ' ' ASN . 90.2 mtt-85 -101.83 13.53 34.58 Favored 'General case' 0 C--N 1.324 -0.527 0 O-C-N 122.201 -0.312 . . . . 0.0 111.514 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.86 154.23 17.34 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.779 0.323 . . . . 0.0 111.143 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 32' ' ' VAL . 21.4 m -120.85 1.66 6.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.559 178.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.517 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.14 155.36 26.62 Favored Glycine 0 N--CA 1.442 -0.939 0 N-CA-C 110.551 -1.019 . . . . 0.0 110.551 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 29.3 m -154.09 129.47 9.82 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.321 0.561 . . . . 0.0 110.589 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.59 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.0 mt -108.96 118.84 37.83 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 177.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.423 ' HA ' HG12 ' A' ' 77' ' ' ILE . 47.8 m -90.57 111.43 22.73 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 179.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 18' ' ' LEU . 28.0 m-85 -104.49 158.22 16.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.57 0.7 . . . . 0.0 110.621 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.477 ' HB2' HD21 ' A' ' 27' ' ' LEU . 19.8 t70 -87.79 169.44 12.07 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.402 176.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.579 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 16.2 pt-20 -71.61 -15.82 62.26 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 120.969 0.414 . . . . 0.0 110.218 178.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -86.87 9.21 19.94 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.008 172.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.486 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 90.0 m-85 65.15 33.68 9.22 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.421 176.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 -104.35 143.76 32.56 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.535 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.1 tp -70.29 128.0 34.72 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.709 178.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.477 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.7 mt -104.33 -55.41 2.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.576 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -140.35 148.34 41.18 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.686 -175.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 22.8 m -122.02 129.57 52.55 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.428 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.8 m -133.97 148.58 51.17 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.662 -177.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.517 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.1 -147.38 46.05 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.369 175.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.571 HG11 ' CE2' ' A' ' 65' ' ' TYR . 33.2 t -65.23 -15.89 19.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.971 0.415 . . . . 0.0 111.367 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.59 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.94 -13.5 25.7 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.382 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -75.04 -28.71 60.53 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.091 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 32' ' ' VAL . 20.4 m -97.37 -21.84 5.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.908 0.385 . . . . 0.0 110.659 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -74.34 145.12 11.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.261 177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -67.02 147.9 52.63 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.64 -59.27 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.724 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.638 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 53.3 m 56.85 -172.53 0.02 OUTLIER Pre-proline 0 CA--C 1.548 0.875 0 O-C-N 123.204 0.315 . . . . 0.0 111.807 170.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.638 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 13.9 Cg_exo -72.66 40.48 0.48 Allowed 'Trans proline' 0 C--N 1.355 0.884 0 C-N-CA 122.436 2.091 . . . . 0.0 113.713 177.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.541 ' O ' HG13 ' A' ' 45' ' ' ILE . 40.3 mt -61.36 -37.85 78.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-O 120.909 0.385 . . . . 0.0 110.1 175.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.486 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -59.56 -34.31 72.53 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.707 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 11.1 tp10 -61.98 -40.05 94.28 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.305 176.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.566 HG21 ' HA ' ' A' ' 59' ' ' VAL . 15.5 mm -77.55 -28.96 16.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.538 -0.465 . . . . 0.0 109.92 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.1 mt -61.97 -46.33 96.72 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.649 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.9 ptm180 -65.09 -40.97 95.36 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.732 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.459 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.2 mttt -60.14 -49.0 79.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.031 0.443 . . . . 0.0 110.137 176.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.558 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.5 m -64.81 -31.36 72.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.74 -179.453 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.478 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 12.8 t30 -65.17 -35.23 80.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.028 0.442 . . . . 0.0 110.85 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.95 -23.08 41.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.016 179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.413 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 6.8 mm-40 -85.41 -46.35 11.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.722 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.6 pp -123.66 166.42 15.54 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.855 0.36 . . . . 0.0 111.453 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -118.29 -1.39 16.13 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.39 -0.91 . . . . 0.0 113.294 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -163.55 -45.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 117.26 0.53 . . . . 0.0 112.079 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 58.8 mt -58.65 165.71 2.13 Favored 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.41 0.444 . . . . 0.0 111.844 -173.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.437 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -99.59 100.91 2.3 Favored Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.646 -0.788 . . . . 0.0 113.376 -176.295 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.49 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 44.6 t80 -79.02 132.47 36.65 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.6 m -70.68 109.0 4.66 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.07 0.462 . . . . 0.0 110.174 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.566 ' HA ' HG21 ' A' ' 44' ' ' ILE . 27.3 m -94.38 -31.22 4.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.402 -176.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -139.19 123.9 18.54 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.285 -178.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.533 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.9 tt0 -118.67 123.5 45.08 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.23 0.538 . . . . 0.0 110.326 178.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.504 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 26.8 t70 -120.89 167.19 12.8 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 177.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.73 -19.34 65.13 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.018 0.437 . . . . 0.0 111.173 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.401 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 26.5 mt-30 -99.67 -51.13 3.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.251 -179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.571 ' CE2' HG11 ' A' ' 32' ' ' VAL . 18.9 m-85 -133.21 165.06 25.68 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.927 0.394 . . . . 0.0 111.332 -172.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.533 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.6 mt -134.74 127.45 49.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.057 177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -95.01 143.17 16.45 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.231 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 41.3 m-70 -130.66 132.16 45.27 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.455 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -87.81 124.6 33.79 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 120.7 0.286 . . . . 0.0 111.716 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.437 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 83.2 m-85 -117.97 140.12 50.19 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.546 176.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.478 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.2 OUTLIER -81.66 120.18 24.76 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.177 174.474 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.511 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.9 mmmt -113.74 -178.14 3.3 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.749 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.51 94.91 0.13 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.899 0.381 . . . . 0.0 111.648 -178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.27 7.34 59.99 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.869 178.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.9 m80 -144.55 173.03 12.16 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.046 0.45 . . . . 0.0 111.191 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 46.5 m-85 -127.75 127.21 43.22 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.779 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.2 mt -127.37 135.19 64.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 C-N-CA 120.255 -0.578 . . . . 0.0 111.239 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 65.8 t -105.06 111.37 34.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.437 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 81.6 m-85 -93.13 124.29 37.0 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.292 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -97.99 118.93 35.69 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.736 -179.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 14' ' ' ALA . 82.3 p -106.88 148.31 36.69 Favored Pre-proline 0 C--N 1.317 -0.815 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -72.88 55.64 2.83 Favored 'Trans proline' 0 N--CA 1.474 0.372 0 C-N-CA 122.606 2.204 . . . . 0.0 112.128 -179.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.504 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 41.6 mttm 60.07 22.78 11.98 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.061 -171.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.413 ' ND2' ' HB3' ' A' ' 13' ' ' ARG . 38.0 t-20 -70.23 114.27 8.21 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.589 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 45.5 pttt -128.74 7.88 5.72 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.772 -1.103 . . . . 0.0 109.4 -176.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 87' ' ' ARG . 73.6 m-20 64.0 -85.02 0.02 OUTLIER 'General case' 0 C--O 1.231 0.096 0 CA-C-N 115.103 -0.953 . . . . 0.0 109.725 -169.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 86' ' ' ASN . 48.5 ttp180 164.08 -47.8 0.0 OUTLIER 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 177.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -68.87 148.48 50.17 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 114.693 -1.139 . . . . 0.0 110.049 179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -78.36 65.69 3.33 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.001 178.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 m -83.76 106.41 14.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.278 0.561 . . . . 0.0 110.769 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -118.98 122.94 29.27 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.883 -178.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.607 ' HD3' ' HD3' ' A' ' 6' ' ' PRO . 76.8 Cg_endo -75.48 133.26 15.68 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 123.037 2.491 . . . . 0.0 112.654 -179.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -61.39 135.41 57.44 Favored 'Trans proline' 0 N--CA 1.464 -0.247 0 C-N-CA 122.583 2.189 . . . . 0.0 111.754 176.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.2 p -73.58 100.4 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.683 0.754 . . . . 0.0 110.839 -178.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -85.67 20.97 16.0 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.771 -0.65 . . . . 0.0 112.848 -177.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.4 mm -79.03 -40.85 22.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.405 0.621 . . . . 0.0 109.537 176.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.8 t -87.6 135.98 33.14 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.319 178.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.558 -0.734 . . . . 0.0 110.592 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.5 tpp . . . . . 0 N--CA 1.48 1.065 0 CA-C-O 121.048 0.451 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -77.34 92.29 3.91 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.27 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -90.09 7.75 36.23 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.74 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.536 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 13.2 m -82.47 101.41 10.66 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.19 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.489 HG23 ' HD2' ' A' ' 6' ' ' PRO . 75.0 mt -109.96 139.24 21.13 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.763 -174.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.606 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 20.1 Cg_endo -62.66 151.37 83.96 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.52 2.147 . . . . 0.0 112.568 -178.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.5 tp -67.19 -25.46 33.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.418 -175.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 6' ' ' PRO . 12.5 t -61.24 -21.57 64.0 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-O 120.902 0.382 . . . . 0.0 110.788 178.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -97.54 -50.6 4.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.27 0.557 . . . . 0.0 110.276 177.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.5 t -67.34 -36.98 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.105 -172.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.72 -62.57 4.35 Favored Pre-proline 0 CA--C 1.541 0.608 0 N-CA-C 112.227 0.455 . . . . 0.0 112.227 -178.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.26 -25.54 57.19 Favored 'Trans proline' 0 C--N 1.351 0.693 0 C-N-CA 121.979 1.786 . . . . 0.0 113.121 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.476 HH12 ' CD ' ' A' ' 88' ' ' GLU . 44.8 mtt180 -92.71 3.98 54.6 Favored 'General case' 0 C--N 1.33 -0.27 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.531 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.19 146.51 27.06 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.164 0.506 . . . . 0.0 111.433 -177.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.4 m -115.08 -0.73 9.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.637 178.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.675 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -160.03 158.82 30.14 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 178.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 p -152.1 134.07 14.94 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.116 0.484 . . . . 0.0 111.399 -178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.558 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 10.2 mt -111.27 119.21 38.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.221 175.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.0 m -93.95 112.83 24.73 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.608 -178.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.451 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.3 m-85 -112.4 152.43 28.66 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.365 0.603 . . . . 0.0 110.437 176.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.461 ' HB2' HD21 ' A' ' 27' ' ' LEU . 24.7 t70 -87.96 168.86 12.5 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.48 174.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.568 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 6.2 pt-20 -62.83 -25.17 68.13 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.83 0.348 . . . . 0.0 110.858 178.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.428 ' HB2' HD22 ' A' ' 25' ' ' ASN . 43.2 m-80 -83.99 10.78 9.08 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.446 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 59.6 m-85 65.96 28.47 10.56 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.82 175.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.428 HD22 ' HB2' ' A' ' 23' ' ' ASN . 59.7 m-80 -93.81 129.37 40.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.936 174.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 33.3 tp -62.14 120.29 10.61 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 121.082 0.468 . . . . 0.0 110.358 174.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.461 HD21 ' HB2' ' A' ' 21' ' ' ASP . 76.2 mt -99.0 -46.25 5.67 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.588 -179.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.442 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 8.3 t70 -148.88 147.8 29.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.431 -174.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.4 m -127.64 117.46 22.02 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.109 177.004 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.1 m -129.68 154.36 47.22 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.114 0.483 . . . . 0.0 111.634 -177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.675 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.0 -150.17 43.85 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.945 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.525 HG11 ' CE2' ' A' ' 65' ' ' TYR . 58.1 t -63.89 -19.22 24.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.071 0.462 . . . . 0.0 111.147 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.558 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.58 -16.27 46.54 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.013 179.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.8 mtmt -73.39 -41.57 63.2 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.836 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.2 m -86.58 -21.83 7.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.027 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 64.5 mt -67.71 140.98 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.238 174.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -67.04 136.31 55.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.439 -177.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -82.95 87.92 6.85 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.076 175.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.414 ' HB3' ' CD ' ' A' ' 40' ' ' PRO . 49.5 m -89.72 177.09 2.62 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.283 175.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.414 ' CD ' ' HB3' ' A' ' 39' ' ' SER . 36.0 Cg_exo -63.61 61.3 0.2 Allowed 'Trans proline' 0 C--N 1.354 0.832 0 C-N-CA 122.898 2.399 . . . . 0.0 113.146 176.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -73.94 -32.45 33.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.197 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.582 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.35 -34.19 68.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.908 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.613 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 7.8 tp10 -63.31 -39.41 94.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.882 176.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.444 HG22 HG12 ' A' ' 59' ' ' VAL . 17.8 mm -78.86 -27.99 13.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.927 179.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.5 mt -61.95 -46.49 96.37 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.672 178.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.613 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 3.4 ptm180 -66.14 -42.93 88.39 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.828 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.586 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.6 mttt -59.44 -47.72 84.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.289 177.278 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 20.4 m -66.75 -26.76 67.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.708 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.702 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.1 t30 -62.7 -36.65 83.61 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.959 0.409 . . . . 0.0 110.318 178.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.89 -24.9 37.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.586 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 19.8 mm-40 -77.44 -34.32 54.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 112.053 -178.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.571 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -141.9 -174.18 4.01 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -172.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -121.91 -89.44 1.0 Allowed Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.653 173.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 14.6 ttm180 -92.72 2.61 56.64 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 121.058 0.456 . . . . 0.0 111.217 -177.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.536 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.9 mm? -83.02 163.32 21.05 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.31 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.14 93.59 0.65 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.709 -179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.571 ' HB2' HD23 ' A' ' 52' ' ' LEU . 91.7 t80 -70.78 137.03 49.23 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 177.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.7 m -68.42 107.78 3.01 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.022 0.439 . . . . 0.0 109.93 178.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.502 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.7 m -96.56 -32.96 4.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.966 -177.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.1 t80 -134.1 108.59 8.41 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.775 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.45 ' HG3' HG12 ' A' ' 66' ' ' ILE . 26.4 tt0 -106.01 120.58 42.14 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.147 0.499 . . . . 0.0 110.459 176.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.51 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -118.51 162.17 18.8 Favored 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 175.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -64.52 -18.09 64.51 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.785 0.326 . . . . 0.0 111.482 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 25.2 mt-30 -98.19 -49.61 4.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.026 179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.525 ' CE2' HG11 ' A' ' 32' ' ' VAL . 35.8 m-85 -136.95 162.58 32.88 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.748 0.309 . . . . 0.0 111.314 -172.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.45 HG12 ' HG3' ' A' ' 61' ' ' GLU . 66.7 mt -130.35 125.77 60.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.392 177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.22 140.98 15.39 Favored Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.089 178.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.512 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 49.3 m-70 -127.91 125.31 39.36 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.502 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.66 123.47 29.84 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.754 -0.378 . . . . 0.0 111.468 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.482 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 78.0 m-85 -114.91 140.06 49.3 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.557 177.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.702 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -81.62 126.02 31.25 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.73 174.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.56 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.6 mmmt -118.06 -179.42 3.76 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -177.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.47 97.49 0.59 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.919 0.39 . . . . 0.0 110.722 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 65.29 16.74 62.99 Favored Glycine 0 N--CA 1.452 -0.243 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.504 -179.037 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -144.26 172.26 13.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.925 0.393 . . . . 0.0 110.921 -174.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.568 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.5 m-85 -135.46 120.51 18.75 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 177.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.56 HG13 ' HG3' ' A' ' 72' ' ' LYS . 51.9 mt -122.71 132.87 70.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.645 -178.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.3 t -103.86 110.22 29.51 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.043 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -91.45 121.37 33.1 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.016 -179.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.403 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.4 m-85 -96.93 120.35 37.11 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.369 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 ' HA ' ' A' ' 14' ' ' ALA . 76.4 p -109.81 158.99 33.37 Favored Pre-proline 0 C--N 1.321 -0.656 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 57.4 Cg_endo -71.44 59.36 2.53 Favored 'Trans proline' 0 N--CA 1.475 0.397 0 C-N-CA 122.761 2.307 . . . . 0.0 112.152 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.51 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.5 mttm 60.36 27.86 17.45 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.982 -174.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -66.0 107.57 1.92 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.723 174.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.453 ' HG2' ' OD1' ' A' ' 86' ' ' ASN . 43.5 tttm -145.29 105.35 4.04 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.25 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.459 ' HA ' ' HB ' ' A' ' 90' ' ' VAL . 3.2 p-10 42.43 44.01 3.3 Favored 'General case' 0 N--CA 1.476 0.833 0 O-C-N 123.953 0.783 . . . . 0.0 111.238 -175.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 11.0 tpt180 -43.81 -70.61 0.1 Allowed 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 114.779 -1.1 . . . . 0.0 112.851 -174.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.476 ' CD ' HH12 ' A' ' 13' ' ' ARG . 0.9 OUTLIER -98.79 35.03 1.93 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.993 0.425 . . . . 0.0 110.797 179.684 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 86.5 34.9 11.09 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.44 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 86' ' ' ASN . 52.1 t -74.86 95.63 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 120.927 0.394 . . . . 0.0 110.661 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.4 m -94.35 115.59 65.43 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.262 175.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.606 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 52.7 Cg_endo -72.85 118.51 5.6 Favored 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.411 2.074 . . . . 0.0 112.887 -178.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -79.97 91.32 1.18 Allowed 'Trans proline' 0 N--CA 1.455 -0.794 0 C-N-CA 122.455 2.103 . . . . 0.0 111.321 176.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.3 m -69.69 108.27 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-O 121.577 0.703 . . . . 0.0 111.813 -176.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -148.32 53.19 0.53 Allowed Glycine 0 N--CA 1.446 -0.641 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.488 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 27.3 pt -83.39 -31.26 8.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.74 0.305 . . . . 0.0 111.158 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.0 p -108.18 137.05 46.82 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.51 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.7 p-10 . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.441 -0.79 . . . . 0.0 110.169 -177.637 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 52.1 mtt . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.959 0.409 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -138.75 93.62 2.74 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.6 m -82.6 82.97 7.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.53 0.681 . . . . 0.0 111.011 -176.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.411 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 12.1 p -126.26 155.67 41.53 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.198 -0.91 . . . . 0.0 108.869 173.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.416 HG23 ' HD2' ' A' ' 6' ' ' PRO . 55.0 mt -131.22 137.78 31.39 Favored Pre-proline 0 C--N 1.322 -0.612 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.538 ' HB2' HG22 ' A' ' 8' ' ' THR . 41.3 Cg_endo -69.42 155.03 68.21 Favored 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.074 1.85 . . . . 0.0 112.254 -179.06 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.4 tp -70.2 -26.17 28.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.838 -175.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.538 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.5 t -58.73 -26.45 63.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.795 177.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -94.83 -48.66 5.93 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.915 177.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.8 t -66.35 -34.13 68.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -173.121 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 15.3 tp -54.92 -63.1 3.22 Favored Pre-proline 0 CA--C 1.544 0.737 0 N-CA-C 111.982 0.364 . . . . 0.0 111.982 -179.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.0 -27.17 30.45 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 122.054 1.836 . . . . 0.0 113.194 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' HH11 ' A' ' 13' ' ' ARG . 60.9 mtt-85 -84.48 -1.25 55.44 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.583 0.216 . . . . 0.0 111.583 -177.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -85.99 154.62 21.32 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.191 0.52 . . . . 0.0 111.415 -177.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' O ' HG23 ' A' ' 32' ' ' VAL . 18.8 m -120.99 2.21 6.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.276 176.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.757 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.59 162.11 34.21 Favored Glycine 0 N--CA 1.447 -0.58 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 177.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 27.6 p -154.02 138.58 16.88 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.15 0.5 . . . . 0.0 111.337 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.548 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.1 mt -117.28 117.96 30.97 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.265 174.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.457 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 24.6 m -94.6 119.12 32.76 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 120.824 0.345 . . . . 0.0 110.315 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 10.6 m-85 -113.77 154.94 26.53 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.497 0.665 . . . . 0.0 110.866 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.59 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 26.7 t70 -91.25 171.89 8.92 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.941 178.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.4 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 8.6 pt-20 -64.64 -22.89 67.09 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.072 0.463 . . . . 0.0 110.348 178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 42.6 m-80 -85.25 13.72 6.09 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.594 177.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 72.2 m-85 62.43 26.46 15.77 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.196 178.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -96.98 132.39 42.84 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.136 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 27.5 tp -65.19 123.05 18.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.026 0.441 . . . . 0.0 111.061 177.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.452 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.6 mt -103.13 -53.31 2.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.853 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.457 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.8 t70 -134.6 141.16 46.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.191 -175.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 27.2 m -126.72 114.96 18.68 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.386 177.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.5 m -131.24 157.3 43.62 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.867 0.365 . . . . 0.0 111.109 -177.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.757 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.95 -152.61 45.85 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.261 -0.495 . . . . 0.0 112.6 178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.677 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.5 t -62.24 -20.83 25.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.092 0.472 . . . . 0.0 110.893 179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.548 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.48 -15.66 29.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.389 -178.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.6 mtmt -72.59 -37.26 68.2 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.768 179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.2 m -93.49 -18.95 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.944 0.402 . . . . 0.0 110.682 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.432 ' HB ' ' HA ' ' A' ' 33' ' ' ALA . 78.3 mt -69.77 135.51 28.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.631 172.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 37' ' ' GLU . 1.5 pm0 -69.66 145.39 52.43 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.15 0.5 . . . . 0.0 111.396 -177.277 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -84.33 85.04 7.43 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.145 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.88 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 12.1 p -79.27 -178.31 1.07 Allowed Pre-proline 0 C--N 1.322 -0.595 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.008 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.88 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 38.3 Cg_endo -67.66 44.65 0.26 Allowed 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 122.634 2.223 . . . . 0.0 113.002 175.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 45' ' ' ILE . 71.4 mt -58.16 -34.68 50.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.732 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.544 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -58.79 -33.17 70.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.341 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.548 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 23.4 tp10 -65.95 -35.68 81.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.568 0.699 . . . . 0.0 109.871 177.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.492 HG21 ' HA ' ' A' ' 59' ' ' VAL . 7.6 mm -80.71 -26.92 11.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.637 179.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 41' ' ' ILE . 48.6 mt -61.97 -48.11 90.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.361 177.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 24' ' ' TYR . 5.5 ptm180 -64.88 -38.41 90.88 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.866 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.568 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 95.1 mttt -58.24 -51.59 69.12 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.177 0.513 . . . . 0.0 109.806 174.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.515 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 15.6 m -67.25 -27.81 67.52 Favored 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.942 -176.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.688 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -64.09 -35.81 81.95 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.204 0.526 . . . . 0.0 110.071 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.17 -28.15 48.17 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.382 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.568 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 22.5 mm-40 -73.03 -43.45 62.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.868 -179.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.591 HD21 ' HB2' ' A' ' 57' ' ' TYR . 3.2 pp -142.57 -175.23 4.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.209 0.528 . . . . 0.0 112.415 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.585 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -125.78 -81.7 0.43 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.435 171.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.57 ' HG2' ' HA ' ' A' ' 98' ' ' ASN . 6.4 tpp180 -89.37 -8.39 53.25 Favored 'General case' 0 CA--C 1.534 0.352 0 CA-C-O 120.831 0.348 . . . . 0.0 111.435 -176.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' SER . 3.4 mm? -81.52 166.98 19.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.803 0.335 . . . . 0.0 110.663 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -109.21 131.95 10.81 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.681 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.591 ' HB2' HD21 ' A' ' 52' ' ' LEU . 28.2 t80 -112.49 129.54 56.31 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -64.32 110.15 2.15 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.86 0.362 . . . . 0.0 110.491 178.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.496 HG11 ' HB2' ' A' ' 69' ' ' ALA . 21.5 m -106.06 -29.36 2.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.434 -178.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -131.98 107.5 8.73 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.423 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -109.9 121.19 44.66 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.237 0.541 . . . . 0.0 110.806 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.544 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.5 t70 -124.22 162.81 22.91 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 175.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.7 -21.83 66.05 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.84 0.352 . . . . 0.0 111.134 179.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.8 mt-30 -92.22 -57.61 2.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.865 178.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.677 ' CE2' HG11 ' A' ' 32' ' ' VAL . 17.8 m-85 -129.81 160.51 33.26 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.129 0.49 . . . . 0.0 111.792 -170.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.423 HG12 ' HG3' ' A' ' 61' ' ' GLU . 67.9 mt -131.49 123.16 52.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.967 176.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.69 141.48 15.59 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.932 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.545 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.6 m-70 -125.39 128.74 48.6 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -178.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.496 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.45 124.4 29.4 Favored 'General case' 0 CA--C 1.518 -0.273 0 CA-C-O 120.98 0.419 . . . . 0.0 111.795 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -116.54 141.92 47.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.504 176.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.688 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -85.04 127.41 34.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 172.438 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.551 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.5 mmmt -114.51 -173.7 2.34 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.222 -178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.52 89.98 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.232 0.539 . . . . 0.0 111.479 -179.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.61 17.09 72.55 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.606 -0.724 . . . . 0.0 112.887 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.59 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 6.2 m170 -146.31 173.58 12.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.863 0.363 . . . . 0.0 111.193 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.4 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.3 m-85 -125.9 128.59 47.82 Favored 'General case' 0 C--O 1.216 -0.681 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.644 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.551 HD12 ' HE2' ' A' ' 72' ' ' LYS . 45.3 mt -130.7 133.54 63.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 C-N-CA 120.391 -0.524 . . . . 0.0 110.77 178.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 58.5 t -104.35 112.63 38.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.115 179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -93.68 123.72 37.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.468 179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.534 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 91.6 m-85 -97.6 117.81 32.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.763 -178.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 62.0 p -108.33 155.41 40.36 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.352 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.48 54.81 2.46 Favored 'Trans proline' 0 N--CA 1.477 0.526 0 C-N-CA 122.962 2.442 . . . . 0.0 112.504 179.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.544 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 32.1 mttm 63.83 31.76 13.85 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.863 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 5.4 t30 -70.06 96.74 1.09 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 172.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -102.21 -81.67 0.49 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.775 -176.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.623 ' HA ' HG21 ' A' ' 90' ' ' VAL . 4.2 p-10 -135.77 118.74 16.34 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.185 0.517 . . . . 0.0 110.825 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -138.77 -78.05 0.35 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.705 176.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -157.34 125.3 5.44 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.408 -176.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 82.04 2.0 90.46 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.458 177.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.623 HG21 ' HA ' ' A' ' 86' ' ' ASN . 34.6 m -89.77 -0.15 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.831 0.348 . . . . 0.0 111.28 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 15.6 m -78.14 121.93 84.61 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-O 121.221 0.534 . . . . 0.0 111.197 -178.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.491 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 50.1 Cg_endo -68.57 136.3 35.91 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.951 2.434 . . . . 0.0 112.715 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.464 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 6.4 Cg_exo -73.24 104.68 1.83 Allowed 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.548 2.165 . . . . 0.0 109.88 171.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 29.7 m -59.44 131.96 24.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.188 0.518 . . . . 0.0 111.868 -171.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 81.11 -58.52 4.82 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.45 -0.795 . . . . 0.0 113.202 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 46.7 mm -95.47 97.47 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.987 0.423 . . . . 0.0 111.737 -174.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 t -176.8 132.14 0.19 Allowed 'General case' 0 C--O 1.236 0.347 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.989 175.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.57 ' HA ' ' HG2' ' A' ' 54' ' ' ARG . 8.8 p30 . . . . . 0 C--O 1.25 1.119 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.077 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.478 0.963 0 CA-C-O 120.967 0.413 . . . . 0.0 110.541 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? -103.09 107.93 18.93 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.4 m -64.75 116.56 6.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.427 0.632 . . . . 0.0 112.265 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 26.8 p -91.39 126.49 36.49 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.257 173.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.413 HG23 ' HD2' ' A' ' 6' ' ' PRO . 63.6 mt -133.82 137.82 29.46 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.861 -0.154 . . . . 0.0 110.752 -172.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.548 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 56.4 Cg_endo -71.64 160.92 46.88 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.669 2.246 . . . . 0.0 112.526 177.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.444 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.2 tp -63.99 -30.13 49.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.845 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 9.7 t -57.46 -25.92 60.43 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.672 0.272 . . . . 0.0 111.256 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.4 mm-40 -99.17 -43.08 6.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.8 0.333 . . . . 0.0 110.648 178.14 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.7 t -64.85 -37.04 79.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.669 -175.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -53.25 -62.43 3.54 Favored Pre-proline 0 CA--C 1.542 0.654 0 N-CA-C 111.958 0.355 . . . . 0.0 111.958 -178.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.97 -24.61 39.29 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.004 1.803 . . . . 0.0 113.051 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -88.04 4.87 43.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.698 0.285 . . . . 0.0 111.614 -178.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.516 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.99 148.65 22.26 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 110.842 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 19.7 m -114.02 -0.15 9.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.295 0.569 . . . . 0.0 110.455 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.11 148.2 14.18 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.3 m -143.3 129.39 19.68 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 117.331 0.566 . . . . 0.0 110.878 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.543 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.3 mt -108.71 116.91 32.87 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.327 175.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.613 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 12.7 m -94.79 117.3 29.92 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.168 -179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 9.2 m-85 -110.99 155.57 22.52 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.491 0.662 . . . . 0.0 110.991 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.444 ' HB2' HD21 ' A' ' 27' ' ' LEU . 29.4 t70 -87.29 170.46 11.41 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.577 -179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -62.08 -25.16 67.53 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.071 177.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 34.9 m-80 -88.13 8.94 24.5 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 121.031 0.444 . . . . 0.0 110.459 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.574 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.7 m-85 66.92 31.77 6.91 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.188 177.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -103.61 145.41 30.09 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 175.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.457 HD13 HD22 ' A' ' 18' ' ' LEU . 42.8 tp -65.08 126.86 29.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.971 0.415 . . . . 0.0 111.594 -179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.444 HD21 ' HB2' ' A' ' 21' ' ' ASP . 87.2 mt -107.34 -54.63 2.45 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.794 176.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.613 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -131.75 141.98 49.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.357 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.2 m -126.65 119.02 25.97 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.843 175.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -132.48 146.51 51.98 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.734 0.302 . . . . 0.0 110.805 -176.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.405 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.19 -150.69 44.29 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.879 175.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 65' ' ' TYR . 47.1 t -60.01 -18.4 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-O 121.054 0.454 . . . . 0.0 111.571 -177.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.543 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.61 -17.07 30.25 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.378 179.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.9 mtmt -76.13 -39.44 55.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.214 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.9 m -89.0 -9.42 10.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-O 121.212 0.529 . . . . 0.0 111.14 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.2 mt -84.4 133.22 29.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.696 171.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.85 149.22 49.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.983 0.42 . . . . 0.0 111.345 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -95.07 82.72 3.82 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.986 -179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.489 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 3.3 p -76.22 179.88 1.36 Allowed Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.749 175.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 24.3 Cg_exo -65.67 58.66 0.38 Allowed 'Trans proline' 0 C--N 1.355 0.878 0 C-N-CA 122.644 2.23 . . . . 0.0 112.755 176.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 45' ' ' ILE . 70.3 mt -69.7 -32.55 52.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.206 178.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.574 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.71 -38.79 75.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.681 -179.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -59.94 -38.65 83.02 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.649 175.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 18.4 mm -78.73 -27.62 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.257 -178.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.6 mt -61.49 -47.9 91.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.478 178.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.449 ' O ' ' HB3' ' A' ' 49' ' ' ASN . 13.1 ptm180 -66.79 -39.8 87.89 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.368 178.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.468 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 99.3 mttt -59.19 -47.76 84.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.204 0.526 . . . . 0.0 109.866 175.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.729 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 31.1 m -68.81 -23.15 64.24 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.896 178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.594 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -64.62 -35.79 82.15 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.182 0.515 . . . . 0.0 110.252 177.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.56 -24.53 36.47 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.121 176.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 61.8 mm-40 -80.81 -55.69 4.64 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.165 0.432 . . . . 0.0 112.165 -178.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.729 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -107.37 -172.32 2.05 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.49 0.662 . . . . 0.0 112.26 -170.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 -70.56 0.02 OUTLIER Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.588 175.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 54' ' ' ARG . 0.2 OUTLIER -110.11 -13.61 14.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.191 0.52 . . . . 0.0 111.082 -177.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.442 ' O ' HD22 ' A' ' 52' ' ' LEU . 2.6 mm? -94.37 149.38 21.3 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -91.85 124.24 7.56 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.699 -0.763 . . . . 0.0 113.135 -177.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.556 ' CB ' HD23 ' A' ' 52' ' ' LEU . 82.2 t80 -100.15 139.95 35.09 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 16.7 m -72.68 108.72 5.84 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.076 0.465 . . . . 0.0 110.417 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 20.3 m -97.29 -28.48 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.582 -179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -127.56 101.41 6.4 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -111.12 107.78 17.25 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.365 0.603 . . . . 0.0 110.507 -175.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.453 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.9 t70 -118.57 163.75 16.34 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.367 -0.833 . . . . 0.0 108.893 -178.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -65.21 -19.33 65.92 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 111.59 0.218 . . . . 0.0 111.59 -177.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -96.27 -57.55 2.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.947 0.403 . . . . 0.0 111.032 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.49 ' CE2' HG11 ' A' ' 32' ' ' VAL . 41.3 m-85 -131.35 165.41 23.52 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.975 0.417 . . . . 0.0 111.113 -173.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 81.6 mt -133.7 123.22 45.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.385 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.554 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -94.83 141.85 15.76 Favored Glycine 0 N--CA 1.449 -0.476 0 CA-C-N 115.925 -0.579 . . . . 0.0 112.038 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.493 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 22.1 m-70 -124.87 132.19 53.34 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -177.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -88.18 125.6 34.71 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 -178.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.444 ' CD2' ' HB ' ' A' ' 7' ' ' ILE . 83.2 m-85 -119.18 143.11 47.42 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.968 0.413 . . . . 0.0 110.894 175.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.594 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.3 OUTLIER -84.06 120.66 26.41 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.907 174.017 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -109.63 178.87 4.3 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.686 -178.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.71 98.8 0.55 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.709 0.29 . . . . 0.0 110.831 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.22 11.38 61.4 Favored Glycine 0 N--CA 1.451 -0.301 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.838 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -143.48 172.43 12.79 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.296 0.57 . . . . 0.0 111.604 -175.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -131.95 128.54 38.67 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.361 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.5 mt -131.28 137.2 56.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 120.274 -0.57 . . . . 0.0 111.088 -179.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 55.6 t -108.37 110.75 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.895 177.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -93.01 121.31 34.21 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.399 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 95.0 m-85 -93.82 116.07 28.51 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.794 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.516 HG22 ' HA ' ' A' ' 14' ' ' ALA . 69.4 p -112.24 143.09 28.13 Favored Pre-proline 0 C--N 1.316 -0.887 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.01 142.48 99.44 Favored 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 121.888 1.725 . . . . 0.0 110.388 177.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.453 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 15.8 mttm -45.38 105.31 0.06 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.94 0.4 . . . . 0.0 111.627 179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -140.14 133.82 30.37 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.059 -0.519 . . . . 0.0 109.628 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.471 ' HE3' ' HB3' ' A' ' 85' ' ' LYS . 1.0 OUTLIER -141.96 120.83 12.75 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.448 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -106.94 -171.1 1.82 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -87.81 32.24 0.74 Allowed 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.485 -0.135 . . . . 0.0 111.083 -178.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 66.15 -85.78 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.285 0 O-C-N 123.628 0.58 . . . . 0.0 110.285 -175.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.33 -98.24 0.5 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 121.306 -0.473 . . . . 0.0 113.3 175.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.2 m -87.29 57.11 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.547 0.689 . . . . 0.0 111.138 -175.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.7 m -68.88 142.42 93.49 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.482 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.548 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 72.7 Cg_endo -75.31 159.79 39.83 Favored 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 122.892 2.394 . . . . 0.0 112.007 176.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -59.18 117.11 3.79 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.395 2.064 . . . . 0.0 111.186 174.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 16.0 m -76.54 132.99 31.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.171 0.51 . . . . 0.0 111.468 -177.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 142.82 -168.04 26.09 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.997 -0.62 . . . . 0.0 111.797 179.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm -97.18 127.05 49.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 20.6 p -81.38 68.46 7.71 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.937 -176.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 72.5 m-20 . . . . . 0 C--O 1.246 0.906 0 CA-C-O 118.451 -0.785 . . . . 0.0 109.64 175.159 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.9 tmm? . . . . . 0 N--CA 1.477 0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.8 mmmt -133.85 175.41 9.49 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.036 179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.6 t -102.96 -28.42 12.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.001 0.429 . . . . 0.0 110.353 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.561 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 17.8 m -78.09 106.98 10.33 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.993 -178.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 84.0 mt -107.89 137.75 19.87 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.76 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' ILE . 18.6 Cg_endo -60.0 149.95 81.31 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 122.677 2.252 . . . . 0.0 112.689 -177.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.432 ' HB ' ' CD2' ' A' ' 70' ' ' PHE . 8.3 tp -66.15 -28.69 44.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.613 -174.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -60.31 -21.84 62.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.908 0.385 . . . . 0.0 110.893 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 21.7 mm-40 -95.27 -50.37 5.06 Favored 'General case' 0 C--O 1.238 0.456 0 CA-C-O 121.604 0.716 . . . . 0.0 110.376 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.411 HG13 ' CG2' ' A' ' 81' ' ' THR . 89.9 t -68.33 -38.22 79.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.938 -172.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.4 tp -54.36 -63.58 2.63 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 112.168 0.432 . . . . 0.0 112.168 -177.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.61 -27.79 53.1 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.752 1.634 . . . . 0.0 112.831 -179.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.696 ' HB3' HD21 ' A' ' 84' ' ' ASN . 65.7 mtt180 -90.9 7.28 40.87 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.466 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -90.0 152.79 21.02 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.013 0.435 . . . . 0.0 111.123 -179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.41 HG21 ' CE1' ' A' ' 65' ' ' TYR . 23.5 m -123.64 4.76 5.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.973 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.556 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.78 149.36 16.57 Favored Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 m -145.46 130.89 18.7 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.488 0.644 . . . . 0.0 110.934 -176.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.53 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.2 mt -108.79 118.64 37.33 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.483 176.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 25.0 m -92.69 114.54 27.12 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.333 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 11.1 m-85 -111.23 152.92 26.56 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.314 0.578 . . . . 0.0 110.616 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.462 ' HB2' HD21 ' A' ' 27' ' ' LEU . 30.8 t70 -85.54 168.02 14.89 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.173 177.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.488 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -61.34 -24.94 66.81 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.83 0.348 . . . . 0.0 110.808 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.6 m-80 -86.77 14.04 7.81 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.75 177.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.532 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 82.9 m-85 63.7 32.52 13.69 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.512 174.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -110.01 144.89 37.9 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.688 0.28 . . . . 0.0 110.465 174.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.443 HD13 HD22 ' A' ' 18' ' ' LEU . 43.4 tp -66.32 127.73 33.39 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.063 179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 21' ' ' ASP . 92.2 mt -102.77 -54.72 2.58 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.578 177.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -144.09 145.9 32.46 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.005 -173.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.437 HG22 ' HG2' ' A' ' 34' ' ' LYS . 27.6 m -125.3 123.39 39.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.776 -178.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 15.3 m -130.49 152.64 49.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.91 0.386 . . . . 0.0 111.199 -178.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.556 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.97 -151.2 43.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.804 175.237 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.593 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.8 t -63.97 -18.56 22.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.991 0.424 . . . . 0.0 111.309 -178.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.53 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.67 -18.17 39.93 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.22 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HG2' HG22 ' A' ' 29' ' ' THR . 54.5 mtmt -73.93 -42.3 60.79 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.999 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 35.9 m -84.88 -15.36 10.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 120.827 0.346 . . . . 0.0 111.052 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.1 mt -78.25 142.62 13.87 Favored 'Isoleucine or valine' 0 C--O 1.236 0.386 0 CA-C-N 116.097 -0.502 . . . . 0.0 109.929 174.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -70.96 147.87 48.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.157 0.503 . . . . 0.0 111.556 -177.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -88.98 83.95 6.6 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.78 -178.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.69 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 47.3 m -73.21 173.27 6.31 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.161 175.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.69 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 40.6 Cg_endo -68.22 54.08 0.69 Allowed 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.815 2.344 . . . . 0.0 112.064 174.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 65.5 mt -61.95 -32.26 53.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -55.85 -36.04 67.09 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.979 0.418 . . . . 0.0 110.893 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.508 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 9.1 tp10 -61.83 -39.83 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.41 177.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.485 HG21 ' HA ' ' A' ' 59' ' ' VAL . 8.1 mm -80.85 -27.93 11.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.868 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 61.4 mt -61.94 -47.75 91.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.156 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.345 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.457 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 3.3 ptm180 -64.53 -42.61 95.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.057 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.508 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.7 mttt -60.39 -46.66 89.17 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.111 0.481 . . . . 0.0 110.354 177.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.476 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.97 -29.33 68.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.779 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.539 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.1 t30 -64.18 -33.85 76.74 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.225 0.536 . . . . 0.0 110.48 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.09 -28.25 43.02 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.752 177.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -76.07 -51.38 12.38 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.213 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.476 ' HG ' ' O ' ' A' ' 48' ' ' SER . 2.8 pp -123.42 -176.63 3.49 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -169.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.633 ' HA3' ' HA ' ' A' ' 96' ' ' ILE . . . -130.34 -70.49 0.11 Allowed Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 114.944 -1.026 . . . . 0.0 111.832 174.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 21.7 tpp180 -95.33 -8.41 35.87 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-O 120.76 0.314 . . . . 0.0 111.475 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.561 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.4 mm? -86.07 167.81 14.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.94 0.4 . . . . 0.0 110.815 -178.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.542 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.7 101.19 0.83 Allowed Glycine 0 N--CA 1.446 -0.669 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.296 177.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.473 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 53.0 t80 -75.05 134.8 41.31 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 48.8 m -68.02 109.57 3.54 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.258 0.551 . . . . 0.0 110.261 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.53 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.3 m -96.48 -32.16 4.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.032 -176.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.563 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 85.2 t80 -131.78 113.0 13.0 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.863 -179.149 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -109.61 112.63 24.82 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.117 0.484 . . . . 0.0 110.185 177.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.605 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 11.8 t70 -104.34 176.48 5.14 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 179.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -79.6 -14.33 58.89 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.529 0.68 . . . . 0.0 109.474 177.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 -103.27 -56.37 2.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.03 -0.986 . . . . 0.0 111.161 -178.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.593 ' CE2' HG11 ' A' ' 32' ' ' VAL . 64.5 m-85 -130.32 166.74 19.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.797 0.332 . . . . 0.0 111.029 -173.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.9 mt -131.04 127.92 61.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.398 178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -96.52 141.27 15.51 Favored Glycine 0 N--CA 1.447 -0.601 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.976 -179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 28.7 m-70 -127.01 129.85 48.88 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.53 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.82 123.62 31.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.84 0.352 . . . . 0.0 111.335 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.542 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.7 m-85 -116.69 141.16 48.56 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.735 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -83.28 119.77 25.0 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.578 173.23 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.51 ' HE2' HD12 ' A' ' 77' ' ' ILE . 27.3 mmmt -112.42 177.79 4.52 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.323 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 95.47 0.1 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 120.848 0.356 . . . . 0.0 111.152 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.33 12.98 64.36 Favored Glycine 0 CA--C 1.519 0.32 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.194 179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 17.9 m170 -144.49 172.25 13.22 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.07 0.462 . . . . 0.0 110.903 -177.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.488 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 82.2 m-85 -127.58 125.8 40.95 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.202 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.51 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.1 mt -127.87 133.17 67.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.843 -179.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.1 t -104.95 109.82 28.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.269 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -91.94 127.28 37.35 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.458 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -100.02 122.45 42.92 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.82 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.609 ' HB ' ' OD1' ' A' ' 84' ' ' ASN . 73.1 p -111.45 154.62 43.71 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.171 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 57.4 Cg_endo -70.54 53.93 1.42 Allowed 'Trans proline' 0 N--CA 1.476 0.462 0 C-N-CA 123.249 2.632 . . . . 0.0 113.564 -178.485 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.605 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 7.0 mttm 56.55 21.16 5.44 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.368 177.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.696 HD21 ' HB3' ' A' ' 13' ' ' ARG . 21.3 p-10 -87.06 111.98 21.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 121.603 0.716 . . . . 0.0 111.058 -177.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -95.21 29.3 2.52 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.393 -178.806 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' HB3' HG11 ' A' ' 90' ' ' VAL . 23.4 t-20 72.78 159.32 0.22 Allowed 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.093 0.871 . . . . 0.0 109.554 -173.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.528 ' HA ' ' NE ' ' A' ' 87' ' ' ARG . 0.0 OUTLIER -54.26 -65.4 0.58 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.035 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 145.06 2.42 Favored 'General case' 0 C--O 1.234 0.271 0 CA-C-O 120.915 0.388 . . . . 0.0 111.829 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 69.09 46.98 56.54 Favored Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.669 -0.696 . . . . 0.0 113.166 172.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.489 HG11 ' HB3' ' A' ' 86' ' ' ASN . 7.7 p -107.62 116.56 51.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.43 0.634 . . . . 0.0 111.079 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.7 t -120.71 97.66 48.38 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.532 174.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.493 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 27.6 Cg_endo -65.0 135.91 46.06 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.798 2.332 . . . . 0.0 112.551 -176.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 2.8 Cg_exo -75.91 138.43 20.9 Favored 'Trans proline' 0 N--CA 1.457 -0.647 0 C-N-CA 123.018 2.479 . . . . 0.0 111.864 177.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 30.2 m -66.13 139.05 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.043 178.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -169.82 128.02 1.59 Allowed Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.376 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.633 ' HA ' ' HA3' ' A' ' 53' ' ' GLY . 11.2 pt -104.49 -38.57 4.94 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 176.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.523 ' HB ' ' O ' ' A' ' 96' ' ' ILE . 13.1 t 171.81 -43.07 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.446 174.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.476 ' HB2' ' O ' ' A' ' 97' ' ' THR . 7.0 t30 . . . . . 0 C--O 1.247 0.936 0 C-N-CA 124.037 0.935 . . . . 0.0 108.782 175.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.2 ptm . . . . . 0 N--CA 1.481 1.079 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.4 mmmt -73.62 103.62 4.28 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.913 0.387 . . . . 0.0 110.206 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -116.38 98.93 6.85 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.199 0.523 . . . . 0.0 111.73 -175.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.42 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 14.9 m -92.55 101.87 14.31 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 27.0 mt -99.87 135.59 20.43 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.411 -166.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HG2' ' HG2' ' A' ' 9' ' ' GLU . 10.2 Cg_endo -55.09 151.09 36.12 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.603 2.869 . . . . 0.0 112.854 177.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.2 tp -68.04 -30.94 49.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.751 -178.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 1.4 m -55.37 -30.79 61.0 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.153 0.501 . . . . 0.0 110.948 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.421 ' HG2' ' HG2' ' A' ' 6' ' ' PRO . 9.2 mm-40 -90.31 -49.34 6.59 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.539 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.418 HG13 ' CG2' ' A' ' 81' ' ' THR . 96.5 t -69.35 -36.11 70.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.207 -172.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.0 tp -52.44 -61.16 4.94 Favored Pre-proline 0 CA--C 1.543 0.674 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.98 -30.32 26.17 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 121.899 1.733 . . . . 0.0 112.759 178.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 51.4 mtp180 -85.14 10.5 12.03 Favored 'General case' 0 C--O 1.234 0.255 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.22 152.72 20.71 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.021 0.439 . . . . 0.0 111.061 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.2 m -119.85 1.28 7.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.864 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.567 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.55 164.43 36.82 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 111.53 -0.628 . . . . 0.0 111.53 178.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 37.7 p -154.61 145.61 22.65 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.282 0.563 . . . . 0.0 111.271 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.55 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.8 mt -118.18 116.58 27.11 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.742 173.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.561 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.1 m -93.49 108.82 20.44 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.499 -178.071 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.454 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 19.2 m-85 -101.83 159.93 14.91 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.144 177.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.437 ' HB2' HD11 ' A' ' 27' ' ' LEU . 38.6 t70 -93.42 171.42 8.92 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.731 175.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.657 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 11.1 pt-20 -68.31 -17.55 64.3 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.684 0.278 . . . . 0.0 110.805 177.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.453 HD22 ' N ' ' A' ' 23' ' ' ASN . 0.9 OUTLIER -85.36 8.49 18.59 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.086 0.47 . . . . 0.0 109.776 172.12 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.408 ' CE1' ' HB3' ' A' ' 46' ' ' ARG . 76.2 m-85 64.73 28.55 13.0 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 115.336 -0.847 . . . . 0.0 112.298 175.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -100.49 139.47 36.12 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 175.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.5 tt -71.62 117.64 13.44 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.152 -178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.437 HD11 ' HB2' ' A' ' 21' ' ' ASP . 67.4 mt -97.25 -54.11 3.26 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.918 0.389 . . . . 0.0 111.106 -177.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.561 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 23.1 t70 -131.54 141.66 49.76 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.147 -174.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.422 HG23 HD21 ' A' ' 18' ' ' LEU . 9.1 m -123.48 116.4 23.15 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.839 176.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.3 m -132.35 150.81 52.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.96 0.41 . . . . 0.0 111.351 -176.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.567 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.22 -150.53 40.71 Favored Glycine 0 N--CA 1.447 -0.59 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.34 177.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.617 HG11 ' CE2' ' A' ' 65' ' ' TYR . 32.1 t -65.29 -17.37 21.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 121.075 0.464 . . . . 0.0 111.085 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.55 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.59 -13.73 24.31 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.642 -179.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.3 mtmt -74.54 -31.82 62.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.129 178.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.1 m -95.92 -23.0 5.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.999 0.428 . . . . 0.0 110.664 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.3 mt -72.63 136.83 24.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.117 177.292 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -70.22 152.5 44.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.685 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.4 mptt -79.6 -42.5 24.84 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.384 -169.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.873 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 55.2 m 60.89 -178.89 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.781 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 174.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.873 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 63.8 Cg_endo -75.05 44.36 1.16 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 122.341 2.027 . . . . 0.0 112.949 174.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.491 ' O ' HG13 ' A' ' 45' ' ' ILE . 38.4 mt -63.29 -36.41 75.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.699 -0.228 . . . . 0.0 111.111 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.09 -41.07 82.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.886 0.374 . . . . 0.0 110.81 -178.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.444 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 8.1 tp10 -61.99 -38.75 89.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.398 176.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.508 HG22 HG12 ' A' ' 59' ' ' VAL . 17.9 mm -77.94 -28.58 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.568 -178.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 49.7 mt -61.72 -46.57 96.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-O 120.689 0.281 . . . . 0.0 110.634 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.444 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 0.4 OUTLIER -68.81 -39.54 80.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.006 179.768 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 96.8 mttt -60.93 -47.06 88.17 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.308 175.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.9 m -69.76 -19.88 63.51 Favored 'General case' 0 C--O 1.22 -0.498 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.835 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.625 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.6 t30 -69.11 -33.24 73.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.346 0.594 . . . . 0.0 109.71 176.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.71 -28.24 55.77 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.018 175.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 24.7 mm-40 -73.47 -40.65 63.97 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.486 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.4 pp -149.55 175.0 11.91 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.25 0.548 . . . . 0.0 112.272 -169.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -143.86 -11.25 0.36 Allowed Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.688 172.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.42 -34.03 2.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.617 0.246 . . . . 0.0 111.229 -176.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -82.21 169.74 16.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.915 0.388 . . . . 0.0 111.056 -178.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.429 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.41 103.91 1.44 Allowed Glycine 0 N--CA 1.445 -0.73 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.999 176.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.504 ' HB2' HD21 ' A' ' 52' ' ' LEU . 39.8 t80 -79.06 134.49 36.76 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 -179.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.2 m -67.81 109.27 3.3 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.075 0.464 . . . . 0.0 110.226 178.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.55 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.2 m -96.53 -29.59 3.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.752 -177.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.667 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 83.2 t80 -139.59 100.15 3.9 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.267 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.542 ' HG3' HG12 ' A' ' 66' ' ' ILE . 27.5 tt0 -99.79 113.07 25.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.464 0.65 . . . . 0.0 109.713 175.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.673 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 18.4 t70 -108.94 167.76 9.85 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -69.16 -19.99 64.01 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 121.083 0.468 . . . . 0.0 110.527 178.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -95.22 -55.7 2.97 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.244 179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.617 ' CE2' HG11 ' A' ' 32' ' ' VAL . 54.2 m-85 -135.94 168.88 18.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.871 -172.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.542 HG12 ' HG3' ' A' ' 61' ' ' GLU . 64.0 mt -131.01 123.54 54.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.508 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -93.52 140.62 15.15 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.1 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.518 ' O ' ' HA ' ' A' ' 78' ' ' VAL . 43.7 m-70 -127.52 130.19 48.72 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -178.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.55 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.57 124.27 31.93 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.765 0.317 . . . . 0.0 111.679 -179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.429 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 87.8 m-85 -115.91 141.21 48.4 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.312 176.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.46 125.14 30.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.126 174.375 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.3 178.73 4.34 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.119 -0.492 . . . . 0.0 109.82 -179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.55 97.95 0.64 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.941 0.401 . . . . 0.0 110.889 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.96 13.96 64.95 Favored Glycine 0 N--CA 1.452 -0.255 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.631 -179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.422 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 30.9 m170 -142.76 171.1 14.52 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.895 0.379 . . . . 0.0 110.67 -176.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.657 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 68.5 m-85 -136.59 116.35 13.06 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.4 mt -116.35 133.32 63.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 C-N-CA 120.158 -0.617 . . . . 0.0 111.36 -175.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.518 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 69.1 t -104.59 111.5 34.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.46 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 54.9 m-85 -91.82 125.14 36.42 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.843 0.354 . . . . 0.0 110.87 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -97.68 116.33 29.69 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.885 -178.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.418 ' CG2' HG13 ' A' ' 10' ' ' VAL . 72.1 p -106.3 144.44 28.97 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.474 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -70.29 63.73 2.1 Favored 'Trans proline' 0 CA--C 1.532 0.387 0 C-N-CA 122.993 2.462 . . . . 0.0 112.824 178.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.673 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 33.8 mttm 49.95 29.63 3.52 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 114.073 1.138 . . . . 0.0 114.073 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -86.2 48.92 1.69 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.588 0.709 . . . . 0.0 109.875 173.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -66.9 -34.96 78.93 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.032 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -148.41 135.97 20.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.192 175.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.433 ' NH2' HG11 ' A' ' 90' ' ' VAL . 19.3 mtm180 -132.7 -68.16 0.61 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 175.045 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -137.65 -143.42 0.17 Allowed 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -74.83 50.33 2.21 Favored Glycine 0 CA--C 1.522 0.491 0 C-N-CA 120.953 -0.641 . . . . 0.0 112.832 177.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.433 HG11 ' NH2' ' A' ' 87' ' ' ARG . 15.5 m -112.4 20.8 6.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.612 0.72 . . . . 0.0 109.903 178.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.549 ' HB ' ' HD2' ' A' ' 92' ' ' PRO . 23.5 m -84.67 163.26 47.49 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.788 -1.097 . . . . 0.0 109.468 175.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 91' ' ' VAL . 1.9 Cg_endo -42.63 116.53 0.68 Allowed 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 123.587 2.858 . . . . 0.0 113.069 179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 17.9 Cg_exo -66.53 108.89 1.49 Allowed 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.781 2.321 . . . . 0.0 111.6 179.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.9 p -68.52 121.48 17.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.356 0.598 . . . . 0.0 110.586 -178.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 171.63 -89.09 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.3 mm -91.47 107.71 19.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 173.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.9 m 67.14 106.35 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 O-C-N 123.625 0.578 . . . . 0.0 110.953 -177.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.309 -178.286 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.6 mtt . . . . . 0 N--CA 1.482 1.125 0 N-CA-C 111.254 0.094 . . . . 0.0 111.254 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.0 tppt? 66.56 110.08 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.177 0 CA-C-O 121.541 0.686 . . . . 0.0 110.237 -173.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.8 m -82.95 25.43 0.68 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.733 -174.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 m -102.01 102.95 13.53 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 175.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.698 HD11 ' HA ' ' A' ' 85' ' ' LYS . 27.1 mt -105.6 141.94 23.72 Favored Pre-proline 0 C--N 1.32 -0.675 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.342 -170.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.545 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 19.3 Cg_endo -63.93 149.62 90.19 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.097 1.865 . . . . 0.0 112.152 177.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.6 tp -70.02 -24.95 26.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.826 -174.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.495 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.9 t -59.7 -22.94 62.7 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-O 120.916 0.389 . . . . 0.0 111.047 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -97.35 -48.9 5.14 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.446 0.641 . . . . 0.0 110.305 177.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' A' ' 81' ' ' THR . 92.9 t -68.39 -38.8 79.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.134 -173.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.5 tp -53.29 -61.31 5.14 Favored Pre-proline 0 CA--C 1.54 0.581 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -177.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.22 -33.63 48.35 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.864 1.71 . . . . 0.0 112.904 179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -89.19 14.24 11.37 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -177.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.93 148.11 22.28 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.839 0.352 . . . . 0.0 110.71 178.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 23.8 m -118.42 1.47 7.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.637 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.541 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.38 165.04 37.61 Favored Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.4 p -156.04 146.5 21.75 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.067 0.461 . . . . 0.0 111.122 179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.563 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.2 mt -121.32 116.1 24.2 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.152 174.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 46.6 m -93.04 112.19 24.07 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.18 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -108.11 155.57 20.26 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.531 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.575 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 31.1 t70 -86.53 170.04 12.26 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.663 176.133 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.414 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 12.1 pt-20 -67.55 -17.82 64.79 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.925 0.393 . . . . 0.0 110.619 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -85.78 6.98 25.51 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.174 173.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 66.72 28.02 9.14 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.035 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -93.41 134.04 36.06 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.451 -0.795 . . . . 0.0 109.844 177.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.432 HD13 HD22 ' A' ' 18' ' ' LEU . 27.0 tp -66.01 122.51 17.56 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.87 0.367 . . . . 0.0 110.646 177.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.6 mt -104.34 -55.98 2.27 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.426 179.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.595 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.0 t70 -132.18 147.08 52.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.284 -174.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 23.7 m -129.46 116.59 19.21 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.903 177.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.1 m -126.14 150.17 48.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.875 0.369 . . . . 0.0 111.264 -176.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.541 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 70.61 -148.34 45.04 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.974 175.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.2 t -64.78 -18.14 22.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 121.068 0.461 . . . . 0.0 111.527 -177.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.563 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -60.92 -15.59 32.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.059 0.457 . . . . 0.0 111.378 -179.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.8 mtmt -71.71 -42.26 67.58 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.826 178.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -87.98 -17.32 8.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 0.0 110.999 -177.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -75.5 136.55 24.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.291 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -70.29 146.64 50.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.453 -178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -89.9 84.4 6.21 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.234 -178.513 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.933 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 24.3 p -76.64 -174.53 0.42 Allowed Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.254 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.933 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 34.4 Cg_endo -65.58 49.57 0.22 Allowed 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 122.89 2.394 . . . . 0.0 113.471 176.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 45' ' ' ILE . 64.1 mt -64.49 -37.61 80.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.914 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.44 -38.8 78.23 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 120.793 0.33 . . . . 0.0 111.264 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' OE2' ' HD3' ' A' ' 46' ' ' ARG . 8.7 tp10 -63.1 -37.28 86.59 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.607 0.718 . . . . 0.0 110.005 178.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.481 HG22 HG12 ' A' ' 59' ' ' VAL . 17.6 mm -78.07 -30.51 16.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.114 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 41' ' ' ILE . 58.6 mt -60.01 -46.41 94.21 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.526 178.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.2 ptm180 -67.79 -41.51 83.09 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.025 -179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.484 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.9 mttt -58.7 -46.64 86.84 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.026 0.441 . . . . 0.0 109.957 175.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.65 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.7 m -67.18 -26.15 66.49 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.992 179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.413 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.1 t30 -65.98 -34.14 77.43 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.113 0.482 . . . . 0.0 110.302 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.66 -38.08 29.73 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.795 175.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.9 mm-40 -60.0 -44.12 94.74 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.918 -179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.7 pp -131.55 173.45 11.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.929 -172.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -109.25 -65.71 0.56 Allowed Glycine 0 N--CA 1.446 -0.655 0 CA-C-N 115.591 -0.732 . . . . 0.0 111.686 174.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpp180 -118.69 10.68 12.53 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.329 0.585 . . . . 0.0 111.41 -175.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -90.08 172.56 8.74 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.335 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.536 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -117.81 101.24 0.9 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.091 -0.576 . . . . 0.0 112.429 178.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 36.0 t80 -76.23 136.25 39.69 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -72.36 110.09 6.54 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.98 0.419 . . . . 0.0 110.13 -179.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.481 HG12 HG22 ' A' ' 44' ' ' ILE . 27.5 m -99.57 -34.45 4.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.367 -175.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.658 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.4 t80 -130.45 103.05 6.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.554 -176.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.544 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -103.48 115.75 31.11 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.038 0.446 . . . . 0.0 109.913 174.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.658 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 12.2 t70 -112.79 170.56 8.11 Favored 'General case' 0 C--N 1.317 -0.826 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.85 -14.43 62.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.306 0.574 . . . . 0.0 110.337 178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -100.83 -55.6 2.53 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.378 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.684 ' CE2' HG11 ' A' ' 32' ' ' VAL . 67.4 m-85 -136.28 164.97 26.85 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.278 -172.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.0 mt -131.46 124.14 54.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.344 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.382 178.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.51 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -98.08 144.14 17.09 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.23 -179.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.0 m-70 -127.03 133.03 50.6 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.489 ' O ' ' HA2' ' A' ' 56' ' ' GLY . . . -83.73 123.75 30.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.71 0.29 . . . . 0.0 111.571 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.536 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.7 m-85 -118.44 141.15 48.84 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.851 177.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.487 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.4 OUTLIER -81.77 128.23 33.78 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.336 172.728 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.508 ' HG3' HG13 ' A' ' 77' ' ' ILE . 29.8 mmmt -120.28 -175.4 2.99 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.12 93.86 0.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.09 0.471 . . . . 0.0 111.089 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.84 10.7 61.77 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.839 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.575 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 10.7 m170 -145.37 173.24 12.16 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.862 0.363 . . . . 0.0 111.688 -174.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.414 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 67.0 m-85 -125.61 127.61 46.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.936 -178.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.508 HG13 ' HG3' ' A' ' 72' ' ' LYS . 50.4 mt -128.66 135.26 62.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.857 179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 60.7 t -104.55 112.54 38.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.034 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -90.23 121.14 31.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.302 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.51 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 80.7 m-85 -95.95 118.53 32.76 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.609 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 14' ' ' ALA . 64.7 p -110.39 157.22 38.77 Favored Pre-proline 0 C--N 1.319 -0.733 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.332 -179.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.38 65.05 3.65 Favored 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 122.536 2.158 . . . . 0.0 112.134 176.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 19.2 mttm 60.83 36.78 19.0 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.516 -179.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -89.86 104.28 16.86 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.658 177.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.698 ' HA ' HD11 ' A' ' 5' ' ' ILE . 55.6 mtmt -124.95 -50.73 1.7 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.937 172.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -156.68 101.69 2.0 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.096 0.474 . . . . 0.0 110.389 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 73.4 ttt180 -142.64 -66.27 0.39 Allowed 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 178.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -130.2 147.26 51.91 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.18 -147.87 18.58 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.148 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 22.0 m -118.05 162.43 16.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.037 0.446 . . . . 0.0 111.076 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.9 m -92.97 155.65 41.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.691 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.545 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 17.7 Cg_endo -59.95 152.03 67.48 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.835 2.357 . . . . 0.0 112.671 176.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 34.1 Cg_exo -60.82 135.48 60.03 Favored 'Trans proline' 0 C--O 1.236 0.377 0 C-N-CA 122.801 2.334 . . . . 0.0 111.974 176.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.7 p -92.43 -20.76 6.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.465 0.65 . . . . 0.0 109.826 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -106.89 -143.56 11.24 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.77 176.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 49.0 mm 65.82 95.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 123.007 0.523 . . . . 0.0 111.745 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.6 p 53.54 70.67 0.57 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.648 175.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 55.4 t30 . . . . . 0 C--O 1.251 1.143 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.616 176.471 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.3 tmm? . . . . . 0 N--CA 1.477 0.891 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.3 mmmt -108.94 -59.69 1.85 Allowed 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -173.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.9 p -74.9 82.91 2.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.103 0.478 . . . . 0.0 111.88 -173.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.449 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 23.6 m -124.93 106.3 9.88 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.698 176.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 34.1 mt -91.49 133.38 31.36 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.525 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.499 ' HB2' HG22 ' A' ' 8' ' ' THR . 36.4 Cg_endo -67.69 154.57 72.93 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.497 2.131 . . . . 0.0 112.685 177.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.9 tp -63.36 -29.62 47.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.563 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.499 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.8 t -57.59 -23.71 52.32 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 120.845 0.355 . . . . 0.0 111.287 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -99.41 -43.81 6.42 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.027 0.441 . . . . 0.0 111.072 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.5 t -71.12 -34.36 54.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.686 -174.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.0 tp -53.74 -62.39 3.8 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -65.36 -31.44 52.4 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 121.874 1.716 . . . . 0.0 112.781 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -85.52 3.59 39.75 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 111.829 0.307 . . . . 0.0 111.829 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.564 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.33 149.18 24.69 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.942 0.401 . . . . 0.0 110.579 178.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.4 m -116.75 -0.2 8.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.393 0.616 . . . . 0.0 110.348 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.705 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.22 162.42 34.78 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 p -154.03 137.08 15.51 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.318 0.58 . . . . 0.0 111.68 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.531 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 15.2 mt -113.12 115.94 29.08 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.818 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.47 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 39.6 m -96.13 110.95 23.13 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.143 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.0 m-85 -104.33 159.51 15.66 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.659 176.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.449 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.6 OUTLIER -96.28 -177.88 4.12 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.282 -0.266 . . . . 0.0 110.282 179.207 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -65.87 -18.5 65.38 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.712 -178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.449 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 44.0 m-80 -96.66 10.11 39.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.661 177.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 66.32 35.17 5.98 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.53 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -103.49 143.18 33.06 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 26.5 tp -71.06 120.7 17.01 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.025 0.441 . . . . 0.0 110.754 177.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 79.9 mt -99.52 -55.55 2.64 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.411 179.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.47 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 17.6 t70 -131.81 133.37 44.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.629 -172.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.2 m -115.94 116.68 28.38 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.992 176.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 66.6 m -134.37 155.48 50.2 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.119 0.485 . . . . 0.0 111.609 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.705 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.29 -150.7 42.5 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.837 177.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.522 HG11 ' CE2' ' A' ' 65' ' ' TYR . 59.0 t -63.58 -18.44 22.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.193 0.52 . . . . 0.0 110.794 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.531 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.51 -15.56 39.29 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.073 179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -77.77 -25.78 49.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.173 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 20.0 m -104.08 -13.43 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.989 0.423 . . . . 0.0 110.892 -178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -80.7 143.36 12.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 173.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -62.97 153.24 34.36 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.248 0.547 . . . . 0.0 111.149 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -92.59 82.88 4.83 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.29 0.567 . . . . 0.0 110.202 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.672 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 14.4 m -73.15 171.83 9.5 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.23 177.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.672 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 44.6 Cg_endo -68.88 55.96 0.98 Allowed 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.823 2.349 . . . . 0.0 111.966 174.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.57 ' O ' HG13 ' A' ' 45' ' ' ILE . 62.7 mt -65.81 -30.64 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.049 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.416 ' HA ' HD12 ' A' ' 45' ' ' ILE . . . -55.61 -33.84 64.34 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.835 0.35 . . . . 0.0 110.99 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.554 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 13.9 tp10 -66.15 -37.65 86.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.38 0.61 . . . . 0.0 110.264 178.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.473 HG22 HG12 ' A' ' 59' ' ' VAL . 10.8 mm -82.22 -27.64 9.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.57 HG13 ' O ' ' A' ' 41' ' ' ILE . 71.7 mt -61.31 -48.17 90.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.217 176.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.0 ptm180 -65.02 -41.2 95.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.535 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.572 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.1 mttt -57.88 -48.48 79.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.915 0.388 . . . . 0.0 110.147 175.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.475 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.1 m -69.44 -21.35 63.74 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.08 -179.011 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.685 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.9 t30 -67.67 -34.14 76.32 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.276 0.56 . . . . 0.0 109.618 177.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.65 -23.07 39.94 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.752 174.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.572 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 10.6 mm-40 -75.91 -37.84 58.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.598 -178.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.557 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -147.11 -173.49 4.26 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -169.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.54 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -120.79 -86.99 0.95 Allowed Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.546 172.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.0 ttm180 -94.71 6.2 49.6 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.202 0.525 . . . . 0.0 111.551 -175.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.449 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 2.7 mm? -89.26 167.63 12.92 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.441 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.99 99.47 1.02 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.813 -0.708 . . . . 0.0 113.282 -178.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.557 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 33.0 t80 -78.54 135.78 37.39 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.2 p -71.0 108.52 4.61 Favored 'General case' 0 N--CA 1.445 -0.677 0 CA-C-O 121.455 0.645 . . . . 0.0 110.402 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.8 m -98.82 -36.94 5.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.09 -176.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.612 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 82.9 t80 -123.8 100.86 6.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -102.04 111.29 23.51 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.094 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.612 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.4 t70 -116.0 164.5 14.35 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -177.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -70.44 -15.0 62.78 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.119 0.485 . . . . 0.0 110.637 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -94.07 -59.84 1.88 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.962 177.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.522 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.9 m-85 -137.49 170.92 15.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.596 -173.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.728 HG13 ' HG2' ' A' ' 83' ' ' LYS . 75.2 mt -131.34 126.12 58.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.53 178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.27 141.11 15.53 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.16 -0.543 . . . . 0.0 111.756 178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.557 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 43.1 m-70 -124.91 125.33 43.77 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.233 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.87 123.11 29.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.878 0.37 . . . . 0.0 111.294 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.441 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 81.4 m-85 -114.97 140.06 49.33 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.45 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.685 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -83.33 119.85 25.13 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 173.056 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.438 ' HE2' HD12 ' A' ' 77' ' ' ILE . 30.2 mmmt -113.2 178.16 4.38 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.585 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.13 91.85 0.17 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.043 0.449 . . . . 0.0 110.971 -179.036 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 73.39 10.65 79.26 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.581 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 33.5 m170 -138.38 169.92 16.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.043 0.449 . . . . 0.0 111.024 -176.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -131.72 115.49 16.07 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.326 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.438 HD12 ' HE2' ' A' ' 72' ' ' LYS . 55.7 mt -120.09 133.5 66.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.038 -176.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 67.4 t -104.44 109.03 26.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.419 -0.809 . . . . 0.0 110.145 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -91.33 123.33 34.68 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.298 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -95.59 119.47 34.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.416 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.564 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.0 p -111.93 161.93 23.54 Favored Pre-proline 0 C--N 1.32 -0.694 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.881 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.545 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.1 Cg_endo -72.71 48.76 1.39 Allowed 'Trans proline' 0 CA--C 1.533 0.46 0 C-N-CA 122.898 2.399 . . . . 0.0 113.445 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.728 ' HG2' HG13 ' A' ' 66' ' ' ILE . 9.8 mtpm? 63.86 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 123.431 0.692 . . . . 0.0 112.441 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -156.04 146.8 22.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.602 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 46.9 mttp -137.43 -26.11 1.0 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.331 173.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 66.66 101.75 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.842 0.714 . . . . 0.0 112.085 178.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 64.7 mtm180 -134.78 149.71 50.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.916 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 59.37 85.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.321 0 O-C-N 123.863 0.727 . . . . 0.0 111.173 -178.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 146.41 -91.43 0.15 Allowed Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.513 -0.767 . . . . 0.0 111.206 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -109.5 122.2 63.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 120.917 0.389 . . . . 0.0 110.14 175.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 31.5 m -123.32 141.08 35.19 Favored Pre-proline 0 C--N 1.322 -0.588 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.852 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 91' ' ' VAL . 2.1 Cg_endo -85.42 123.66 2.62 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 123.019 2.479 . . . . 0.0 111.741 175.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.96 72.68 3.88 Favored 'Trans proline' 0 CA--C 1.53 0.324 0 C-N-CA 122.573 2.182 . . . . 0.0 112.114 178.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 5.1 p -64.76 125.07 20.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.269 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.42 33.69 0.48 Allowed Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.643 -177.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 55.7 mt -98.33 135.34 33.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 -179.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 31.4 m -61.81 137.26 58.23 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.622 178.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.2 t30 . . . . . 0 C--O 1.246 0.876 0 CA-C-O 118.433 -0.794 . . . . 0.0 111.198 -178.921 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 mmt . . . . . 0 N--CA 1.482 1.155 0 CA-C-O 120.922 0.391 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -75.94 126.42 30.97 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.4 179.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -165.57 115.48 1.04 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.059 0.456 . . . . 0.0 110.433 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 23.2 m -95.38 104.09 15.98 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 48.2 mt -90.83 135.72 28.54 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.79 -170.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.736 ' HG3' ' HD2' ' A' ' 93' ' ' PRO . 42.8 Cg_endo -67.69 159.16 53.92 Favored 'Trans proline' 0 C--O 1.237 0.453 0 C-N-CA 122.856 2.371 . . . . 0.0 112.441 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.9 tp -69.64 -26.17 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.227 -174.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 8.9 t -59.99 -21.33 61.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.137 179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -98.35 -48.99 4.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.367 0.604 . . . . 0.0 110.325 178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.9 t -70.41 -34.73 59.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.028 -172.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 tp -53.42 -62.03 4.19 Favored Pre-proline 0 CA--C 1.544 0.736 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -68.13 -26.14 36.8 Favored 'Trans proline' 0 C--N 1.352 0.713 0 C-N-CA 121.913 1.742 . . . . 0.0 112.97 178.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 72.5 mtt180 -90.26 4.63 50.08 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -177.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.489 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -92.1 157.07 16.94 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.732 0.301 . . . . 0.0 111.084 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.3 m -122.61 2.03 6.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.149 0.499 . . . . 0.0 110.745 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.612 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.13 162.81 35.55 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.239 -0.745 . . . . 0.0 111.239 178.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 51.2 p -151.64 141.61 22.07 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 117.264 0.532 . . . . 0.0 111.474 -179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.494 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.8 mt -117.52 115.32 24.9 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.837 173.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 45.1 m -93.3 114.26 26.67 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.749 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.449 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 3.9 m-85 -108.16 158.43 17.43 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HA ' ' HD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -92.22 179.18 5.63 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 175.123 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -65.09 -20.21 66.37 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.772 0.32 . . . . 0.0 111.77 -177.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.408 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 43.4 m-80 -95.72 13.24 27.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.925 0.393 . . . . 0.0 110.532 178.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 68.14 30.89 5.6 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.377 -0.829 . . . . 0.0 112.369 173.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -97.34 137.62 36.06 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 31.5 tp -69.4 121.01 16.09 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.038 0.447 . . . . 0.0 110.807 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.3 mt -100.83 -49.85 4.03 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.672 179.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 22.4 t70 -137.31 141.58 41.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.623 -175.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 26.3 m -122.74 116.7 24.18 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.672 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.9 m -132.32 154.06 50.09 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.126 0.489 . . . . 0.0 111.679 -176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.612 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.75 -147.59 38.69 Favored Glycine 0 N--CA 1.449 -0.492 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.548 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.549 HG11 ' CE2' ' A' ' 65' ' ' TYR . 26.0 t -67.03 -16.47 21.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 121.095 0.474 . . . . 0.0 111.048 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.494 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.4 -14.16 37.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.298 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.5 mtmt -76.74 -32.44 57.78 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.363 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 m -96.3 -21.93 5.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.012 0.434 . . . . 0.0 110.596 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 87.1 mt -72.87 144.47 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 172.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -64.03 150.39 45.43 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.1 -38.7 61.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.597 -175.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.622 ' HB3' HG13 ' A' ' 41' ' ' ILE . 8.1 t 65.09 160.19 0.12 Allowed Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 123.661 0.601 . . . . 0.0 111.596 170.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.96 45.33 0.9 Allowed 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.835 2.357 . . . . 0.0 112.121 172.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.622 HG13 ' HB3' ' A' ' 39' ' ' SER . 56.4 mt -60.99 -27.73 42.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.562 -176.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -54.95 -34.6 63.42 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.898 0.38 . . . . 0.0 110.978 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.592 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 16.2 tp10 -67.06 -36.75 82.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.327 179.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 13.5 mm -81.97 -27.7 9.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.08 0.467 . . . . 0.0 109.987 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.531 HG13 HG22 ' A' ' 41' ' ' ILE . 66.7 mt -63.67 -44.72 98.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.433 177.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 2.4 ptm180 -66.57 -40.4 88.97 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.722 0.296 . . . . 0.0 110.555 178.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.592 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 91.5 mttt -60.47 -50.02 75.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.505 177.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.479 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 62.8 p -68.38 -26.28 65.49 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.8 -178.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.626 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -64.69 -34.67 78.84 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.955 0.407 . . . . 0.0 110.439 177.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.13 -26.99 39.17 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.78 176.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.521 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.0 mm-40 -74.27 -42.21 59.97 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.492 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.9 pp -138.14 -179.93 6.07 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.609 -172.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.588 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -134.18 -58.38 0.07 OUTLIER Glycine 0 N--CA 1.445 -0.708 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.759 173.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 23.1 tpt180 -93.28 -16.85 24.29 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.924 0.393 . . . . 0.0 111.742 -174.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -93.48 173.31 7.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.843 0.354 . . . . 0.0 111.137 -175.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.541 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -118.92 115.22 3.02 Favored Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.366 179.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 69.5 t80 -90.17 138.69 31.31 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -177.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.3 m -66.53 109.06 2.63 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.935 0.398 . . . . 0.0 110.072 177.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.547 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.3 m -101.3 -34.05 3.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.299 -176.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -130.8 100.14 5.18 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.142 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.515 ' HG3' HG12 ' A' ' 66' ' ' ILE . 45.3 tt0 -102.91 118.52 37.01 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 120.981 0.42 . . . . 0.0 110.536 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.654 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 25.5 t70 -120.16 168.25 11.41 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 174.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -67.1 -19.68 65.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.741 0.305 . . . . 0.0 110.936 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.5 mt-30 -91.06 -60.19 1.97 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.028 0.442 . . . . 0.0 111.025 178.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.549 ' CE2' HG11 ' A' ' 32' ' ' VAL . 51.7 m-85 -132.68 164.39 26.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.964 -171.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.515 HG12 ' HG3' ' A' ' 61' ' ' GLU . 73.8 mt -132.18 124.48 52.61 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.271 178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.433 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.78 142.43 15.98 Favored Glycine 0 N--CA 1.449 -0.493 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.94 178.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.483 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 61.7 m-70 -125.22 129.84 50.88 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.547 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -85.25 123.63 30.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.727 0.299 . . . . 0.0 111.23 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.541 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 70.2 m-85 -116.15 138.9 50.86 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.339 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.626 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -82.25 116.49 21.8 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 172.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -107.26 -176.77 3.16 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.447 -175.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.31 92.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.907 0.384 . . . . 0.0 110.915 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 67.01 16.03 65.84 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.917 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 23.5 m170 -142.76 172.3 12.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.066 0.46 . . . . 0.0 111.361 -175.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -128.95 119.66 24.74 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.423 177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 54.1 mt -125.31 133.79 68.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 C-N-CA 120.374 -0.53 . . . . 0.0 110.863 -177.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 57.8 t -104.31 110.51 30.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.076 179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 56.3 m-85 -90.81 121.32 32.58 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.193 -179.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.433 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 73.1 m-85 -93.87 118.43 31.45 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.814 -178.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 84' ' ' ASN . 53.7 p -108.91 153.79 42.24 Favored Pre-proline 0 C--N 1.317 -0.82 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.279 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.09 60.75 5.59 Favored 'Trans proline' 0 CA--C 1.528 0.193 0 C-N-CA 122.491 2.128 . . . . 0.0 111.492 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.654 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 43.8 mttm 52.3 62.48 2.67 Favored 'General case' 0 CA--C 1.521 -0.159 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.476 -174.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.543 ' HB3' ' HB ' ' A' ' 81' ' ' THR . 0.5 OUTLIER -76.73 157.58 31.59 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.003 -177.451 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.667 ' HD3' ' HG2' ' A' ' 88' ' ' GLU . 2.3 tmmt? 70.38 80.82 0.17 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.793 0.806 . . . . 0.0 110.856 179.419 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 -110.65 124.85 52.7 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 171.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 70.16 98.54 0.06 Allowed 'General case' 0 C--N 1.332 -0.18 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -169.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.667 ' HG2' ' HD3' ' A' ' 85' ' ' LYS . 23.9 mt-10 -72.94 80.04 1.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.74 -0.663 . . . . 0.0 111.773 -170.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.01 -53.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.351 175.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 6.9 p -77.01 124.96 36.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.102 0.477 . . . . 0.0 110.18 176.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -118.24 153.51 51.57 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.578 -178.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.565 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 3.4 Cg_endo -49.94 119.66 5.11 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 123.347 2.698 . . . . 0.0 112.727 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.736 ' HD2' ' HG3' ' A' ' 6' ' ' PRO . 23.9 Cg_exo -64.91 100.66 0.36 Allowed 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.894 2.396 . . . . 0.0 111.687 176.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 15.9 m -109.11 179.24 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.638 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -174.28 -117.13 0.46 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.868 -0.682 . . . . 0.0 111.701 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 39.7 pt -103.91 152.51 6.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.9 t -99.4 156.67 16.89 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.323 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 49.1 t-20 . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.561 -0.733 . . . . 0.0 109.254 178.874 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 44.8 ttm . . . . . 0 N--CA 1.48 1.038 0 CA-C-O 120.785 0.326 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -72.05 -50.4 28.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.465 175.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.8 m -90.49 92.97 9.1 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.023 0.44 . . . . 0.0 111.105 -177.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.1 m -93.31 139.21 30.9 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 31.7 mt -103.02 138.75 19.64 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.686 -167.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.585 ' HD3' ' HB3' ' A' ' 92' ' ' PRO . 53.4 Cg_endo -69.71 160.61 49.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.561 2.174 . . . . 0.0 112.065 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -67.96 -26.09 33.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.432 -174.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.0 t -61.2 -19.13 61.25 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 121.119 0.485 . . . . 0.0 111.207 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 37.4 mm-40 -102.44 -47.66 4.4 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.506 177.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.3 -32.94 52.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.086 -0.507 . . . . 0.0 112.096 -173.41 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.1 -62.3 3.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 N-CA-C 111.683 0.253 . . . . 0.0 111.683 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -69.63 -26.85 27.78 Favored 'Trans proline' 0 C--N 1.35 0.629 0 C-N-CA 121.931 1.754 . . . . 0.0 113.097 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.562 ' HD3' ' OD1' ' A' ' 84' ' ' ASN . 53.0 mtt180 -86.83 1.52 52.1 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -177.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -95.06 148.85 21.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.747 0.308 . . . . 0.0 111.143 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 25.5 m -117.12 4.65 7.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.313 0.578 . . . . 0.0 110.856 -179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -157.5 153.97 25.13 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 178.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.6 p -147.93 127.4 13.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.251 0.548 . . . . 0.0 111.954 -177.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.583 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.9 mt -108.92 116.45 32.02 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.95 173.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 27.6 m -95.08 115.19 27.11 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.727 -178.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 26.5 m-85 -107.65 156.63 18.84 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.434 178.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.55 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 32.2 t70 -87.33 167.94 13.61 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.382 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.533 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.1 pt-20 -64.51 -20.73 66.39 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.841 0.353 . . . . 0.0 110.71 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.493 ' HB2' ' ND2' ' A' ' 25' ' ' ASN . 46.7 m-80 -88.61 16.58 6.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.756 176.007 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CZ ' ' HB3' ' A' ' 46' ' ' ARG . 51.4 m-85 65.54 23.24 11.79 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.325 0.65 . . . . 0.0 112.58 172.387 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.493 ' ND2' ' HB2' ' A' ' 23' ' ' ASN . 6.6 p30 -102.0 138.39 39.02 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 176.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 50.9 tp -66.74 134.29 51.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.12 0.486 . . . . 0.0 111.421 -178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.3 mt -109.74 -58.02 2.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.61 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.489 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 24.0 t70 -131.54 138.07 48.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.549 -173.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.418 HG23 HD21 ' A' ' 18' ' ' LEU . 8.2 m -120.86 116.55 25.39 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.124 176.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -135.52 160.46 38.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.946 0.403 . . . . 0.0 111.099 -178.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.62 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.66 -153.14 50.05 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.211 -0.519 . . . . 0.0 112.4 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.419 HG11 ' CE2' ' A' ' 65' ' ' TYR . 30.9 t -65.89 -15.72 19.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.108 0.48 . . . . 0.0 110.984 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.583 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -64.31 -12.32 40.76 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.324 -178.834 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 56.5 mtmt -76.71 -34.47 58.14 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.27 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 34.0 m -93.03 -18.78 6.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.071 0.462 . . . . 0.0 110.75 -178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -78.13 135.12 26.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.855 174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -60.0 133.5 56.16 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 110.709 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -37.4 71.52 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.417 -175.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.737 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.6 m 64.31 172.23 0.08 OUTLIER Pre-proline 0 CA--C 1.538 0.492 0 CA-C-O 120.977 0.418 . . . . 0.0 111.807 175.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.614 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 93.6 Cg_endo -80.97 40.95 1.06 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.403 2.069 . . . . 0.0 111.745 172.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.737 HG13 ' HB2' ' A' ' 39' ' ' SER . 60.3 mt -59.66 -30.89 45.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.342 -177.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -54.35 -34.31 60.83 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.214 0.531 . . . . 0.0 111.042 178.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.561 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 6.4 tp10 -67.91 -38.12 82.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.059 178.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 14.8 mm -78.94 -27.79 13.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.026 -178.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.491 HG13 ' O ' ' A' ' 41' ' ' ILE . 66.3 mt -62.51 -47.96 90.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.578 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.561 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 2.6 ptm180 -65.64 -38.75 90.24 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.125 178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.523 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 93.4 mttt -60.01 -51.52 69.29 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.036 0.446 . . . . 0.0 110.041 175.173 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.1 m -64.94 -28.74 69.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.728 -179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.698 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 11.2 t30 -66.14 -38.22 87.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.003 0.43 . . . . 0.0 110.377 -179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.39 -29.58 61.59 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.387 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.523 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 48.0 mm-40 -73.43 -55.77 5.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.833 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.488 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.2 pp -121.09 -170.68 2.06 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -169.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -138.17 -71.5 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.654 0 CA-C-N 114.994 -1.003 . . . . 0.0 111.894 174.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -90.54 -15.41 30.71 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -173.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.41 HD22 ' N ' ' A' ' 55' ' ' LEU . 2.6 mm? -88.79 162.77 16.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.641 0.258 . . . . 0.0 110.668 -177.059 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.464 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -109.86 100.59 1.33 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 121.066 -0.588 . . . . 0.0 112.669 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.488 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 79.5 t80 -68.59 133.15 48.09 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -69.73 108.32 3.85 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.411 HG11 ' HB2' ' A' ' 69' ' ' ALA . 30.1 m -98.89 -32.93 3.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.304 -175.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -133.25 100.05 4.73 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.344 -178.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.2 tt0 -98.13 116.03 29.51 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.304 0.573 . . . . 0.0 110.557 176.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.541 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.6 t70 -110.59 167.18 10.41 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 175.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.23 -21.89 64.82 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 120.758 0.313 . . . . 0.0 111.18 -178.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.508 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 14.7 mt-30 -100.21 -46.31 5.33 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 120.908 0.385 . . . . 0.0 110.984 -179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.508 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 24.5 m-85 -131.83 163.12 28.95 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.951 0.405 . . . . 0.0 111.345 -171.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.4 mt -133.84 123.52 45.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.173 177.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.62 141.13 15.51 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.938 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.461 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 58.4 m-70 -128.23 130.43 47.95 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.411 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.56 123.26 30.11 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.419 179.032 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.464 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 66.5 m-85 -116.54 139.18 50.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.923 178.335 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.698 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.4 OUTLIER -84.36 117.9 23.89 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.232 173.655 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.538 ' HG3' HG13 ' A' ' 77' ' ' ILE . 27.9 mmmt -108.96 176.35 5.13 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -178.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.48 96.1 0.08 Allowed 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.876 0.37 . . . . 0.0 111.116 178.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.82 10.93 65.35 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 113.337 178.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.55 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 11.5 m170 -146.96 172.93 12.95 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.883 0.342 . . . . 0.0 110.835 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.533 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 72.0 m-85 -128.52 134.23 48.62 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.538 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.0 mt -132.51 134.43 58.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 C-N-CA 120.356 -0.537 . . . . 0.0 110.663 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 59.5 t -104.52 110.59 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.882 178.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -92.3 123.62 35.77 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.441 -179.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -96.8 115.29 27.18 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.793 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 64.9 p -102.14 149.66 36.78 Favored Pre-proline 0 C--N 1.316 -0.887 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.83 179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -72.94 57.9 3.28 Favored 'Trans proline' 0 N--CA 1.473 0.269 0 C-N-CA 122.648 2.232 . . . . 0.0 111.699 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.541 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 48.4 mttm 53.47 59.79 4.13 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.731 -172.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.562 ' OD1' ' HD3' ' A' ' 13' ' ' ARG . 8.9 t30 -74.84 98.21 3.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.541 175.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 58.4 mtpt -89.24 109.93 20.76 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.602 -177.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -73.68 93.6 2.1 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 173.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 62.5 ttt180 -107.33 -26.95 10.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.77 -171.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -163.88 157.31 18.58 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.089 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.66 -131.12 10.49 Favored Glycine 0 N--CA 1.445 -0.718 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 53.8 t -76.12 98.98 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.893 0.378 . . . . 0.0 110.069 175.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.1 p -93.12 129.06 40.67 Favored Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.919 179.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.585 ' HB3' ' HD3' ' A' ' 6' ' ' PRO . 48.6 Cg_endo -68.96 127.47 15.28 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 123.137 2.558 . . . . 0.0 114.379 -172.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -93.42 -168.11 0.18 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 123.378 2.719 . . . . 0.0 110.932 169.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 41.2 t -116.31 -56.05 4.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.949 0.404 . . . . 0.0 110.467 178.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 85.14 -167.44 41.61 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.168 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.481 ' O ' HG22 ' A' ' 96' ' ' ILE . 26.7 mm 68.47 18.76 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-O 121.278 0.561 . . . . 0.0 110.382 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.7 p 51.61 98.82 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 123.92 0.888 . . . . 0.0 113.11 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.683 178.717 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -172.06 -33.32 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.266 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 47.5 m 63.1 31.14 16.0 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.082 179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 5.9 p -74.53 106.57 6.18 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 116.053 -0.522 . . . . 0.0 110.425 178.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.4 ' HA ' ' HG2' ' A' ' 92' ' ' PRO . 50.1 mt -91.28 135.08 28.65 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.478 -175.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -71.08 159.74 51.39 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.693 2.262 . . . . 0.0 112.51 179.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.8 tp -65.84 -26.45 38.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.733 -176.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.8 t -63.23 -19.53 64.62 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 120.888 0.375 . . . . 0.0 111.146 -177.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 62.8 mm-40 -98.45 -47.14 5.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.268 0.556 . . . . 0.0 110.516 176.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.2 t -70.4 -35.81 63.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.95 -172.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.9 tp -55.38 -61.68 5.67 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.025 0.38 . . . . 0.0 112.025 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.35 -28.58 54.82 Favored 'Trans proline' 0 C--N 1.35 0.611 0 C-N-CA 121.919 1.746 . . . . 0.0 112.979 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 13' ' ' ARG . 52.5 mtt180 -86.54 -0.71 56.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 112.157 0.429 . . . . 0.0 112.157 -178.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -79.58 146.58 32.5 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.1 0.476 . . . . 0.0 111.805 -175.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.29 -1.19 9.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.384 177.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.606 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -162.31 165.02 35.86 Favored Glycine 0 N--CA 1.447 -0.603 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 178.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 35.7 p -155.85 141.8 18.14 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 117.21 0.505 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 9.5 mt -121.07 114.88 22.11 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.463 172.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.538 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 86.6 m -93.45 119.14 32.19 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.29 -178.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -115.59 153.78 30.62 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.32 0.581 . . . . 0.0 110.462 177.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 75' ' ' HIS . 30.4 t70 -83.3 175.87 9.56 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.297 179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -62.73 -24.25 67.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.06 0.457 . . . . 0.0 110.226 175.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -85.78 6.54 27.51 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.341 175.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.565 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 98.5 m-85 65.36 24.09 12.06 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.216 179.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -86.75 142.05 28.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.535 176.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.402 HD21 ' OG1' ' A' ' 29' ' ' THR . 4.6 tt -72.11 122.96 21.86 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.984 0.421 . . . . 0.0 109.987 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -104.87 -51.18 3.1 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.874 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 13.4 t70 -135.74 145.08 46.25 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.253 -174.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.402 ' OG1' HD21 ' A' ' 26' ' ' LEU . 27.8 m -129.88 115.08 16.69 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.064 174.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 74.7 m -132.05 156.42 46.32 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.925 0.393 . . . . 0.0 111.181 -176.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.606 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 66.71 -151.25 52.3 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.943 -0.571 . . . . 0.0 113.019 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.7 t -62.68 -16.61 17.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.051 0.453 . . . . 0.0 111.536 -177.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.82 -13.13 29.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.793 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 50.3 mtmt -73.92 -40.37 63.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.041 179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.8 m -90.54 -20.59 6.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.046 0.45 . . . . 0.0 111.215 -177.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -73.48 142.48 14.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 174.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -68.44 145.89 53.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.047 0.451 . . . . 0.0 110.13 178.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.92 -37.52 55.22 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.517 -175.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.918 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 86.2 p 51.68 -174.6 0.01 OUTLIER Pre-proline 0 CA--C 1.551 0.986 0 C-N-CA 123.468 0.707 . . . . 0.0 112.383 173.025 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.918 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 71.7 Cg_endo -78.68 43.19 1.4 Allowed 'Trans proline' 0 C--N 1.352 0.726 0 C-N-CA 122.089 1.859 . . . . 0.0 112.739 173.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.539 ' O ' HG13 ' A' ' 45' ' ' ILE . 47.4 mt -59.02 -39.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-O 120.523 0.202 . . . . 0.0 111.011 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.565 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.79 -34.49 69.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.173 -178.297 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 34.8 tt0 -66.96 -37.12 83.67 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.265 178.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.29 -28.03 16.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.55 HD12 ' HA ' ' A' ' 42' ' ' ALA . 83.6 mt -62.39 -45.79 97.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.186 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.566 178.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 13.3 ptm180 -68.39 -38.83 81.71 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.127 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 94.5 mttt -59.32 -47.22 86.22 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.156 0.503 . . . . 0.0 109.832 174.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.48 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -69.45 -22.63 63.63 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.596 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.585 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.9 t30 -67.11 -34.3 77.32 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.111 0.481 . . . . 0.0 110.18 178.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.89 -24.02 41.46 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.351 175.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.418 ' HB2' ' HA ' ' A' ' 48' ' ' SER . 55.7 mm-40 -77.74 -38.34 47.21 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.063 -179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.616 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.5 pp -143.26 -176.45 4.94 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 112.068 -173.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.634 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -128.54 -70.88 0.14 Allowed Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.722 171.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.414 ' HD2' ' HA ' ' A' ' 54' ' ' ARG . 20.4 tpt180 -97.19 8.34 44.75 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.911 0.337 . . . . 0.0 111.911 -172.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.48 ' HB2' HD22 ' A' ' 52' ' ' LEU . 2.2 mm? -101.33 167.1 10.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.78 0.324 . . . . 0.0 110.724 -178.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.498 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -112.74 96.46 0.83 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.401 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.616 ' HB2' HD21 ' A' ' 52' ' ' LEU . 20.5 t80 -71.56 134.76 46.67 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 22.4 m -68.97 108.13 3.39 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 177.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.566 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.1 m -104.24 -32.37 2.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.143 -175.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 69.6 t80 -127.38 100.72 6.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.878 178.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 53.1 tt0 -100.21 113.9 26.93 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.193 178.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.648 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 21.4 t70 -113.85 165.21 12.81 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -68.53 -18.72 64.42 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.753 0.311 . . . . 0.0 111.221 -177.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -99.79 -53.05 3.28 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.978 0.418 . . . . 0.0 111.066 -179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . . . . . . . . . 20.4 m-85 -131.48 168.84 16.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.652 -172.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 79.6 mt -134.74 127.01 48.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.93 0.395 . . . . 0.0 110.473 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.34 143.54 16.62 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.132 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.532 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 36.0 m-70 -127.45 127.37 43.97 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -176.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.566 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.11 123.96 29.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.658 0.266 . . . . 0.0 111.252 178.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.498 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 71.8 m-85 -117.9 141.28 48.61 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.994 177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.634 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -84.48 119.2 24.88 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.409 171.508 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.509 ' HE2' HD12 ' A' ' 77' ' ' ILE . 28.9 mmmt -111.49 -176.69 3.01 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.901 -175.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.7 93.79 0.27 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.994 0.426 . . . . 0.0 110.971 -178.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 66.29 14.81 62.45 Favored Glycine 0 N--CA 1.45 -0.369 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.694 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.401 ' HD2' ' HA ' ' A' ' 21' ' ' ASP . 31.1 m80 -142.69 172.86 12.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.931 0.396 . . . . 0.0 111.071 -176.105 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -129.98 116.12 18.14 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.979 -0.555 . . . . 0.0 109.633 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.509 HD12 ' HE2' ' A' ' 72' ' ' LYS . 54.4 mt -123.09 134.64 65.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 C-N-CA 120.229 -0.588 . . . . 0.0 110.939 -176.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.1 t -103.74 113.33 40.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.047 178.306 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 47.3 m-85 -91.86 121.68 33.7 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.731 179.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -96.03 117.71 31.21 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.346 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 14' ' ' ALA . 70.9 p -111.74 160.71 28.62 Favored Pre-proline 0 C--N 1.313 -1.011 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 176.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -62.22 154.36 63.61 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 120.976 1.117 . . . . 0.0 109.25 169.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.648 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 36.7 mttm -44.5 100.94 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.016 0.436 . . . . 0.0 111.591 174.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -112.12 84.47 1.97 Allowed 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -142.33 78.6 1.63 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.682 -179.196 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -90.53 151.97 21.12 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.33 -179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.458 ' HA ' ' HD2' ' A' ' 87' ' ' ARG . 26.4 tpt180 -75.99 83.93 2.88 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.146 0.498 . . . . 0.0 110.676 -179.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -137.51 157.48 46.46 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.588 177.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.69 28.07 11.04 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.943 -0.646 . . . . 0.0 111.973 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.4 t -82.75 123.03 38.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.459 . . . . 0.0 110.168 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.44 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.9 p -130.92 114.17 16.4 Favored Pre-proline 0 C--N 1.321 -0.651 0 CA-C-O 121.316 0.579 . . . . 0.0 110.219 179.421 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.463 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 21.2 Cg_exo -66.06 151.37 84.01 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.846 2.364 . . . . 0.0 112.627 -178.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 24.3 Cg_exo -65.42 165.84 21.3 Favored 'Trans proline' 0 C--O 1.233 0.262 0 C-N-CA 123.102 2.535 . . . . 0.0 112.178 176.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.404 ' O ' HD21 ' A' ' 55' ' ' LEU . 9.2 p -90.3 6.1 4.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.622 0.725 . . . . 0.0 110.741 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 140.96 -164.03 26.52 Favored Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.155 177.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 13.4 tt -83.63 -25.89 7.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.072 0.463 . . . . 0.0 110.646 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 13.4 p -84.9 150.72 24.77 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.197 -178.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.384 -0.817 . . . . 0.0 110.107 179.681 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.477 ' HE3' ' H ' ' A' ' 58' ' ' SER . 1.4 tmt? . . . . . 0 N--CA 1.48 1.055 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 28.4 mmmt 50.75 33.71 8.85 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 113.169 0.804 . . . . 0.0 113.169 173.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.43 ' O ' HG13 ' A' ' 5' ' ' ILE . 18.1 m -132.06 30.78 4.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.016 0.436 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 25.5 p -62.22 105.38 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.821 178.535 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.588 HD11 ' HA ' ' A' ' 86' ' ' ASN . 68.1 mt -122.61 134.59 25.02 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.909 -178.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.42 159.11 51.94 Favored 'Trans proline' 0 C--O 1.236 0.385 0 C-N-CA 122.838 2.359 . . . . 0.0 112.653 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.1 tp -65.05 -28.55 45.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.436 -175.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 13.3 t -58.87 -21.11 56.54 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-O 120.695 0.283 . . . . 0.0 111.437 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -102.0 -43.75 5.68 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.039 0.447 . . . . 0.0 110.793 178.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 85.8 t -69.99 -35.81 65.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.747 -175.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 11.6 tp -54.22 -60.69 6.9 Favored Pre-proline 0 CA--C 1.538 0.506 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -64.03 -27.19 65.87 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 121.989 1.793 . . . . 0.0 112.508 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 78.9 mtt85 -80.94 -11.45 59.57 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 178.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.452 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -85.37 152.39 23.28 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.166 0.507 . . . . 0.0 111.64 -176.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.1 m -122.58 2.16 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.993 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.691 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.87 164.12 36.8 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 178.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.454 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 5.5 p -154.76 141.97 19.45 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.245 0.545 . . . . 0.0 111.793 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.483 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.4 mt -115.4 119.1 35.14 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.153 176.258 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.3 m -94.45 117.7 30.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.776 0.322 . . . . 0.0 110.96 -178.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.439 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 4.3 m-85 -113.31 154.67 26.46 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.753 175.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 23' ' ' ASN . 0.5 OUTLIER -89.75 -175.8 4.76 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 178.776 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -67.63 -20.54 65.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.728 -178.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.423 ' H ' ' CG ' ' A' ' 21' ' ' ASP . 40.8 m-80 -95.22 8.21 43.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.929 0.395 . . . . 0.0 110.177 176.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.552 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 96.2 m-85 68.59 36.05 2.97 Favored 'General case' 0 CA--C 1.53 0.195 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.449 174.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -97.55 135.58 39.19 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.113 173.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.434 HD13 HD22 ' A' ' 18' ' ' LEU . 32.5 tp -59.87 117.45 5.04 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.214 0.53 . . . . 0.0 110.867 173.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.4 mt -99.39 -54.76 2.86 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.328 178.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -135.94 146.86 47.76 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.17 -175.493 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 36.0 m -124.58 123.0 39.14 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.762 176.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.8 t -137.01 153.78 50.57 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.92 0.391 . . . . 0.0 110.992 -177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.691 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.98 -153.83 44.09 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.367 178.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.543 HG11 ' CE2' ' A' ' 65' ' ' TYR . 39.7 t -61.63 -19.32 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.195 0.521 . . . . 0.0 110.952 179.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.483 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.82 -15.66 22.52 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.397 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.421 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.3 mtmt -76.12 -29.41 57.85 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.35 -178.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 28.1 m -96.38 -23.6 4.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.833 0.349 . . . . 0.0 110.872 177.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.9 mt -68.2 141.24 17.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.454 177.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -64.99 140.17 58.84 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.758 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -85.65 85.69 7.4 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.681 -0.691 . . . . 0.0 110.263 178.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.629 ' HB2' ' HD2' ' A' ' 40' ' ' PRO . 4.8 p -81.33 172.64 9.25 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.0 176.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.629 ' HD2' ' HB2' ' A' ' 39' ' ' SER . 41.7 Cg_endo -67.82 51.67 0.5 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 122.932 2.421 . . . . 0.0 112.495 176.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.6 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.0 mt -61.79 -26.32 39.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.11 -177.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.552 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.66 -33.61 66.54 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.13 0.49 . . . . 0.0 110.747 -179.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.573 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 6.8 tp10 -66.5 -39.99 89.01 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.541 178.163 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.482 HG22 HG12 ' A' ' 59' ' ' VAL . 12.6 mm -78.77 -28.76 14.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.179 -177.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.6 HG13 ' O ' ' A' ' 41' ' ' ILE . 72.4 mt -62.39 -46.91 95.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.556 178.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -66.36 -39.78 89.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.653 -179.922 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.573 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 68.4 mttm -58.72 -47.8 83.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.972 0.415 . . . . 0.0 109.891 175.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.504 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.6 m -68.67 -22.6 64.37 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.929 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.531 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.8 t30 -67.12 -33.77 76.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.246 0.546 . . . . 0.0 109.83 177.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -81.67 -21.43 38.11 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.849 176.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.514 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 27.1 mm-40 -80.18 -37.47 33.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.56 -179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.549 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -144.37 -175.78 4.77 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -171.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.543 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -119.79 -91.24 1.29 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.521 172.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -91.27 13.36 17.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.022 0.439 . . . . 0.0 111.233 -176.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -93.12 167.5 11.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.048 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -114.4 102.97 1.24 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.732 -0.746 . . . . 0.0 113.24 -178.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.579 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 34.2 t80 -84.06 136.25 34.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.477 ' H ' ' HE3' ' A' ' 1' ' ' MET . 1.8 p -69.9 108.27 3.92 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.212 0.529 . . . . 0.0 110.27 177.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.554 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.5 m -98.6 -33.44 4.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.105 -175.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.497 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 89.8 t80 -134.5 102.74 5.42 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.379 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -98.45 118.6 35.5 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.225 0.536 . . . . 0.0 110.256 173.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.497 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 15.1 t70 -104.7 -171.23 1.88 Allowed 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -84.34 -18.53 35.93 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.431 0.634 . . . . 0.0 109.771 176.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.3 mt-30 -102.96 -55.4 2.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.449 -0.796 . . . . 0.0 111.349 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.543 ' CE2' HG11 ' A' ' 32' ' ' VAL . 69.6 m-85 -127.19 164.79 20.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.836 0.35 . . . . 0.0 111.518 -171.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 71.5 mt -130.08 125.13 59.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.973 178.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.411 ' O ' ' HA ' ' A' ' 58' ' ' SER . . . -89.8 143.23 17.01 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 121.153 -0.546 . . . . 0.0 111.94 178.262 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 72.1 m-70 -127.17 124.67 39.58 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.554 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -81.47 123.2 28.4 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.788 0.328 . . . . 0.0 111.051 179.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.465 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 63.5 m-85 -116.18 139.55 50.22 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.474 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.554 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.3 OUTLIER -82.22 117.9 22.69 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 173.229 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.46 ' HE2' HD12 ' A' ' 77' ' ' ILE . 29.7 mmmt -111.49 -176.37 2.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 -175.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.48 89.39 0.06 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.099 0.476 . . . . 0.0 111.387 -178.374 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.27 8.19 69.67 Favored Glycine 0 N--CA 1.45 -0.389 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.665 179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -137.13 172.56 12.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.881 0.372 . . . . 0.0 110.964 -176.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -128.73 117.43 21.13 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.539 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.46 HD12 ' HE2' ' A' ' 72' ' ' LYS . 53.9 mt -121.95 135.48 61.93 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.691 -177.016 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 17' ' ' SER . 65.5 t -103.88 112.1 36.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.308 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -89.85 119.87 30.6 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.31 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -94.48 119.82 33.78 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.859 -178.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.452 HG22 ' HA ' ' A' ' 14' ' ' ALA . 63.1 p -110.58 153.3 43.62 Favored Pre-proline 0 C--N 1.317 -0.83 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.128 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.485 ' HA ' ' CD1' ' A' ' 65' ' ' TYR . 61.2 Cg_endo -73.13 55.83 3.0 Favored 'Trans proline' 0 CA--C 1.529 0.272 0 C-N-CA 122.719 2.279 . . . . 0.0 112.089 176.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . . . . . . . . . 48.2 mttm 54.52 73.81 0.38 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.193 -175.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -80.21 -28.54 38.59 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.451 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.6 mttt 60.17 -88.98 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.862 -176.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.588 ' HA ' HD11 ' A' ' 5' ' ' ILE . 28.6 t-20 -160.48 -63.52 0.06 Allowed 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.418 HH11 ' HD3' ' A' ' 87' ' ' ARG . 13.6 ttm-85 58.03 -95.02 0.05 Allowed 'General case' 0 CA--C 1.537 0.461 0 O-C-N 123.763 0.664 . . . . 0.0 111.292 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -147.85 162.47 39.2 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 120.793 0.33 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 144.05 -153.79 25.24 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.2 t -77.44 88.18 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 120.963 0.411 . . . . 0.0 110.031 176.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 4.4 p -92.02 109.9 40.45 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-O 121.352 0.596 . . . . 0.0 109.718 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.411 ' HA ' ' HD3' ' A' ' 93' ' ' PRO . 76.6 Cg_endo -82.62 123.85 3.89 Favored 'Trans proline' 0 N--CA 1.457 -0.624 0 C-N-CA 122.76 2.306 . . . . 0.0 112.938 -175.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 4.3 Cg_exo -76.42 95.24 1.04 Allowed 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.83 2.353 . . . . 0.0 110.459 172.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.5 p -79.31 129.2 37.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.427 0.632 . . . . 0.0 111.169 -174.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -126.65 -52.71 0.15 Allowed Glycine 0 N--CA 1.448 -0.508 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 178.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 69.9 mt -80.69 110.74 16.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 177.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -143.47 -45.35 0.28 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.021 0.438 . . . . 0.0 111.067 -177.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 . . . . . 0 C--O 1.248 1.014 0 CA-C-O 118.697 -0.668 . . . . 0.0 110.572 -173.607 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 80.3 mtp . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 121.004 0.43 . . . . 0.0 110.755 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.518 ' HD2' ' HE1' ' A' ' 57' ' ' TYR . 16.6 tppt? -109.5 91.02 3.48 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 p -91.98 99.88 12.64 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.512 0.672 . . . . 0.0 111.812 -173.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.491 ' O ' ' HG3' ' A' ' 92' ' ' PRO . 23.1 m -114.35 102.96 10.6 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 170.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -100.83 135.2 20.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.692 -168.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.522 ' HB2' HG22 ' A' ' 8' ' ' THR . 17.8 Cg_endo -61.16 152.32 72.62 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.777 2.318 . . . . 0.0 112.635 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 10.3 tp -64.14 -25.16 37.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.293 -176.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' HB2' ' A' ' 6' ' ' PRO . 14.7 t -61.68 -20.32 63.31 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-O 120.948 0.404 . . . . 0.0 111.027 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -98.08 -52.69 3.61 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.371 0.605 . . . . 0.0 109.799 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.44 -37.62 80.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.447 -172.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 14.6 tp -56.13 -64.91 1.86 Allowed Pre-proline 0 CA--C 1.541 0.622 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 -177.305 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.82 -26.37 44.95 Favored 'Trans proline' 0 C--N 1.35 0.632 0 C-N-CA 121.976 1.784 . . . . 0.0 112.902 -178.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 21.9 mtp180 -95.49 14.49 22.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.906 0.384 . . . . 0.0 111.583 -175.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.39 161.41 14.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.972 0.415 . . . . 0.0 110.976 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.445 HG13 ' HD3' ' A' ' 82' ' ' PRO . 17.4 m -123.56 -2.16 6.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.957 178.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.466 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.83 166.55 38.66 Favored Glycine 0 N--CA 1.445 -0.728 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.3 p -153.28 145.15 23.58 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 117.151 0.475 . . . . 0.0 111.48 -179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.505 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 14.5 mt -118.9 115.79 25.14 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.714 173.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 28.4 m -92.85 113.01 25.16 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.497 -178.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 32.8 m-85 -106.19 153.33 22.27 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.233 0.54 . . . . 0.0 110.291 177.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -83.13 172.61 12.49 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.983 175.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.468 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 13.8 pt-20 -63.24 -23.58 67.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.996 0.427 . . . . 0.0 110.339 177.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 50.3 m-80 -86.33 10.24 15.49 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.624 175.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.569 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 74.1 m-85 64.66 30.98 12.36 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.296 178.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -94.97 127.28 40.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.209 177.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.44 HD13 HD22 ' A' ' 18' ' ' LEU . 29.1 tp -59.63 114.77 2.9 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.013 0.435 . . . . 0.0 111.068 175.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 81.4 mt -98.41 -52.79 3.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.627 -179.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.548 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 20.7 t70 -135.01 138.7 44.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.066 -173.402 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.426 HG23 HD21 ' A' ' 18' ' ' LEU . 24.9 m -121.49 116.13 24.13 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 177.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 72.4 m -129.02 152.39 48.68 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.191 0.519 . . . . 0.0 112.005 -174.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.466 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 69.16 -146.91 45.2 Favored Glycine 0 N--CA 1.449 -0.448 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.749 176.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.552 HG11 ' CE2' ' A' ' 65' ' ' TYR . 40.1 t -65.14 -16.38 19.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.017 0.437 . . . . 0.0 111.413 -178.227 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.505 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.56 -15.27 37.17 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.134 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.402 ' HG2' HG22 ' A' ' 29' ' ' THR . 52.6 mtmt -78.64 -21.39 48.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.932 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.8 m -104.44 -16.25 7.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.968 0.413 . . . . 0.0 110.87 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.0 mt -78.34 150.95 5.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.244 176.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -69.46 146.48 51.92 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.937 0.399 . . . . 0.0 111.101 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.442 ' O ' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -78.85 -68.45 0.65 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.085 178.297 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.92 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 42.4 m 63.39 -178.77 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.804 0 O-C-N 123.152 0.282 . . . . 0.0 111.498 172.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.92 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 56.6 Cg_endo -71.25 44.99 0.59 Allowed 'Trans proline' 0 C--N 1.355 0.903 0 C-N-CA 122.563 2.175 . . . . 0.0 114.145 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.518 ' O ' HG13 ' A' ' 45' ' ' ILE . 35.3 mt -62.88 -35.03 69.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.734 0.302 . . . . 0.0 110.657 176.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.569 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.64 -36.29 71.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.975 0.417 . . . . 0.0 110.953 -179.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 42.9 tt0 -68.55 -34.11 75.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.412 178.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 22.4 mm -75.97 -28.67 19.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 121.112 0.482 . . . . 0.0 109.793 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 41' ' ' ILE . 74.1 mt -63.99 -46.75 93.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.567 178.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.427 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 10.4 ptm180 -64.67 -40.58 95.65 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.716 -0.22 . . . . 0.0 111.36 178.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.575 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 89.3 mttt -59.8 -48.65 80.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.228 0.537 . . . . 0.0 109.838 176.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.753 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 30.0 m -66.59 -29.24 69.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.898 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.573 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.4 t30 -60.93 -38.39 85.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.919 0.39 . . . . 0.0 110.761 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.53 -28.22 41.31 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.167 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 52.6 mm-40 -76.04 -60.79 2.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.72 -179.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.753 ' HG ' ' O ' ' A' ' 48' ' ' SER . 4.2 pp -95.36 179.16 5.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.6 -172.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.23 -30.34 0.47 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.978 -0.63 . . . . 0.0 112.601 177.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -149.97 -20.21 0.26 Allowed 'General case' 0 CA--C 1.531 0.242 0 O-C-N 122.524 -0.398 . . . . 0.0 111.453 -177.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' O ' HD22 ' A' ' 52' ' ' LEU . 71.0 mt -78.06 163.83 25.56 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.509 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -104.3 94.69 1.08 Allowed Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.879 -0.676 . . . . 0.0 112.51 179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.63 ' HB2' HD23 ' A' ' 52' ' ' LEU . 72.9 t80 -69.39 134.96 49.65 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 177.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.6 m -68.78 110.66 4.44 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.678 -178.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.517 HG11 ' HB2' ' A' ' 69' ' ' ALA . 22.2 m -99.96 -26.73 3.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.976 -177.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.534 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 66.7 t80 -136.07 125.07 24.26 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.871 -179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.546 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.9 tt0 -130.83 113.39 14.02 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.224 0.535 . . . . 0.0 110.199 176.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 5.1 t70 -109.64 -169.88 1.55 Allowed 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 179.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -82.13 -17.98 44.5 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.869 0.366 . . . . 0.0 110.87 -178.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -109.05 -47.14 3.48 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.332 -178.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.552 ' CE2' HG11 ' A' ' 32' ' ' VAL . 58.8 m-85 -131.96 162.21 31.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.941 0.4 . . . . 0.0 111.707 -171.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.546 HG12 ' HG3' ' A' ' 61' ' ' GLU . 63.6 mt -132.23 128.52 58.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -99.57 139.31 14.36 Favored Glycine 0 N--CA 1.444 -0.778 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.018 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -125.79 130.77 52.1 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -86.46 124.02 32.32 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.898 0.38 . . . . 0.0 111.39 -178.007 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.509 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 82.8 m-85 -117.3 139.73 50.46 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.592 177.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.573 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.27 130.54 35.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.675 173.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.475 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.3 mmmt -118.02 179.38 4.11 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.27 94.68 0.27 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.047 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 69.49 16.54 71.74 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.157 -0.544 . . . . 0.0 112.608 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 21.0 m80 -145.5 171.94 13.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.849 0.357 . . . . 0.0 111.025 -177.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.468 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 91.2 m-85 -134.86 122.09 21.53 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.859 -0.609 . . . . 0.0 109.653 -178.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.475 HG13 ' HG3' ' A' ' 72' ' ' LYS . 56.5 mt -125.91 133.83 68.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.013 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.3 t -104.36 111.79 35.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.741 177.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -90.43 124.18 34.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.071 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -97.5 117.04 30.87 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.722 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.427 HG22 ' HA ' ' A' ' 14' ' ' ALA . 39.9 p -105.61 156.65 36.12 Favored Pre-proline 0 C--N 1.317 -0.828 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.318 179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.445 ' HD3' HG13 ' A' ' 15' ' ' VAL . 57.0 Cg_endo -71.43 64.86 2.89 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.674 2.249 . . . . 0.0 111.935 176.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.52 ' HA ' HG13 ' A' ' 66' ' ' ILE . 8.1 mttm 59.41 37.48 23.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.571 -178.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 6.5 t30 -72.93 98.63 2.52 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 173.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.603 ' HG3' ' H ' ' A' ' 86' ' ' ASN . 22.9 tptm -132.72 177.64 7.47 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.223 -0.899 . . . . 0.0 108.976 -172.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.603 ' H ' ' HG3' ' A' ' 85' ' ' LYS . 10.2 t-20 67.69 -165.05 0.21 Allowed 'General case' 0 CA--C 1.531 0.221 0 O-C-N 123.334 0.396 . . . . 0.0 110.319 173.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -112.62 107.9 16.77 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 177.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -123.65 -53.65 1.77 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.489 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.41 -121.55 3.99 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.335 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.72 116.84 16.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 120.837 0.351 . . . . 0.0 110.733 -179.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.3 m -92.15 133.94 29.35 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.166 176.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.491 ' HG3' ' O ' ' A' ' 4' ' ' SER . 46.7 Cg_endo -69.27 116.65 4.61 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.664 2.243 . . . . 0.0 112.327 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 92' ' ' PRO . 3.5 Cg_exo -77.51 168.69 22.31 Favored 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.917 2.412 . . . . 0.0 111.556 177.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.2 p -82.72 74.85 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.326 1.06 . . . . 0.0 110.001 176.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -155.01 90.62 0.12 Allowed Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.668 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 15.3 pt -111.47 108.39 25.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.165 0.507 . . . . 0.0 110.956 -179.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 46.9 m -79.81 130.0 34.96 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.668 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.3 t30 . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.555 -0.736 . . . . 0.0 110.562 179.692 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 tpt . . . . . 0 N--CA 1.482 1.131 0 CA-C-O 121.605 0.716 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.4 ' HD2' ' HB2' ' A' ' 4' ' ' SER . 17.2 tppt? -82.2 113.69 20.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.439 -177.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.1 p -95.2 0.02 53.61 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.098 0.475 . . . . 0.0 110.872 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.545 ' HB3' ' HB3' ' A' ' 55' ' ' LEU . 18.2 m -85.81 103.5 14.62 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.978 177.486 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.469 HG23 ' HD2' ' A' ' 6' ' ' PRO . 59.5 mt -107.7 141.14 22.41 Favored Pre-proline 0 C--N 1.32 -0.715 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.988 -173.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.482 ' CD ' ' HB3' ' A' ' 92' ' ' PRO . 17.9 Cg_endo -62.09 150.64 85.82 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.612 2.208 . . . . 0.0 112.657 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.7 tp -68.27 -27.34 36.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.293 -174.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.462 HG22 ' HB2' ' A' ' 6' ' ' PRO . 10.7 t -62.27 -19.03 62.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.021 0.439 . . . . 0.0 110.616 178.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -100.81 -47.41 4.82 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.672 178.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.7 t -69.33 -38.75 77.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.908 -174.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.67 -61.87 4.09 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -178.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -64.55 -30.38 61.17 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 121.92 1.747 . . . . 0.0 112.562 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -86.15 2.18 47.77 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 111.922 0.342 . . . . 0.0 111.922 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.428 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -94.59 148.51 22.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.921 0.391 . . . . 0.0 110.992 -179.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 m -116.12 3.04 7.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.778 -179.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.537 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -164.21 164.0 36.36 Favored Glycine 0 N--CA 1.445 -0.748 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 178.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 28.8 p -158.46 141.18 14.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.202 0.525 . . . . 0.0 111.273 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.577 HD21 HG23 ' A' ' 29' ' ' THR . 19.4 mt -116.4 117.42 29.89 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.038 175.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 33.7 m -92.67 113.64 25.97 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 16.9 m-85 -105.08 159.82 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.92 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.528 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 1.9 p-10 -94.62 -176.67 3.97 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 177.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -67.19 -19.19 65.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.727 0.299 . . . . 0.0 111.576 -177.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -94.9 10.19 36.38 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.152 0.501 . . . . 0.0 110.069 177.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 88.7 m-85 65.36 35.07 7.73 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.134 -0.939 . . . . 0.0 112.276 174.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -105.57 145.57 30.78 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 173.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 42.6 tp -69.73 131.19 44.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.156 0.503 . . . . 0.0 111.089 -179.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.1 mt -107.75 -58.55 1.95 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.393 177.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -131.74 136.95 48.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.442 -174.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.577 HG23 HD21 ' A' ' 18' ' ' LEU . 12.4 m -113.81 120.35 40.46 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.896 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.6 t -130.23 145.31 51.73 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.865 0.364 . . . . 0.0 111.093 -175.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.537 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 74.43 -150.38 41.8 Favored Glycine 0 N--CA 1.453 -0.208 0 CA-C-N 116.105 -0.498 . . . . 0.0 113.125 174.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.558 HG11 ' CE2' ' A' ' 65' ' ' TYR . 38.5 t -60.83 -19.08 18.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.064 0.459 . . . . 0.0 111.297 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.54 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -61.77 -14.35 31.75 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.445 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 51.9 mtmt -76.31 -26.21 55.59 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.354 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 32' ' ' VAL . 18.2 m -100.56 -20.85 5.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.972 0.415 . . . . 0.0 110.895 -179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.0 mt -78.27 146.15 8.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.583 176.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.59 157.17 35.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.849 0.357 . . . . 0.0 110.567 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -80.61 -44.22 19.28 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.322 -176.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 90.1 p 54.06 -179.37 0.02 OUTLIER Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.488 0.715 . . . . 0.0 112.231 175.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.544 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 6.3 Cg_exo -76.95 45.11 1.59 Allowed 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 122.816 2.344 . . . . 0.0 113.02 176.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.516 ' O ' HG13 ' A' ' 45' ' ' ILE . 57.0 mt -62.06 -35.44 68.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.584 0.231 . . . . 0.0 110.94 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -56.25 -36.7 68.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.375 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 9.7 tp10 -62.41 -38.67 90.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.542 0.687 . . . . 0.0 110.284 177.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.443 HG22 HG12 ' A' ' 59' ' ' VAL . 11.1 mm -80.22 -27.88 12.02 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.934 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 41' ' ' ILE . 69.5 mt -61.42 -47.56 92.85 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.422 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 43' ' ' GLU . 1.5 ptm180 -65.62 -41.11 93.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.015 179.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 97.2 mttt -58.88 -47.07 86.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.054 0.455 . . . . 0.0 110.269 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.547 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 23.5 m -67.02 -26.3 66.71 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.599 -179.512 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.728 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.4 t30 -68.03 -34.18 76.0 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.011 0.434 . . . . 0.0 110.671 179.281 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.54 -29.81 52.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.558 177.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.403 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 55.4 mm-40 -80.07 -35.23 37.31 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.839 -0.619 . . . . 0.0 112.375 -177.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.0 pp -141.41 176.64 8.7 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.12 0.486 . . . . 0.0 111.827 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -129.34 -66.32 0.11 Allowed Glycine 0 N--CA 1.443 -0.872 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.742 172.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 3.9 tpt85 -93.68 3.27 55.73 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.842 0.353 . . . . 0.0 111.859 -173.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' HB3' ' HB3' ' A' ' 4' ' ' SER . 3.0 mm? -105.13 170.6 7.78 Favored 'General case' 0 C--N 1.324 -0.506 0 O-C-N 122.206 -0.308 . . . . 0.0 110.817 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.523 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -119.22 107.54 1.4 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.413 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.509 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 60.0 t80 -85.74 139.18 31.55 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -67.22 109.93 3.29 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 178.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG11 ' HB2' ' A' ' 69' ' ' ALA . 33.2 m -102.02 -37.15 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.534 -177.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -130.52 107.08 8.95 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.413 -177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.436 ' HG3' HG12 ' A' ' 66' ' ' ILE . 35.1 tt0 -105.92 132.75 51.64 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.451 0.644 . . . . 0.0 111.064 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.485 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 24.7 t70 -128.61 166.58 18.61 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 172.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -62.36 -21.07 65.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.086 0.47 . . . . 0.0 110.929 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 34.8 mt-30 -93.56 -61.3 1.58 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.307 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.558 ' CE2' HG11 ' A' ' 32' ' ' VAL . 52.6 m-85 -129.64 165.61 21.44 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.409 -171.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.437 HD11 ' HG2' ' A' ' 83' ' ' LYS . 74.7 mt -131.31 125.81 57.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.284 178.061 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.49 137.86 14.01 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 121.084 -0.579 . . . . 0.0 111.964 177.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.487 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 64.5 m-70 -123.63 127.07 47.72 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 -179.175 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.529 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -83.11 123.75 29.82 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.834 0.35 . . . . 0.0 111.638 -178.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.523 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 67.4 m-85 -116.1 141.0 48.71 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 177.298 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.81 120.45 26.46 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.703 173.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -116.05 179.15 4.07 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.537 -176.083 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.41 95.6 0.07 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.917 0.389 . . . . 0.0 111.307 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.54 4.66 61.61 Favored Glycine 0 N--CA 1.451 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 113.251 177.207 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.528 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 26.6 m170 -141.13 172.06 13.2 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.838 0.351 . . . . 0.0 111.112 -175.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -130.12 117.35 19.82 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.792 -179.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 53.0 mt -119.71 134.75 62.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.058 -176.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 17' ' ' SER . 67.0 t -104.51 111.08 32.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.174 178.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -91.62 123.31 34.92 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.262 -179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.25 117.97 31.87 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.858 -178.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HA ' ' A' ' 14' ' ' ALA . 49.7 p -107.02 154.98 40.01 Favored Pre-proline 0 C--N 1.318 -0.802 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.868 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.47 52.91 2.09 Favored 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.735 2.29 . . . . 0.0 112.407 178.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.485 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 30.8 mttm 63.92 -76.93 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.312 0.645 . . . . 0.0 111.434 -174.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 66.3 13.46 9.2 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 121.121 0.486 . . . . 0.0 111.294 176.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.41 ' HB3' ' HE2' ' A' ' 85' ' ' LYS . 35.7 mtpt -91.91 39.39 1.01 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.949 0.404 . . . . 0.0 111.218 -178.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -67.5 -41.64 84.18 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 175.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 5.6 tpt180 -152.85 138.85 18.15 Favored 'General case' 0 C--N 1.322 -0.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 176.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -69.95 -50.2 44.27 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.893 0.377 . . . . 0.0 110.481 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 68.37 -99.23 0.56 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.814 176.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.07 128.07 41.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.241 0.544 . . . . 0.0 111.162 -176.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.7 m -83.47 129.08 61.57 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.908 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.482 ' HB3' ' CD ' ' A' ' 6' ' ' PRO . 14.4 Cg_endo -57.57 118.83 5.77 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 123.493 2.795 . . . . 0.0 113.519 -176.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -79.24 122.2 5.11 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.617 2.212 . . . . 0.0 111.917 175.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 48.5 t -98.59 -48.5 12.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.163 0.506 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 88.04 170.26 45.85 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.932 -0.651 . . . . 0.0 111.803 -178.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.441 HG13 ' N ' ' A' ' 97' ' ' THR . 23.2 pt -76.26 -45.77 34.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 120.89 0.376 . . . . 0.0 110.459 177.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.441 ' N ' HG13 ' A' ' 96' ' ' ILE . 18.9 m -149.56 -56.84 0.19 Allowed 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 . . . . . 0 C--O 1.244 0.769 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.293 174.706 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.1 ptp . . . . . 0 N--CA 1.481 1.098 0 CA-C-O 120.874 0.369 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.4 tppt? -135.43 94.71 3.15 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.3 m -117.83 42.79 2.55 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.295 0.569 . . . . 0.0 110.532 -176.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.62 ' HB2' HG12 ' A' ' 94' ' ' VAL . 14.6 m -78.4 106.11 10.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.082 177.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 59.0 mt -114.0 133.43 22.33 Favored Pre-proline 0 C--N 1.32 -0.693 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.227 -176.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 37.0 Cg_endo -67.25 155.6 69.85 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.837 2.358 . . . . 0.0 112.624 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.7 tp -66.13 -27.67 41.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.696 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.5 t -61.96 -19.95 63.33 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 121.105 0.478 . . . . 0.0 110.53 -179.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.5 mm-40 -94.01 -54.22 3.68 Favored 'General case' 0 N--CA 1.453 -0.308 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.265 174.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.4 t -64.52 -38.06 81.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.456 -171.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.8 tp -54.0 -64.1 2.12 Favored Pre-proline 0 CA--C 1.543 0.704 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -177.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.4 -25.04 30.64 Favored 'Trans proline' 0 C--N 1.35 0.627 0 C-N-CA 121.999 1.8 . . . . 0.0 112.796 -179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -91.86 7.43 41.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.674 0.273 . . . . 0.0 111.454 -177.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.544 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -91.3 159.3 16.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.056 0.455 . . . . 0.0 110.999 178.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.2 m -118.13 -2.12 9.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.622 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.557 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.74 162.67 35.24 Favored Glycine 0 N--CA 1.448 -0.533 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 178.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 11.6 p -155.42 140.55 17.47 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.269 0.557 . . . . 0.0 111.445 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.529 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 18.1 mt -116.43 120.25 38.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.178 175.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 29.7 m -94.75 119.53 33.51 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.676 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.427 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 35.8 m-85 -113.69 156.43 23.77 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.13 176.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.428 ' HB3' HD11 ' A' ' 27' ' ' LEU . 1.0 OUTLIER -93.88 -176.06 3.92 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 177.698 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -64.88 -23.95 67.39 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 111.664 0.246 . . . . 0.0 111.664 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -88.29 5.33 42.34 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 120.704 0.287 . . . . 0.0 110.343 177.198 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . . . . . . . . . 91.2 m-85 67.02 34.53 5.1 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.689 -0.687 . . . . 0.0 112.034 176.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -101.09 146.63 27.21 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 174.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.43 HD13 HD22 ' A' ' 18' ' ' LEU . 39.6 tp -68.17 123.97 22.16 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.989 0.424 . . . . 0.0 111.065 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.428 HD11 ' HB3' ' A' ' 21' ' ' ASP . 87.4 mt -104.76 -48.42 3.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.057 178.31 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -142.53 137.67 30.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.362 -174.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 31.6 m -120.87 121.51 38.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.2 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 19.5 m -133.31 151.05 51.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.965 0.412 . . . . 0.0 111.666 -174.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.557 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 73.12 -145.12 35.8 Favored Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.958 -0.564 . . . . 0.0 112.985 174.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 65' ' ' TYR . 28.3 t -67.47 -18.58 24.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.075 0.464 . . . . 0.0 110.807 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.86 -15.37 54.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.023 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 28.8 mtpp -75.46 -27.14 58.76 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.019 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.0 m -102.6 -23.56 4.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 CA-C-O 120.77 0.319 . . . . 0.0 110.948 179.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -69.25 144.18 14.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.783 174.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -71.53 142.29 50.1 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.975 0.417 . . . . 0.0 110.519 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -63.76 -34.56 78.17 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.51 -173.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.747 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 29.9 m 62.23 177.6 0.05 OUTLIER Pre-proline 0 CA--C 1.541 0.608 0 O-C-N 123.373 0.42 . . . . 0.0 111.941 172.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.747 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 72.3 Cg_endo -78.71 39.48 0.8 Allowed 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.452 2.101 . . . . 0.0 111.959 170.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.741 HG13 ' HB2' ' A' ' 39' ' ' SER . 55.9 mt -61.87 -36.5 74.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.536 -175.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.72 -36.14 71.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.087 0.47 . . . . 0.0 110.833 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.579 ' OE1' ' HD2' ' A' ' 46' ' ' ARG . 3.8 tp10 -65.26 -38.72 91.18 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.275 177.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.467 HG22 HG12 ' A' ' 59' ' ' VAL . 15.1 mm -78.64 -27.54 14.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.319 -178.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 41' ' ' ILE . 78.2 mt -62.88 -47.71 91.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.55 -0.295 . . . . 0.0 110.54 178.518 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.579 ' HD2' ' OE1' ' A' ' 43' ' ' GLU . 5.6 ptp180 -63.72 -39.95 95.55 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.614 177.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.56 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 91.6 mttt -59.65 -49.25 78.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.989 0.423 . . . . 0.0 110.221 176.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.514 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 19.9 m -67.16 -26.1 66.49 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.822 -178.281 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.604 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.5 t30 -64.7 -36.69 85.08 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.913 0.387 . . . . 0.0 110.267 177.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.39 -15.77 45.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.122 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.56 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 16.4 mm-40 -83.89 -41.17 17.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.823 -179.696 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.548 ' CD2' ' HB2' ' A' ' 57' ' ' TYR . 2.4 pp -131.37 -176.23 3.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.478 0.547 . . . . 0.0 112.478 -172.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -121.2 -74.73 0.37 Allowed Glycine 0 N--CA 1.445 -0.712 0 CA-C-N 115.416 -0.811 . . . . 0.0 112.058 176.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.6 tpt180 -110.87 1.67 17.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.921 0.391 . . . . 0.0 111.319 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -90.09 174.37 7.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.202 -178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -111.52 127.53 8.21 Favored Glycine 0 N--CA 1.445 -0.7 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.324 178.458 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.548 ' HB2' ' CD2' ' A' ' 52' ' ' LEU . 31.8 t80 -102.35 133.26 47.56 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.5 p -68.29 108.65 3.28 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.18 0.514 . . . . 0.0 109.962 177.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 34.9 m -100.14 -31.38 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.057 -177.037 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.567 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 86.7 t80 -134.44 105.58 6.63 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.156 -0.475 . . . . 0.0 109.992 179.177 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.449 ' HG3' HG12 ' A' ' 66' ' ' ILE . 34.7 tt0 -105.39 112.07 25.03 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.273 0.558 . . . . 0.0 109.541 178.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.567 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 13.5 t70 -110.38 168.26 9.59 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -178.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -71.07 -12.51 61.55 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.154 0.502 . . . . 0.0 110.138 178.656 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -103.08 -61.64 1.38 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.074 178.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.573 ' CE2' HG11 ' A' ' 32' ' ' VAL . 60.1 m-85 -128.67 166.49 18.82 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.073 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.449 HG12 ' HG3' ' A' ' 61' ' ' GLU . 75.9 mt -129.98 126.04 61.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.494 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -94.23 142.27 15.95 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.04 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.522 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 11.9 m-70 -127.65 126.46 42.02 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.34 123.9 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 111.34 179.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -117.16 141.29 48.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.622 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.604 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.5 OUTLIER -82.82 125.06 30.88 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.503 172.99 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.483 ' HG3' HG13 ' A' ' 77' ' ' ILE . 28.6 mmmt -112.13 -177.94 3.29 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.531 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.3 92.02 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.984 0.421 . . . . 0.0 111.224 179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 70.88 6.84 60.75 Favored Glycine 0 N--CA 1.451 -0.333 0 CA-C-N 115.791 -0.641 . . . . 0.0 113.447 179.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 26.2 m80 -142.01 173.57 11.39 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.945 0.372 . . . . 0.0 111.144 -174.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -128.32 129.3 46.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.448 -176.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.483 HG13 ' HG3' ' A' ' 72' ' ' LYS . 54.4 mt -132.16 135.08 58.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.902 0.382 . . . . 0.0 110.766 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 61.9 t -104.76 113.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.348 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -94.39 127.62 40.39 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.378 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -100.98 122.4 43.46 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.696 -178.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 14' ' ' ALA . 68.6 p -114.25 159.11 37.76 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.354 179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.473 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.3 Cg_endo -72.46 61.91 3.54 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.946 2.431 . . . . 0.0 113.446 -178.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.429 ' HA ' HG13 ' A' ' 66' ' ' ILE . 0.6 OUTLIER 61.58 18.75 9.79 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 114.869 -1.06 . . . . 0.0 113.328 170.82 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -81.7 80.23 8.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.569 0.699 . . . . 0.0 109.769 172.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 20.8 tptm -59.3 -44.86 92.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.254 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -167.03 85.48 0.26 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 114.599 -1.182 . . . . 0.0 108.633 171.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.769 ' HA ' ' HE ' ' A' ' 87' ' ' ARG . 0.7 OUTLIER -67.07 -54.92 16.93 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.541 -174.157 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 87' ' ' ARG . 1.7 mp0 -82.8 158.77 22.66 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.774 175.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -89.92 44.55 3.0 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.796 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 29.6 m -96.13 146.54 7.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 120.903 0.382 . . . . 0.0 111.02 -176.374 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 5.0 m -129.78 102.72 17.72 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.397 0.617 . . . . 0.0 110.793 177.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.462 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 88.6 Cg_endo -82.36 177.16 7.34 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.865 2.376 . . . . 0.0 111.666 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_exo -61.88 104.64 0.34 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.12 1.88 . . . . 0.0 111.508 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.62 HG12 ' HB2' ' A' ' 4' ' ' SER . 35.9 m -84.24 -14.24 11.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.896 -176.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -166.94 110.1 0.38 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.039 178.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 37.9 pt -99.82 -33.33 3.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.133 0.492 . . . . 0.0 110.602 177.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.0 m -95.98 87.64 4.65 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 20.5 m120 . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.61 -0.71 . . . . 0.0 109.734 178.067 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.4 tpt . . . . . 0 N--CA 1.481 1.078 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.6 tppt? 73.44 112.5 0.06 Allowed 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.298 0.639 . . . . 0.0 111.333 179.238 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.1 t -84.29 83.29 8.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.56 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.1 m -131.84 123.11 26.87 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.035 174.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.424 HG23 ' HD2' ' A' ' 6' ' ' PRO . 64.2 mt -128.56 136.77 29.63 Favored Pre-proline 0 C--N 1.327 -0.391 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.619 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 36.6 Cg_endo -65.6 156.95 61.05 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.915 2.41 . . . . 0.0 112.855 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.4 tp -65.52 -26.72 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.803 -175.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.407 HG22 ' HB2' ' A' ' 6' ' ' PRO . 9.6 t -60.87 -22.48 64.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.407 -177.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.2 mm-40 -101.6 -44.01 5.71 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.304 0.573 . . . . 0.0 110.015 179.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 98.9 t -68.74 -36.52 74.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.758 -174.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.1 tp -53.44 -61.42 5.06 Favored Pre-proline 0 CA--C 1.542 0.635 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -179.259 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_endo -65.49 -25.85 55.28 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 121.815 1.677 . . . . 0.0 113.073 179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 89.5 mtt180 -92.65 9.76 33.44 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.787 0.327 . . . . 0.0 111.581 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.542 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -93.55 148.36 22.16 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.019 0.438 . . . . 0.0 111.163 179.463 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -116.31 -6.39 11.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.985 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.729 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -156.98 171.65 34.45 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 178.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 55.6 p -156.8 145.62 20.04 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.246 0.546 . . . . 0.0 111.384 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.515 HD21 ' HE2' ' A' ' 38' ' ' LYS . 8.7 mt -122.82 119.6 31.06 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.837 174.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.567 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 36.9 m -98.17 118.82 35.66 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 116.488 -0.324 . . . . 0.0 111.224 -176.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.455 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.9 m-85 -114.43 155.47 26.29 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.702 177.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.542 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 0.5 OUTLIER -90.22 178.68 6.09 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 175.525 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.437 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 3.1 pm0 -65.82 -19.84 66.03 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.743 0.306 . . . . 0.0 111.514 -177.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 -91.07 8.24 36.47 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.012 0.434 . . . . 0.0 110.48 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.452 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 81.4 m-85 66.77 35.55 5.01 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.244 175.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -101.12 134.54 43.98 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 173.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.7 tt -69.24 119.82 14.12 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.039 0.447 . . . . 0.0 110.019 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.419 HD11 ' HB3' ' A' ' 21' ' ' ASP . 74.2 mt -100.48 -53.24 3.15 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.793 -178.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.567 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 19.9 t70 -131.81 141.69 49.52 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.306 -172.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 48.3 m -123.64 118.62 27.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.75 175.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.6 m -134.16 157.8 45.28 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.072 0.463 . . . . 0.0 111.409 -177.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.729 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.05 -150.93 46.57 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.504 178.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.483 HG11 ' CE1' ' A' ' 65' ' ' TYR . 46.9 t -64.91 -16.41 19.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.086 0.47 . . . . 0.0 111.151 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.428 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.03 -14.54 36.68 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.183 179.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -77.2 -23.31 51.46 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.737 179.719 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.1 m -103.96 -19.21 6.39 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-O 121.026 0.441 . . . . 0.0 110.873 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.5 mt -76.06 142.13 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.35 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -72.8 141.82 48.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.267 0.556 . . . . 0.0 111.341 -176.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.515 ' HE2' HD21 ' A' ' 18' ' ' LEU . 0.6 OUTLIER -83.34 87.94 6.96 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.035 -179.714 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.812 ' HB3' ' HD2' ' A' ' 40' ' ' PRO . 54.5 m -75.1 177.33 2.37 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.297 173.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.812 ' HD2' ' HB3' ' A' ' 39' ' ' SER . 38.7 Cg_endo -67.22 57.6 0.61 Allowed 'Trans proline' 0 C--N 1.356 0.928 0 C-N-CA 122.825 2.35 . . . . 0.0 112.455 175.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.591 ' O ' HG13 ' A' ' 45' ' ' ILE . 68.0 mt -69.49 -34.27 61.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.643 -178.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.452 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.98 -37.13 73.65 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-O 120.909 0.385 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.543 ' HG3' ' HE3' ' A' ' 47' ' ' LYS . 29.5 tp10 -65.09 -35.86 82.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.36 177.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.461 HG22 HG12 ' A' ' 59' ' ' VAL . 14.1 mm -79.58 -28.87 13.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 116.211 -0.45 . . . . 0.0 109.876 179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.591 HG13 ' O ' ' A' ' 41' ' ' ILE . 73.4 mt -61.12 -47.35 93.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.316 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -65.14 -43.29 92.33 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.543 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 98.4 mttt -60.15 -46.28 90.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.854 0.359 . . . . 0.0 110.29 177.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.453 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 22.6 m -67.04 -26.71 66.89 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.879 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.518 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 10.2 t30 -65.18 -36.58 84.66 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.954 0.407 . . . . 0.0 110.305 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -75.91 -30.97 58.97 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.591 176.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.475 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 15.6 mm-40 -69.86 -52.81 21.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.136 -178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.492 HD23 ' HB2' ' A' ' 57' ' ' TYR . 2.3 pp -124.64 -173.59 2.82 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -169.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 96' ' ' ILE . . . -122.18 -89.84 1.0 Allowed Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.281 173.145 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -87.54 -12.18 46.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.084 0.468 . . . . 0.0 111.067 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.532 HD11 ' HA ' ' A' ' 94' ' ' VAL . 91.9 mt -68.26 158.71 32.74 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.017 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.528 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -111.48 104.44 1.69 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.67 178.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.492 ' HB2' HD23 ' A' ' 52' ' ' LEU . 87.1 t80 -81.43 133.75 35.45 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.719 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.9 m -67.86 108.7 3.1 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.053 0.454 . . . . 0.0 109.96 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.492 HG11 ' HB2' ' A' ' 69' ' ' ALA . 32.1 m -99.43 -33.41 3.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.574 -175.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.546 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 88.9 t80 -132.68 112.45 12.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.166 -178.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 66' ' ' ILE . 46.0 tt0 -108.95 109.63 20.74 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.186 0.517 . . . . 0.0 110.199 177.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.551 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 14.3 t70 -97.23 175.39 6.3 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -76.07 -16.03 60.0 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.098 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -104.92 -51.44 3.05 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.449 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CE1' HG11 ' A' ' 32' ' ' VAL . 66.0 m-85 -129.91 171.58 12.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.139 -171.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 61' ' ' GLU . 74.8 mt -136.21 125.56 38.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.592 179.147 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.48 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.64 148.0 18.83 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.187 -0.53 . . . . 0.0 112.257 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.476 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 21.4 m-70 -131.89 130.7 41.98 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 -177.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.492 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.73 124.36 31.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.715 0.293 . . . . 0.0 111.502 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.528 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.3 m-85 -117.49 140.56 49.45 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.644 177.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.522 ' HB2' ' O ' ' A' ' 53' ' ' GLY . 0.4 OUTLIER -81.7 124.16 29.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.518 173.422 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.479 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.5 mmmt -114.7 179.07 4.06 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.292 -0.413 . . . . 0.0 109.892 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.06 95.26 0.27 Allowed 'General case' 0 C--O 1.235 0.319 0 CA-C-O 121.028 0.442 . . . . 0.0 110.94 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.65 14.3 67.11 Favored Glycine 0 N--CA 1.449 -0.475 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.831 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.542 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 16.0 m170 -145.83 172.74 12.88 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.849 0.324 . . . . 0.0 111.002 -177.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.437 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 75.4 m-85 -128.95 123.54 32.75 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 177.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.479 HG13 ' HG3' ' A' ' 72' ' ' LYS . 49.3 mt -126.13 135.13 64.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.832 -178.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 62.8 t -103.76 111.57 33.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.716 178.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 32.8 m-85 -89.34 119.83 30.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.892 -179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.48 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 67.2 m-85 -93.57 117.16 29.74 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.751 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 ' HA ' ' A' ' 14' ' ' ALA . 67.0 p -106.09 170.0 6.3 Favored Pre-proline 0 C--N 1.312 -1.065 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 174.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.502 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 27.8 Cg_endo -64.79 165.46 20.95 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 121.152 1.234 . . . . 0.0 109.762 167.892 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.551 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 27.0 mttm -47.85 100.81 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.0 0.428 . . . . 0.0 110.534 171.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . 0.451 ' H ' HD12 ' A' ' 66' ' ' ILE . 7.1 t30 -137.75 81.57 1.87 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.428 0.632 . . . . 0.0 110.388 -174.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -117.02 -42.71 2.91 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 172.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 7.9 m120 64.67 -72.84 0.06 Allowed 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.961 172.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 7.8 tpt180 -170.32 -57.69 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 -174.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -175.3 89.54 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 114.369 -1.287 . . . . 0.0 108.809 173.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -56.53 -51.6 55.46 Favored Glycine 0 C--N 1.329 0.172 0 CA-C-N 115.734 -0.666 . . . . 0.0 113.153 -174.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.5 p -159.73 145.9 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -110.6 97.61 33.29 Favored Pre-proline 0 C--N 1.322 -0.595 0 CA-C-O 121.292 0.568 . . . . 0.0 111.398 178.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.619 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 56.1 Cg_endo -90.56 173.38 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 123.402 2.734 . . . . 0.0 111.582 176.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.34 116.66 4.01 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.077 1.852 . . . . 0.0 111.426 174.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.532 ' HA ' HD11 ' A' ' 55' ' ' LEU . 29.8 t -76.95 88.84 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.082 0.468 . . . . 0.0 110.632 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.01 -134.03 4.77 Favored Glycine 0 N--CA 1.447 -0.587 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.737 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 53' ' ' GLY . 44.2 mm -128.51 -71.88 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 42.1 m -122.3 97.69 5.58 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 16.2 m120 . . . . . 0 C--O 1.25 1.102 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.737 -175.571 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.467 ' HA ' ' OE2' ' A' ' 88' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.674 0.273 . . . . 0.0 111.191 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.5 tppt? -107.71 92.69 4.18 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.5 m -66.3 135.06 53.86 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.351 0.596 . . . . 0.0 112.573 -170.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -82.37 127.29 33.11 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.459 HG23 ' HD2' ' A' ' 6' ' ' PRO . 58.2 mt -125.67 139.21 33.54 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.43 -169.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.459 ' HD2' HG23 ' A' ' 5' ' ' ILE . 40.0 Cg_endo -67.94 158.74 56.01 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.551 2.167 . . . . 0.0 112.432 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 9.0 tp -62.91 -28.92 45.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.052 -175.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 10.1 t -62.49 -16.33 54.97 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 120.852 0.358 . . . . 0.0 111.149 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -102.66 -49.03 3.94 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.715 176.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.2 t -70.59 -34.37 56.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.846 -172.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.5 tp -55.25 -63.68 2.81 Favored Pre-proline 0 CA--C 1.541 0.618 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -67.48 -34.01 27.49 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.021 1.814 . . . . 0.0 113.086 -178.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -86.11 2.58 46.15 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -174.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.47 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -81.2 162.56 23.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.116 0.484 . . . . 0.0 111.31 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.59 -1.61 7.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.644 178.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.774 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.5 158.41 30.83 Favored Glycine 0 N--CA 1.443 -0.871 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.735 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.4 m -153.41 129.77 10.56 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 117.487 0.643 . . . . 0.0 111.43 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.575 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 13.0 mt -108.93 117.46 34.26 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.276 176.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 19.6 m -92.65 113.37 25.63 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.037 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.429 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 8.8 m-85 -108.45 154.97 21.12 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.627 0.727 . . . . 0.0 111.078 -179.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.489 ' HB2' HD21 ' A' ' 27' ' ' LEU . 28.6 t70 -87.94 165.06 15.51 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.175 -0.921 . . . . 0.0 110.692 179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -61.86 -24.86 67.18 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.165 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 36.1 m-80 -91.51 14.31 15.25 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-O 120.892 0.377 . . . . 0.0 110.603 177.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.502 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 86.4 m-85 63.61 42.08 6.72 Favored 'General case' 0 C--O 1.234 0.239 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.206 175.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -115.17 145.85 41.97 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 172.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.441 HD21 ' OG1' ' A' ' 29' ' ' THR . 41.6 tp -70.44 129.04 38.21 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.996 0.427 . . . . 0.0 110.978 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.489 HD21 ' HB2' ' A' ' 21' ' ' ASP . 85.8 mt -103.16 -51.87 3.15 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.66 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.549 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 7.1 t70 -140.46 137.91 34.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.288 -174.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . 0.441 ' OG1' HD21 ' A' ' 26' ' ' LEU . 17.6 m -118.26 119.62 35.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.264 176.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 65.1 m -133.04 155.62 48.87 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.797 0.332 . . . . 0.0 111.162 -178.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.774 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 72.23 -155.15 51.34 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.872 176.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.579 HG11 ' CE2' ' A' ' 65' ' ' TYR . 46.2 t -61.19 -18.82 18.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 111.205 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.575 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.65 -14.26 41.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.305 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.404 ' HE2' ' O ' ' A' ' 31' ' ' GLY . 50.4 mtmt -71.8 -37.04 70.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 116.445 -0.343 . . . . 0.0 111.043 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 36.0 m -92.87 -21.7 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -178.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.7 mt -71.07 146.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.368 175.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.418 ' HG3' ' OG ' ' A' ' 39' ' ' SER . 13.6 pt-20 -71.42 137.04 48.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.69 0.281 . . . . 0.0 110.693 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -59.02 -44.55 91.72 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.348 -174.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.553 ' HB2' HG13 ' A' ' 41' ' ' ILE . 22.9 m 66.9 173.15 0.08 OUTLIER Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 170.521 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -77.04 40.51 0.82 Allowed 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 123.191 2.594 . . . . 0.0 112.131 173.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.558 ' O ' HG13 ' A' ' 45' ' ' ILE . 59.9 mt -61.32 -34.41 60.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.069 -178.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.502 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.22 -37.52 72.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.41 -177.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.509 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 13.9 tp10 -65.6 -36.87 84.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.394 0.616 . . . . 0.0 110.266 178.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.485 HG22 HG12 ' A' ' 59' ' ' VAL . 16.3 mm -79.14 -27.73 13.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.09 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.558 HG13 ' O ' ' A' ' 41' ' ' ILE . 60.4 mt -60.59 -47.31 93.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.49 177.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HB3' ' CZ ' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -68.61 -38.51 80.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.069 -179.356 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.509 ' HG3' ' O ' ' A' ' 43' ' ' GLU . 90.9 mttt -61.14 -48.45 81.57 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.139 0.495 . . . . 0.0 110.158 175.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.54 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 18.4 m -67.6 -23.04 65.33 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.708 179.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.744 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 8.3 t30 -67.3 -33.78 76.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.268 0.556 . . . . 0.0 110.147 177.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -74.1 -33.52 63.64 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.519 176.314 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 27.2 mm-40 -75.02 -40.92 60.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.4 -177.753 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.1 pp -141.36 -176.69 4.82 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -169.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 98' ' ' ASN . . . -135.33 -65.48 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 114.92 -1.036 . . . . 0.0 111.571 170.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.489 ' HD2' ' O ' ' A' ' 54' ' ' ARG . 0.9 OUTLIER -96.37 4.27 52.34 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-O 120.9 0.381 . . . . 0.0 111.288 -173.83 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 94' ' ' VAL . 2.8 mm? -100.2 164.15 12.09 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.662 0.267 . . . . 0.0 110.37 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.414 ' HA3' ' CZ ' ' A' ' 70' ' ' PHE . . . -113.48 93.25 0.65 Allowed Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.859 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 68' ' ' HIS . 62.4 t80 -73.38 137.7 44.84 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 177.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 3.8 p -69.85 108.43 3.97 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-O 121.154 0.502 . . . . 0.0 110.303 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.531 HG11 ' HB2' ' A' ' 69' ' ' ALA . 35.9 m -96.82 -30.48 3.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.844 -178.067 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 57.3 t80 -135.67 122.47 21.12 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.664 -178.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -114.84 134.47 55.11 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.639 0.733 . . . . 0.0 110.731 176.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 10.2 t70 -127.93 168.73 14.83 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 114.569 -1.196 . . . . 0.0 108.416 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.0 -23.7 66.62 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 111.504 0.187 . . . . 0.0 111.504 -177.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -111.7 -35.93 5.61 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 121.059 -0.257 . . . . 0.0 111.485 178.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.579 ' CE2' HG11 ' A' ' 32' ' ' VAL . 21.5 m-85 -129.73 161.89 29.65 Favored 'General case' 0 C--O 1.222 -0.347 0 CA-C-O 121.268 0.556 . . . . 0.0 112.495 -169.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.492 HG13 ' HA ' ' A' ' 83' ' ' LYS . 75.8 mt -137.68 127.37 35.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.896 177.085 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -91.3 141.8 15.83 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 121.136 -0.554 . . . . 0.0 111.809 178.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 40.0 m-70 -127.29 124.27 38.38 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.531 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.0 122.9 29.4 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.334 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.414 ' CZ ' ' HA3' ' A' ' 56' ' ' GLY . 77.0 m-85 -113.97 140.08 48.71 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.571 177.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.744 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -82.68 123.62 29.45 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.838 173.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.487 ' HG3' HG13 ' A' ' 77' ' ' ILE . 31.0 mmmt -114.87 -179.39 3.61 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -67.61 95.46 0.48 Allowed 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.802 0.334 . . . . 0.0 110.896 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 68.27 15.63 68.06 Favored Glycine 0 CA--C 1.517 0.171 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.68 -179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -146.2 172.81 12.89 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.954 0.407 . . . . 0.0 111.162 -176.006 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -132.26 128.96 38.95 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.333 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.487 HG13 ' HG3' ' A' ' 72' ' ' LYS . 55.7 mt -129.36 133.56 65.26 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 C-N-CA 120.246 -0.582 . . . . 0.0 110.767 178.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 60.4 t -104.9 108.0 23.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.214 179.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -90.92 122.07 33.29 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.429 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -95.08 118.19 31.46 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.715 -179.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.47 HG22 ' HA ' ' A' ' 14' ' ' ALA . 65.3 p -105.85 162.01 21.05 Favored Pre-proline 0 C--N 1.316 -0.888 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 176.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.456 ' HD2' ' HB ' ' A' ' 81' ' ' THR . 60.2 Cg_endo -72.67 59.6 3.39 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.422 2.081 . . . . 0.0 111.404 176.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.526 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 45.4 mttm 67.14 -68.02 0.16 Allowed 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.214 -171.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 47.1 t30 60.7 89.2 0.07 Allowed 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.76 0.662 . . . . 0.0 111.571 177.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -111.39 -54.56 2.59 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.475 176.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 53.7 t30 60.7 -81.41 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.112 -177.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 27.5 ttm180 179.88 125.3 0.07 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.467 ' OE2' ' HA ' ' A' ' 1' ' ' MET . 13.5 pt-20 -93.28 -172.87 3.07 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 138.04 -45.99 1.02 Allowed Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -177.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 47.4 t -107.34 117.02 52.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.36 129.79 76.55 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-O 121.023 0.44 . . . . 0.0 110.824 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.95 162.86 40.62 Favored 'Trans proline' 0 C--O 1.235 0.34 0 C-N-CA 122.643 2.229 . . . . 0.0 112.413 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.53 132.87 48.35 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.841 2.361 . . . . 0.0 112.584 179.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.685 ' HA ' HD11 ' A' ' 55' ' ' LEU . 27.4 m -84.66 -167.57 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.029 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -99.27 124.04 8.1 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.41 177.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 11.4 pt -71.17 92.79 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.096 0.474 . . . . 0.0 111.368 -178.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 28.9 m 61.34 74.75 0.43 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.499 -177.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.526 ' HB3' ' HA3' ' A' ' 53' ' ' GLY . 13.2 m120 . . . . . 0 C--O 1.247 0.957 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.19 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.6 tpt . . . . . 0 N--CA 1.479 1.003 0 CA-C-O 120.827 0.346 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 17.1 tppt? -143.39 107.04 4.61 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 62.9 m -76.27 88.88 3.12 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.33 0.586 . . . . 0.0 110.973 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . 0.548 ' HB2' HD13 ' A' ' 55' ' ' LEU . 8.9 p -85.11 104.26 14.85 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 109.764 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 52.0 mt -121.19 134.79 24.52 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.922 -174.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.468 ' HD3' ' HG3' ' A' ' 92' ' ' PRO . 48.6 Cg_endo -70.93 159.32 52.89 Favored 'Trans proline' 0 C--O 1.237 0.467 0 C-N-CA 122.54 2.16 . . . . 0.0 112.377 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.0 tp -61.37 -29.23 45.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.889 -176.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 14.0 t -59.2 -25.03 63.62 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.647 0.261 . . . . 0.0 111.115 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 60.5 mm-40 -101.78 -39.24 7.5 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.985 0.421 . . . . 0.0 110.902 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.412 HG21 ' HZ ' ' A' ' 70' ' ' PHE . 89.7 t -71.27 -33.73 51.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.373 -176.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.7 tp -53.28 -61.84 4.38 Favored Pre-proline 0 CA--C 1.539 0.527 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -64.85 -32.3 55.79 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 121.934 1.756 . . . . 0.0 112.825 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 82.5 mtt85 -83.46 -1.35 53.38 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.415 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -87.22 151.08 23.47 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 120.858 0.361 . . . . 0.0 110.866 179.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.42 ' O ' HG23 ' A' ' 32' ' ' VAL . 19.6 m -120.74 5.56 6.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.343 0.592 . . . . 0.0 110.567 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.721 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -163.24 154.57 25.56 Favored Glycine 0 N--CA 1.442 -0.911 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 78' ' ' VAL . 16.5 m -152.44 135.11 15.37 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 117.429 0.615 . . . . 0.0 110.804 -178.344 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.509 ' HG ' ' HB1' ' A' ' 33' ' ' ALA . 12.5 mt -111.26 119.13 37.87 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.255 175.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 31.0 m -90.78 114.31 26.65 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 120.951 0.405 . . . . 0.0 110.442 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.426 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 28.4 m-85 -110.38 152.03 26.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.49 0.662 . . . . 0.0 110.482 178.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.479 ' HB2' HD21 ' A' ' 27' ' ' LEU . 34.7 t70 -81.2 170.04 16.6 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.259 177.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.477 ' HA ' ' CE2' ' A' ' 76' ' ' PHE . 5.7 pt-20 -64.24 -24.22 67.59 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.054 0.454 . . . . 0.0 110.505 177.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -88.53 12.6 14.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.244 174.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.412 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 89.0 m-85 64.67 28.78 13.11 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.294 -0.867 . . . . 0.0 112.535 175.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -96.8 139.75 32.39 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 32.5 tp -65.18 125.24 24.37 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 121.016 0.436 . . . . 0.0 110.961 178.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.479 HD21 ' HB2' ' A' ' 21' ' ' ASP . 82.8 mt -105.24 -53.03 2.73 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.502 179.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 10.1 t70 -137.88 147.81 44.79 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.997 -175.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 25.1 m -126.28 116.7 21.67 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.824 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.8 m -130.83 157.76 42.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.028 0.442 . . . . 0.0 111.405 -177.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.721 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 71.32 -155.24 52.35 Favored Glycine 0 N--CA 1.447 -0.627 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.437 179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.646 HG11 ' CE2' ' A' ' 65' ' ' TYR . 48.8 t -61.36 -18.96 19.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.943 0.402 . . . . 0.0 111.368 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.509 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -59.08 -17.35 25.38 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.271 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -71.73 -36.31 70.43 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.043 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.6 m -92.99 -17.81 7.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.3 mt -71.25 136.63 25.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.483 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -67.99 138.63 56.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.39 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -85.27 91.31 8.13 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.699 -177.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.427 ' HB2' ' CD ' ' A' ' 40' ' ' PRO . 13.7 p -80.6 176.83 3.41 Favored Pre-proline 0 C--N 1.318 -0.774 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.71 171.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.427 ' CD ' ' HB2' ' A' ' 39' ' ' SER . 23.5 Cg_exo -67.15 55.67 0.52 Allowed 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.872 2.381 . . . . 0.0 112.611 175.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 45' ' ' ILE . 67.5 mt -63.93 -33.94 65.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.856 -179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.04 -36.33 70.35 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.072 0.463 . . . . 0.0 110.962 179.744 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 tp10 -63.79 -37.76 88.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.106 178.003 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.537 HG22 HG12 ' A' ' 59' ' ' VAL . 15.6 mm -80.59 -27.67 11.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.066 -0.516 . . . . 0.0 109.929 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 41' ' ' ILE . 68.1 mt -61.83 -46.22 96.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.159 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.543 177.641 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 46' ' ' ARG . 1.4 ptm180 -67.21 -39.78 86.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.825 179.452 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.595 ' O ' ' HG2' ' A' ' 51' ' ' GLU . 98.9 mttt -57.89 -51.19 70.63 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 174.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.603 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 17.3 m -67.49 -21.36 65.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.033 -179.24 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.607 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 9.9 t30 -66.95 -36.13 81.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 0.0 110.431 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -80.6 -28.26 37.12 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.771 177.278 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.595 ' HG2' ' O ' ' A' ' 47' ' ' LYS . 30.6 mm-40 -72.73 -38.1 67.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.033 -177.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.603 ' HG ' ' O ' ' A' ' 48' ' ' SER . 3.5 pp -139.09 177.9 7.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.062 0.458 . . . . 0.0 112.212 -172.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 71' ' ' LYS . . . -122.15 -50.34 0.24 Allowed Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.182 176.189 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.4 tpp180 -129.39 2.53 5.1 Favored 'General case' 0 C--O 1.235 0.333 0 O-C-N 122.479 -0.424 . . . . 0.0 111.709 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.548 HD13 ' HB2' ' A' ' 4' ' ' SER . 90.1 mt -88.39 171.2 10.3 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.648 0.261 . . . . 0.0 110.509 177.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -116.0 95.82 0.71 Allowed Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.697 -0.763 . . . . 0.0 113.126 -178.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.477 ' HB2' HD23 ' A' ' 52' ' ' LEU . 59.6 t80 -75.31 134.08 41.13 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 19.1 m -68.63 109.56 3.84 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.008 0.432 . . . . 0.0 110.057 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.537 HG12 HG22 ' A' ' 44' ' ' ILE . 35.5 m -96.2 -36.06 6.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.913 -178.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.561 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 80.0 t80 -133.05 104.78 6.7 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.376 -178.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.538 ' HG3' HG12 ' A' ' 66' ' ' ILE . 44.1 tt0 -99.99 118.11 35.69 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.263 0.554 . . . . 0.0 110.495 174.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.561 ' HB2' ' CE2' ' A' ' 60' ' ' TYR . 18.5 t70 -111.54 165.67 11.8 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 175.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -66.22 -22.78 66.34 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.995 0.426 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -93.75 -50.35 5.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.392 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.646 ' CE2' HG11 ' A' ' 32' ' ' VAL . 29.1 m-85 -134.1 162.68 31.45 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.816 0.341 . . . . 0.0 111.407 -170.255 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.538 HG12 ' HG3' ' A' ' 61' ' ' GLU . 69.2 mt -130.57 122.89 53.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.093 177.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.525 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -92.88 142.83 16.15 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.181 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.473 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 50.3 m-70 -127.76 129.13 46.53 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -178.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.513 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -84.19 123.66 30.34 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.29 -179.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . 0.412 ' HZ ' HG21 ' A' ' 10' ' ' VAL . 74.0 m-85 -116.51 141.49 48.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.642 178.273 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.607 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.6 OUTLIER -84.53 123.97 30.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.456 172.224 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.407 ' HG3' HD12 ' A' ' 77' ' ' ILE . 14.6 mmmm -114.18 -176.29 2.87 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.56 94.5 0.09 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.998 0.428 . . . . 0.0 111.845 -177.609 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 74.69 0.82 60.18 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.822 -0.626 . . . . 0.0 113.335 178.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -142.24 173.58 11.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.01 0.405 . . . . 0.0 111.395 -173.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.477 ' CE2' ' HA ' ' A' ' 22' ' ' GLU . 85.2 m-85 -123.95 131.62 53.6 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.175 -177.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.407 HD12 ' HG3' ' A' ' 72' ' ' LYS . 50.2 mt -133.54 135.17 56.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 C-N-CA 120.71 -0.396 . . . . 0.0 110.851 179.145 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.432 ' O ' ' HA ' ' A' ' 17' ' ' SER . 62.7 t -104.78 115.65 47.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.455 179.048 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -97.17 121.99 39.68 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.07 0.462 . . . . 0.0 110.68 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.525 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 92.8 m-85 -95.79 119.41 34.24 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.655 -179.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.415 HG22 ' HA ' ' A' ' 14' ' ' ALA . 61.0 p -107.58 153.81 41.16 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.083 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -71.12 63.98 2.61 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.656 2.237 . . . . 0.0 112.233 177.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.541 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 47.3 mttm 50.73 52.37 15.04 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.55 -175.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -74.83 98.7 3.58 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 174.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 38.8 pttt -154.66 168.08 27.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.18 -172.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 10.1 t30 71.07 -58.73 0.56 Allowed 'General case' 0 N--CA 1.471 0.598 0 O-C-N 123.977 0.798 . . . . 0.0 111.912 173.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 41.0 ttm180 -78.68 102.16 7.89 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 178.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -75.42 109.69 9.16 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.241 -176.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -77.81 -94.54 0.24 Allowed Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.023 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 62.0 t -105.06 108.34 24.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 p -89.01 131.63 40.53 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.314 -175.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.468 ' HG3' ' HD3' ' A' ' 6' ' ' PRO . 96.3 Cg_endo -81.06 177.17 8.17 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 123.052 2.502 . . . . 0.0 112.012 177.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -55.49 151.4 37.98 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.385 2.057 . . . . 0.0 112.035 174.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.4 t -66.62 -36.92 78.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.86 -177.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 155.94 52.32 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.29 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 59.1 mt -81.26 92.97 2.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.023 0.44 . . . . 0.0 109.974 179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.2 t -174.09 149.55 1.46 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.717 -179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.476 -0.773 . . . . 0.0 110.034 179.433 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.3 mmt . . . . . 0 N--CA 1.482 1.167 0 CA-C-O 120.939 0.399 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 15.3 tppt? -113.96 -46.36 3.02 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.3 m 58.9 80.37 0.19 Allowed 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.769 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 20.3 m -95.55 114.14 25.86 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.65 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.574 HD11 ' HB2' ' A' ' 86' ' ' ASN . 55.6 mt -127.01 133.39 25.0 Favored Pre-proline 0 C--N 1.326 -0.419 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.925 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.79 ' HB3' HG22 ' A' ' 94' ' ' VAL . 30.9 Cg_endo -65.94 155.16 70.83 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.676 2.251 . . . . 0.0 112.496 178.402 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 8.1 tp -63.53 -26.36 40.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.657 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.415 HG22 ' HB2' ' A' ' 6' ' ' PRO . 15.3 t -61.36 -18.76 60.22 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.119 0.485 . . . . 0.0 111.014 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -102.75 -46.06 4.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.611 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 91.5 t -68.36 -35.08 69.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.876 -174.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.1 tp -53.05 -62.05 3.99 Favored Pre-proline 0 CA--C 1.542 0.652 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.15 -30.55 37.96 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.101 1.868 . . . . 0.0 113.192 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 41.6 mtt180 -83.43 -1.52 53.71 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 111.655 0.243 . . . . 0.0 111.655 -177.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.549 ' HA ' HG22 ' A' ' 81' ' ' THR . . . -86.03 148.21 25.84 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.057 0.456 . . . . 0.0 111.548 -177.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.9 m -115.27 0.7 8.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.761 179.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 31' ' ' GLY . . . -165.09 160.98 34.38 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.182 -0.767 . . . . 0.0 111.182 177.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 53.5 p -151.9 142.63 22.84 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.298 0.57 . . . . 0.0 111.498 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.482 ' HB3' ' HE1' ' A' ' 20' ' ' PHE . 9.3 mt -113.62 118.47 34.47 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.297 -0.865 . . . . 0.0 109.756 175.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.563 ' HB ' ' HB3' ' A' ' 28' ' ' ASP . 11.6 m -92.87 116.88 29.44 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.236 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.482 ' HE1' ' HB3' ' A' ' 18' ' ' LEU . 25.0 m-85 -113.38 153.89 27.82 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.43 0.633 . . . . 0.0 110.602 178.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.407 ' HA ' ' CD2' ' A' ' 75' ' ' HIS . 24.7 t70 -90.0 169.72 10.96 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.775 177.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -64.06 -24.76 67.82 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-O 121.071 0.462 . . . . 0.0 110.084 177.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 39.7 m-80 -82.77 9.86 8.86 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.718 176.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 42' ' ' ALA . 78.8 m-85 63.4 29.52 15.57 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.405 178.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -93.75 133.64 36.92 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.552 176.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.0 tt -70.71 117.83 12.73 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 80.4 mt -97.54 -52.76 3.66 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.005 -177.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . 0.563 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 21.2 t70 -135.97 140.67 44.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.292 -173.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' THR . . . . . . . . . . . . . 20.0 m -123.11 114.79 20.81 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.778 175.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 69.2 m -129.98 148.86 51.88 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.069 0.461 . . . . 0.0 111.528 -176.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 16' ' ' GLY . . . 75.06 -150.34 40.69 Favored Glycine 0 N--CA 1.449 -0.477 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.771 176.295 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.5 t -63.24 -16.67 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.082 0.468 . . . . 0.0 111.249 -178.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.453 ' HB1' ' HG ' ' A' ' 18' ' ' LEU . . . -62.68 -15.79 54.09 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.165 179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -74.19 -37.75 63.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.201 178.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 25.4 m -89.67 -19.75 7.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.016 0.436 . . . . 0.0 110.643 -177.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 75.0 mt -76.7 140.96 16.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.809 174.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -67.21 133.08 49.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.958 0.409 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -57.4 -41.73 80.88 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.637 -174.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.504 ' HB2' HG13 ' A' ' 41' ' ' ILE . 20.8 m 62.64 172.14 0.08 OUTLIER Pre-proline 0 CA--C 1.54 0.567 0 N-CA-C 112.146 0.424 . . . . 0.0 112.146 174.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -77.68 45.9 1.89 Allowed 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.826 2.351 . . . . 0.0 111.675 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' ILE . 54.2 mt -62.12 -33.62 59.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.379 -176.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 24' ' ' TYR . . . -57.92 -33.72 69.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.836 0.35 . . . . 0.0 111.138 -178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.646 ' OE1' ' HD3' ' A' ' 46' ' ' ARG . 5.2 tp10 -67.72 -37.23 81.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.64 0.734 . . . . 0.0 109.798 177.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 13.4 mm -77.99 -27.75 15.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.717 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 41' ' ' ILE . 65.0 mt -62.29 -46.84 95.49 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.673 178.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.646 ' HD3' ' OE1' ' A' ' 43' ' ' GLU . 10.6 ptm180 -65.21 -42.14 93.77 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.82 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.504 ' HE3' ' HG3' ' A' ' 43' ' ' GLU . 96.6 mttt -60.94 -48.59 81.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 110.247 177.609 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.524 ' O ' ' HG ' ' A' ' 52' ' ' LEU . 16.0 m -68.22 -25.7 65.33 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.615 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.78 ' HA ' ' HD3' ' A' ' 71' ' ' LYS . 7.5 t30 -65.07 -37.22 86.83 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.095 0.474 . . . . 0.0 110.29 179.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.22 -23.99 47.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.381 177.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -78.55 -40.4 35.01 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.401 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.593 HD21 ' HB2' ' A' ' 57' ' ' TYR . 2.8 pp -142.25 -179.14 6.08 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 113.332 0.864 . . . . 0.0 113.332 -168.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -124.35 -83.45 0.57 Allowed Glycine 0 N--CA 1.449 -0.49 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.789 172.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.8 mpt_? -91.33 11.48 23.51 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -94.31 156.24 16.61 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 178.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -106.87 94.64 0.94 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.619 -0.8 . . . . 0.0 113.345 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' TYR . . . . . 0.593 ' HB2' HD21 ' A' ' 52' ' ' LEU . 13.9 t80 -69.3 124.14 23.06 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 176.122 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 20.3 m -68.53 107.55 2.97 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.101 0.477 . . . . 0.0 109.744 176.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.463 HG11 ' HB2' ' A' ' 69' ' ' ALA . 27.9 m -99.6 -25.08 3.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.09 -175.205 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 62' ' ' ASP . 67.7 t80 -137.6 108.45 6.68 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.146 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 66' ' ' ILE . 40.7 tt0 -109.96 113.95 27.09 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 109.773 -0.455 . . . . 0.0 109.773 176.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.703 ' O ' ' HE2' ' A' ' 83' ' ' LYS . 8.1 t70 -108.81 -167.98 1.29 Allowed 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -85.2 -20.11 30.67 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.812 0.339 . . . . 0.0 111.121 -178.036 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' A' ' 65' ' ' TYR . 0.9 OUTLIER -108.87 -43.81 4.14 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.231 179.982 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.418 ' CD2' ' HB2' ' A' ' 64' ' ' GLN . 49.2 m-85 -131.49 165.62 23.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.943 0.401 . . . . 0.0 111.735 -171.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.537 HG12 ' HG3' ' A' ' 61' ' ' GLU . 81.8 mt -136.15 124.77 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.094 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.459 ' HA2' ' HA ' ' A' ' 80' ' ' PHE . . . -95.61 143.18 16.5 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.088 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.521 ' HA ' ' O ' ' A' ' 57' ' ' TYR . 30.1 m-70 -129.18 127.68 41.85 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 -177.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.463 ' HB2' HG11 ' A' ' 59' ' ' VAL . . . -82.89 124.27 30.18 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.69 0.281 . . . . 0.0 111.365 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -117.34 141.15 48.67 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.085 178.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.78 ' HD3' ' HA ' ' A' ' 49' ' ' ASN . 0.7 OUTLIER -82.37 127.69 33.5 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.651 172.766 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.485 ' HG3' HG13 ' A' ' 77' ' ' ILE . 30.3 mmmt -118.13 178.16 4.53 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.532 -178.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.31 94.77 0.08 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.99 0.424 . . . . 0.0 111.241 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 72.47 4.7 61.49 Favored Glycine 0 N--CA 1.45 -0.379 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.952 179.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.407 ' CD2' ' HA ' ' A' ' 21' ' ' ASP . 14.2 m170 -141.61 173.55 11.39 Favored 'General case' 0 C--N 1.325 -0.472 0 O-C-N 122.357 -0.496 . . . . 0.0 111.418 -175.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.78 127.72 42.56 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.594 -178.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.485 HG13 ' HG3' ' A' ' 72' ' ' LYS . 57.7 mt -129.84 134.19 63.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.455 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 41' ' ' ILE . 59.4 t -104.38 111.6 34.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.143 179.351 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 41.0 m-85 -91.71 124.37 35.81 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.228 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.459 ' HA ' ' HA2' ' A' ' 67' ' ' GLY . 83.8 m-85 -99.15 118.47 35.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.655 -178.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 14' ' ' ALA . 71.3 p -110.73 151.65 42.99 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 177.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -63.25 137.81 63.09 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 C-N-CA 121.456 1.437 . . . . 0.0 109.875 173.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' LYS . . . . . 0.703 ' HE2' ' O ' ' A' ' 62' ' ' ASP . 16.2 mttm -30.44 99.85 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 O-C-N 124.348 1.03 . . . . 0.0 112.77 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 -128.65 90.81 3.12 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.956 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . 0.845 ' HD3' ' H ' ' A' ' 85' ' ' LYS . 0.0 OUTLIER -72.16 99.94 2.45 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.479 0.657 . . . . 0.0 109.691 178.495 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.574 ' HB2' HD11 ' A' ' 5' ' ' ILE . 26.4 t-20 -62.47 142.5 57.88 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.548 -179.19 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 26.7 tpt180 -73.24 73.81 1.29 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 177.524 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -70.61 172.8 7.99 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-O 121.369 0.604 . . . . 0.0 111.393 -175.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 103.31 -40.02 2.59 Favored Glycine 0 N--CA 1.445 -0.755 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -165.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.03 86.28 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 169.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.3 m -80.61 139.07 50.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.637 -173.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -67.41 121.66 8.8 Favored 'Trans proline' 0 CA--C 1.529 0.244 0 C-N-CA 122.994 2.462 . . . . 0.0 112.277 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -74.42 160.54 41.65 Favored 'Trans proline' 0 C--O 1.237 0.443 0 C-N-CA 122.592 2.195 . . . . 0.0 112.222 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.79 HG22 ' HB3' ' A' ' 6' ' ' PRO . 45.0 t -92.94 -53.87 8.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.987 -0.552 . . . . 0.0 109.934 179.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.16 -130.19 5.82 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.316 179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.1 mt -116.15 -47.03 4.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.893 0.378 . . . . 0.0 110.661 -178.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 8.6 p -128.36 124.6 36.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.355 -177.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.4 t30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.819 176.406 . . . . . . . . 0 0 . 1 stop_ save_